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Vaccination is considered to be one of the most effective methods of preventing infectious diseases. 
Vaccines can prevent or ameliorate the effects of infection by pathogens and can be defined as 
the administration of antigenic substance to stimulate the immune system to develop adaptive 
immunity to a disease. The earliest documented examples of vaccination are from India and China in 
the 17th century, where vaccination with powdered scabs from people infected with smallpox was 
used to protect against the disease1. In1721 Lady Montagu brought the knowledge of variolation 
to England after witnessing the practice of inoculation against smallpox – variolation – in Turkey. 
Although the immunity acquired after variolation was considered reliable, the death rate was 
reported to still be around a tenth of that from natural infection (20–30%). An important step 
forward was made by Benjamin Jesty who deliberately inoculated his children with cowpox after 
noting that people infected with cowpox, a relatively mild disease, were subsequently protected 
against smallpox1. Later, in 1798, the British scientist Edward Jenner published the results of his 
experiments of inoculation with cowpox which showed that using cowpox for variolation was less 
dangerous but just as effective as using human smallpox2. These experiments inspired the word 
vaccination which is derived from vacca, the Latin word for cow. Given the relatively short history of 
vaccines, vaccine developments over the last century have been unprecedented.
National Immunization Program in the Netherlands
The first experiment with cowpox vaccination started in the Netherlands in 1799 and in 1823 
vaccination policies required that children received the vaccine before entering school3,4. In the 
next century the vaccine uptake varied but was generally low. In the 1940s, effective whole–cell 
vaccines against Bordetella pertussis were developed, which became available in the Netherlands 
in 19495,6. From 1953 a combination vaccine against diphtheria, tetanus and pertussis (DTP) was 
freely available for the Dutch population within mass vaccination programmes5. The coordination 
and surveillance was in the hands of a wide variety of organizations and differed significantly from 
one area of the country to another7. After a poliomyelitis epidemic in 1956 the government initiated 
a centrally organized mass vaccination campaign against polio in 1957 which is considered to be 
the start of the National Immunization Programme (NIP). The NIP expanded gradually since 1957 
and covers currently 12 infectious diseases (see Table 1). The most recent additions to the Dutch 
NIP are the bivalent HPV vaccine targeting 12–year–old girls and a hepatitis B vaccine administered 
concomitantly with the DTaP, Haemophilus influenzae type b and polio vaccine components8. Next 
to these 12 infectious diseases, several new candidate vaccines are available targeting infectious 
agents such as a rotavirus and varicella (zoster) virus9,10. Besides targeting new infectious agents, 
the currently used vaccines in the infant programme could also be extended to other risk groups. 
For example, the current pertussis vaccination programme could be extended to adolescents 
while high–risk groups and the elderly could be vaccinated against pneumococcal disease. Also 
the replacement of current vaccines included in the NIP by vaccines which can prevent a larger 
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burden of disease, such as the 13–valent pneumococcal conjugated vaccine (PCV13) in the case 
of pneumococcal vaccination or the quadrivalent HPV vaccine for the protection against cervical 
cancer and genital warts, can be considered. 
Table 1. The current Dutch National Immunization Programme12
Age Injection 1 Injection 2
0 Months HepBa
2 Months DTaP, IPV, Hib, HepB Pneu
3 Months DTaP, IPV, Hib, HepB Pneu
4 Months DTaP, IPV, Hib, HepB Pneu
11 Months DTaP, IPV, Hib, HepB Pneu 
14 Months MMR Men C
4 years DTaP, IPV, Hib
9 years DT–IPV MMR
12 years HPV (3x)
a= Only for children of whom the mother tested positive for HBsAg, Hib= Haemophilus influenzae type b, HepB= Hepatitis B, 
Pneu= Pneumococcal vaccination, MMR= Mumps, Measles and Rubella (German Measles), Men C= Meningitis C, HPV= Human 
Papilloma Virus (girls only), DTaP= Diphtheria, tetanus, and acellular pertussis, IPV= Polio–myelitis vaccine (inactivated)
Infectious disease modelling
Given the multitude of (new) vaccines available for possible introduction into NIPs, health 
economic modelling of new vaccines is becoming increasingly important in informing decisions on 
allocating scarce resources. For example, in the Netherlands the decision to introduce the 7–valent 
pneumococcal conjugated vaccine (PCV7) into the Dutch NIP for infants, has in part been driven by 
cost–effectiveness considerations11. 
 To estimate the epidemiological and the economic impact of vaccination programs two types of 
models can be used, i.e. ‘static’ and ‘dynamic’ models13-15. The traditional static models for evaluation 
of infectious disease interventions are not always appropriate. This type of model ignores the 
fundamentally transmissible nature of infectious diseases, which can lead to distorted estimates 
of program effectiveness and cost–effectiveness. Yet, static models can provide useful initial or 
preliminary estimates. In particular, the risk of acquiring a transmissible infection is often related to 
the number of infectious individuals in the population. So, if an immunization program can reduce 
the number of infectious individuals in the population also non–vaccinated individuals can be 
indirectly protected against disease. This indirect protection of unvaccinated individuals is called 
‘herd–immunity’16. Next to positive indirect herd effects, vaccination can also have negative indirect 
effects, such as an increase in the average age of infection. Only dynamic models are able to predict 
these indirect effects. Hence, it is usually preferable to use a dynamic model to determine the effects 








Focus of this thesis
The focus of this thesis is on vaccines which can either replace the currently used vaccines in the 
NIP or which can be used for the extension of the currently targeted individuals in the NIP by using 
both static and dynamic models. In particular, static models will be used to estimate the impact 
of the pneumococcal vaccines that recently became available. A dynamic model will be used to 
estimate the impact of extending the current Dutch childhood pertussis vaccination programme to 
adolescents and/or adults. 
Pneumococcal disease 
Streptococcus pneumoniae is a gram–positive capsulated bacterium and is a common colonizer of 
the human nasopharynx. Next to being commensal, pneumococci are also opportunistic pathogens. 
Infections caused by S. pneumoniae are a major cause of morbidity and mortality worldwide, with the 
highest incidence rates seen among the infants, immunocompromised and elderly. Pneumococcal 
infections include frequently occurring mucosal non–invasive infections such as acute otitis media 
(AOM) and non–bacteraemic pneumonia, but also less common diseases that may be invalidating or 
fatal such as pneumococcal sepsis and meningitis. More than 90 immunologically distinct serotypes 
of the pneumococcus have been described that vary in their capsular polysaccharide composition. 
These serotypes are further categorized into 46 different serogroups based on immunological 
cross–reactivity17. Of all known serotypes, approximately 15 are assumed to be responsible for the 
majority of all invasive pneumococcal disease (IPD)18. 
Polysaccharide vaccines
A 23–valent pneumococcal polysaccharide vaccine (PPV23) has been available since the early 
1980s which progressed from a 4–valent precursor vaccine over a 50 year time period19. Although 
many countries recommend this vaccine for vaccination of elderly, the efficacy and the duration of 
protection of this vaccine is uncertain and most probably limited, and there is a reduced antibody 
response to revaccination20-22. PPV23 stimulates mature B–lymphocytes, but not T–lymphocytes 
resulting in an immune response which is neither long–lasting nor characterized by an anamnestic 
(i.e., booster) response upon re–vaccination23,24. PPV23 does not elicit a protective immune response 
among infants and very young children, since children respond poorly to T–independent antigens. 
However, protein–conjugated polysaccharides do stimulate a T–helper–cell response, resulting in a 
substantial primary response among infants and a strong booster response at re–exposure24.
Conjugated pneumococcal vaccines 
In 2000, the 7–valent pneumococcal conjugated vaccine (PCV7) that covers seven serotypes (4, 6B, 
9V, 14, 18C, 19F and 23F), was licensed for vaccination among infants and children in the USA. It has 
been shown in clinical trials and post licensure studies that PCV7 is highly effective in preventing 
invasive disease in young children25-33. Several other PCVs containing additional serotypes have been 
clinically investigated. Of these vaccines, a 10–valent vaccine (PCV10), containing the serotypes 
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included in PCV7 and serotypes 1, 5, and 7A is currently licensed for the use in infants and young 
children34. In addition to PCV10, the 13–valent vaccine (PCV13) also includes serotypes 3, 6A and key 
replacement serotype 19A. Similar to PCV10, PCV13 can also be used in infants and children, but in 
addition, it is also licensed for the use in adults aged 50 years and older35.
Pneumococcal vaccination in the Dutch NIP
In the Netherlands, an infant pneumococcal vaccination programme with PCV7 was introduced 
in June 2006 using the recommended 3+1 dose schedule without a catch–up campaign. In other 
countries, such as the UK, PCV7 was introduced using a schedule of 2, 4, and 13 months, combined 
with a catch–up vaccination for children aged up to 2 years36. Next to favourable direct effects, herd 
protection and serotype replacement effects were additionally seen. Partially, due to replacement 
disease, PCV7 is being substituted in most countries by PCV1328,36. In the Netherlands, however, as 
from 2011 PCV7 has been replaced by PCV10 using a 3+1 dose schedule. 
Pertussis
B. pertussis is a small, gram–negative bacterium with exclusive affinity for the mucosal layers of the 
human respiratory tract. It can cause pertussis, or whooping cough, which is a highly contagious 
infection of the respiratory tract. Most cases of clinically recognizable pertussis occur in children 
aged 1–5 years, while most severe disease and death occur in infants aged less than 2 months who 
are unimmunized37. Clinical manifestations of whooping cough may show substantial variation 
depending on age, clinical condition, and previous vaccination or infection. In general, a patient 
will develop catarrhal symptoms including cough after an incubation period of 9–10 days. In the 
subsequent paroxysmal phase, lasting several weeks, severe and spasmodic cough episodes with 
a characteristic whoop occur, often with cyanosis and vomiting37. In young infants, who may not 
have the strength to have a whoop, pertussis may cause apnoea and cyanosis. Finally, the last 
convalescent phase, is characterized by a continuous decline of the cough. However, paroxysms 
with subsequent respiratory infections may recur for many months after the initial onset of pertussis.
Pertussis vaccines
Two types of pertussis vaccines are available, i.e. whole–cell vaccines and acellular vaccines. Whole–
cell pertussis vaccines are suspensions of inactivated B. pertussis organisms, while acellular vaccines 
are based on highly purified, selected components of this agent. 37. The efficacies of the whole–cell 
vaccines and acellular pertussis vaccines vary depending on the case definition of pertussis used, but 
are generally considered as being equally effective37. A difference between the vaccines concerns 
the frequency of minor adverse reactions. The whole–cell vaccines are frequently associated (1 in 
2–10 injections) with adverse reactions such as local redness and swelling, while the adverse event 








Pertussis vaccination in the Dutch NIP
In the Netherlands, a vaccination against DTP was introduced in 1953 for a large part of the 
population. The NIP offering DTP and inactivated polio vaccination in a programmatic approach to 
all children born from 1945 onwards started in 195739. Until 2001, the pertussis vaccination schedule 
in the Netherlands consisted of four doses (currently at ages 2, 3, 4 months and a booster at age 
11 months) of the whole–cell pertussis vaccine within the combination of diphtheria, tetanus and 
polio vaccine. From 2001 onwards, an additional acellular booster vaccination was given to 4–year–
old children. Starting in 2005, the pertussis component in the combination vaccine was changed 
from the whole cell to an acellular one.
Aim and outline of this thesis
The general aim of this thesis is to provide analyses of both the epidemiological and economic 
impact of new pneumococcal and pertussis vaccination strategies. The thesis is structured into two 
parts. In PART I the epidemiology and economics of pneumococcal vaccination are presented while 
PART II focuses on the impact of the introduction of extended pertussis vaccination strategies.
PART I
In many European countries, the implementation of pneumococcal vaccination programs against S. 
pneumoniae has partially been driven by the indirect beneficial impact as observed among various 
non–targeted age groups in Northern America. Chapter 2 focuses on the transferability of these 
indirect effects using the post–marketing experiences with PCV7. In particular, this chapter provides 
a descriptive overview of the available epidemiological post–marketing data and experiences with 
PCV7 in different countries and populations. The impact of extrapolating net–indirect effects in 
non–vaccine protected groups from the USA to the Netherlands is analysed in chapter 3. Chapter 
4 provides an estimate of the cost–effectiveness of pneumococcal vaccination by using PCV7, 
PCV10, or PCV13. In contrast to chapter 3, for this analysis we did include serotype placement 
for vaccinated children. In chapter 5, the  cost–effectiveness of extending the pneumococcal 
vaccination programme to elderly was calculated. Next to elderly, also individuals with certain 
clinical conditions such as immunocompromised patients are at increased risk of IPD40. Therefore, 
the impact of vaccinating these high–risk groups was calculated in chapter 6. In contrast to the 
other chapters in this thesis, this study was not performed for the Dutch setting but focused on the 
UK. One of the outcomes of chapters 5 and 6 is that the cost–effectiveness is largely influenced by 
the etiological fraction of S. pneumoniae causing community acquired pneumonia (CAP). Therefore, 
chapter 7 presents a meta–analysis to specifically estimate this fraction. 
PART II
The second part of this thesis discusses the epidemiological and economic impact of extended 
pertussis vaccination booster strategies using dynamic models. In chapter 8 a dynamic model is 
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presented which was used to estimate the epidemiological impact of various booster vaccination 
strategies. In chapter 9, it is described how the model as presented in chapter 8 was extended 
and modified in order to calculate the cost–effectiveness of various vaccination strategies. Several 
analyses were performed to determine the most cost–effective vaccination strategy. In chapter 
10, all the published dynamic models which have been used to analyse the impact of a pertussis 
vaccination are reviewed.
Finally, the results of this thesis are summarized and discussed in chapter 11. Here, the findings of 
the thesis are translated into final conclusions and recommendations. 
Part I
Costs and effectiveness of extended vaccination 
strategies against pneumococcal disease
2




Healthcare decisions on vaccination programs mainly rely on the direct burden of illness and 
related costs of the disease. Next to the expected direct beneficial effect of pediatric immunization 
programs against Streptococcus pneumoniae, worldwide implementation of these programs has 
also been driven by the indirect beneficial impact as observed among various nontargeted age 
groups in Northern America. In this article, we provide a descriptive overview of the post–marketing 
surveillance and show that there are large differences in the observed disease epidemiology after 
implementation of pediatric pneumococcal immunization programs across countries. Possible 
factors responsible for these differences may include vaccine–serotype coverage, implemented 
vaccination schedules, antibiotic resistance rates and pneumococcal disease incidence prior to 
vaccination. A potential limitation can be found in the installation or enhancement of existing 
surveillance systems as well as other potential confounding bias, which may have influenced 
observed disease rates in the included observational studies. We conclude that the health and 
economic impact should be addressed in light of the country specific pneumoccocal disease 
epidemiology to support decisions on immunization programs. 








Currently, many countries have introduced, decided to introduce or are on the brink of deciding 
to introduce a childhood vaccination program against Streptococcus pneumoniae41,42. Conversely, 
several countries, in particular low–income countries, have not yet implemented a vaccination 
program or only recommend vaccination strategies directed at certain high–risk groups42. In 
such countries, budget constraints especially have been the principal driver in decision making. 
In European countries, favorable (cost–) effectiveness outcomes have played a decisive role43. In 
most European countries these cost–effectiveness outcomes were driven by the inclusion of 
indirect protection benefits in nontargeted populations43. Indirect protection benefits were based 
on the observed herd–protection effects in adults after nationwide implementation of the seven–
valent pneumococcal–conjugated vaccine (PCV7) in the USA in 200043. In the USA, only limited 
replacement disease was identified (i.e., pneumococcal disease caused by serotypes not covered 
by the vaccine44-46. 
 It is important to discuss the use and applicability of country specific epidemiological data 
for healthcare decision making on immunization programs. In particular, as an example, it was 
recently shown that epidemiological data on pneumococcal infections – both before and after 
implementation of a pediatric pneumococcal vaccination program – did not consistently support 
previous (cost–) effectiveness outcomes43,47. Therefore, we hypothesized that post–marketing 
experience with immunization programs and effectiveness of vaccines may be substantially 
different between countries and/or even specific populations. 
 In the current article, we aimed to address the following aspects: first, to provide a descriptive 
overview of the available epidemiological post–marketing data and experience with PCV7 in 
different countries and populations; second, to explore potential influencing factors that could 
explain observed differences; and third, to discuss issues related to the use of the national data in 
(cost–) effectiveness modeling. By achieving these aims, our review might help in understanding 
the factors responsible for epidemiological differences between countries, which could be 
important both from the perspective of the WHO and from national/regional policy makers who are 
responsible for the recommendation or introduction of national immunization programs48. 
METHODS
We searched PubMed for relevant post–marketing studies published after 2000 (the introduction 
year of PCV7 in the USA). Additional information was retrieved from references (‘snowballing’) from 
relevant articles. Search terms included ‘pneumococ*’, ‘pneumococcal infections’, and ‘epidemiology’. 
The search was performed during November 2009 and February 2010. All studies published in 
English that determined the effects of pediatric immunization with pneumococcal vaccines on the 
epidemiology of invasive pneumococcal disease (IPD) were reviewed. For that reason we included 
original research papers that investigated the epidemiology of IPD before and after implementation 
or recommendation of a conjugated pneumococcal infant vaccination program. Papers describing 
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the epidemiology before the introduction of routine infant vaccination, focusing on the impact of 
the polysaccharide vaccine among elderly, or on pneumococcal carriage or noninvasive disease 
rather than on IPD were excluded. 
RESULTS
Pneumococcal disease 
Infections caused by S. pneumoniae are a major cause of morbidity and mortality worldwide, 
with the highest incidence rates seen among the elderly and infants. Pneumococcal infections 
include frequently occurring mucosal noninvasive infections such as acute otitis media (AOM) 
and nonbacteremic pneumonia, but also less common diseases that may be invalidating or fatal 
such as bacteremic pneumonia and meningitis. More than 90 immunologically distinct serotypes 
of pneumococcus have been described that vary in their capsular polysaccharide composition. 
These serotypes are further categorized into 46 different serogroups based on immunological 
cross–reactivity17. Of all known serotypes, approximately 15 are assumed to be responsible for the 
majority of all IPD18. 
PCv7 
In 2000, the seven–valent pneumococcal conjugated vaccine that covers seven serotypes (4, 6B, 9V, 
14, 18C, 19F and 23F), was licensed for vaccination among infants and children in the USA. In Europe 
and the USA, PCV7 is registered and indicated for the prevention of sepsis, meningitis, bacteraemia, 
pneumonia and AOM in infants and children from 2 months to 5 years of age49. It was shown in 
clinical trials that PCV7 is highly effective in preventing invasive disease in young children25,26. 
Although a 3+1 dosing schedule is recommended, alternatively, a 2+1 dosing schedule may also be 
provided (see later) 26,28,50. 
Other more valent vaccines: PCv10 & PCv13 
Several other PCVs containing additional serotypes have been clinically investigated. Of these 
vaccines, a 10–valent vaccine (PCV10) is registered for use in Europe and a 13–valent vaccine 
(PCV13) is licensed in both Europe and the USA34,35,51. Also, other countries such as Canada, Australia 
and Argentina recently approved (one) of these more valent vaccines. For the 10–valent vaccine, 
which in addition contains serotypes 1, 5 and 7F, a 3+1 dose vaccination schedule is recommended 
by the European Medicines Agency (EMA)34,52. In addition to PCV10, PCV13 also includes serotypes 
3, 6A and 19A and both a 3+1 and 2+1 dose schedule have been approved by the EMA51. No study 
for one of these more valent vaccines has yet proven protective efficacy against IPD. The efficacy 
claim is based on the assessment of the immune responses as recommended by the WHO53. Clinical 
trials showed that both vaccines elicit an immune response to all included serotypes35. However, 
compared with PCV7, these more valent vaccines seem to be (slightly) less immunogenic for some 
serotypes; the clinical relevance of this is as yet unknown34,35.







Pneumococcal vaccination implementation & vaccination schedules among different countries 
In Europe, 24 countries recommended or have implemented a routine infant pneumococcal vac-
cination program of which 17 (partly) reimburse vaccination for all infants rather than only for 
high–risk groups (see also Figure 1). A growing number of countries recommend a 2+1 dose vac-
cination schedule rather than a 3+1 dose schedule42. Clinical protection against IPD after less than 
four doses was already observed in the PCV7 licensure study25. Furthermore, evidence for reduced–
dose schedules in preventing invasive disease in vaccinated individuals was also observed in a large 
case–control study during a period of vaccine shortage in the USA. This study showed an effective-
ness against vaccine serotype (VT)–IPD of 98% (95% CI: 75–100%) for a 2+1 dose schedule and even 
a comparable effectiveness of 95% (95% CI: 88–99%) for a 2–dose schedule28. Furthermore, recent 
immunogenicity studies also support introduction of a reduced–dose schedule50,54. Consequently, 
more than 60% of the European countries which introduced a pneumococcal vaccination use a 
2+1 dose schedule42. Besides these European countries only few countries (notably USA, Australia, 
Canada, New Zealand, Hong Kong, Costa Rica, Mexico, South Africa, Uruguay, Brazil, Israel and South 
Korea) implemented routine vaccination for (high–risk) children41,55.
Figure 1. Countries colored light grey represent countries in which universal pneumococcal vaccination is 
free of charge, medium gray represents countries in which universal pneumococcal vaccination is only free of 
charge for children at increased risk of infection, and dark grey represents those countries where vaccination 
is not available free of charge42,56. No data were available for countries colored black. (A) In Slovakia, 96% of 
the costs of pneumococcal vaccination are reimbursed42. (B) Depending on the insurance status, vaccination is 
completely reimbursed or only for 65% in France42. (C) Although not reported on the website of EUVAC.NET56, 
a recent paper reported that in Slovenia vaccination is completely reimbursed for children at increased risk for 
invasive pneumococcal disease42. (D) In Italy, in 15 out of the 20 regions, vaccination is offered free of charge to 
children, while in five regions it is free of charge for high–risk children42. (E) In Spain, the vaccine is reimbursed 
for all children under 5 years of age who are at increased risk for infection. In addition, in the Madrid region the 
vaccine is also included free of charge for all children as from November 2006.
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Indirect effects & differences across countries 
Immunization programs can result in two types of effects: first, direct effects – protecting those 
successfully immunized from carriage or infection; and second, indirect effects – providing 
protection in unsuccessfully immunized and unvaccinated individuals by reducing the transmission 
of the organism in the population. As (young) children are the main pneumococci reservoir with 
high colonization rates, eradication of the colonizing VT by vaccination of these children reduces 
transmission to adults and subsequently the community (herd–protection effects). Several studies 
have shown reductions in carriage after vaccination with conjugated pneumococcal vaccines57-60. 
However, eradication of these VTs in asymptomatic carriers has created an ecological niche for 
nonvaccine serotypes (NVTs), which has led to rapid increase of colonization by NVTs57-60. This 
indirect effect is known as serotype replacement. Serotype replacement in the nasopharynx may be 
problematic if these NVTs cause disease. 







recommended and extent 
Coverage of serotypes that 
cause IPD before vaccination
References
USA 3+1 Yesa 2000 universal 82% (<5yr) 
74% (Alaska Native children)
25,63,66-68







2004 universal in Quebec 
2002 universal in Alberta 
>80% (Children) 71,72
France 2+1/3+1e Yesa 2003 risk based 
2006 universal 
68% (<2yr) 73
Spain 3+1 NA 2001 risk based 
2006 universal (Madrid 
region) 
68% (Children) 74,75
Portugal 3+1 NA 2001 risk based 56% (<1yr)
70% (1–5 yr)
76





Norway 2+1 Yesf 2006 universal 73% (<5yr) 78
Netherlands 3+1 No 2006 universal 69% (<5yr) 79
UK 2+1 Yesg 2002 risk based 
2006 universal 
73% (<2yr) 80,81
Denmark 2+1 Yesh 2007 universali 60–65% (<5yr) 82
Austria 3+1 No 2003 universal 82% (1–2yr)
65% (2–5yr)
83
a All children up to 23 months and up to 59 months for high–risk children.
b Healthy children get a 3+0 dose schedule, children at risk do get fourth dose of PCV at 12 months of age, and a booster dose 
of 23–valent polysaccharide vaccine at 4 years of age.
c Children born between 1 January 2003 and 31 December 2004.
d All children up to 5 years of age in Quebec and all high–risk children up to 5 years in Alberta.
e Conflicting results are reported for France, the use of a 2+1 dose schedules is reported by EUVAC and by Carcalho et al.42,107), 
while a 3+1 dose schedule is reported by Le Poutre et al.73.
f All children born in 2006.
g All children up to 2 years of age (in 2002 PCV7 use was alreasy recommended to cover at risk children up to 5 years of age).
h All children between 12 and 17 months born after 30 April 2006.
i Before 2007 PCV7 was also recommended for high–risk children.
IPD= invasive pneumococcal disease; NS= not stated; NA= not applicable.







 In this article, the direct and indirect impact of vaccination on disease incidence and/or prevalence 
for vaccinated as well as for unvaccinated cohorts will be discussed based on observed epidemiology 
data for various countries and/or populations (see Table 1 & Supplementary Table). Data from the 
USA, Canada and Australia will be reviewed first after which data from European countries will be 
discussed. The rationale for this separation was based on measured prevaccination epidemiological 
differences18,25,46,61,62, the earlier introduction of a national pneumococcal immunization program in 
the USA compared with other countries24, the expectation that the indirect effects in the European 
countries would be comparable to those observed in the USA and the presence of some specific 
ethnic populations with an increased risk of pneumococcal disease in the USA and Australia63-65.
Direct & indirect effects in the USA, Canada & Australia 
In the USA, routine infant pneumococcal vaccination was implemented in the second half of the year 
2000 for all children 2–23 months of age, with additional recommendations for immunization of all 
children up to 59 months of age who were at increased risk for pneumococcal disease24. Although 
there was a vaccine shortage from August 2001 until September 2004, in 2001 the VT–IPD incidence 
was reduced by 78% (95% CI: 74–82%) in children less than 2 years of age compared with 1998 and 
1999 data 46.  Furthemore, in 2007, the IPD incidence due to VT in children less than 5 years of age 
had declined by 100% (95% CI: 99–100%)84. While, VT–IPD incidence continued to decline until 2007, 
overall IPD incidence rates leveled out after the first years owing to the increase in the incidence of 
NVT–IPD67,84. Overall, the reduction in incidence in 2007 was estimated at 76% (95% CI: 73–79%)84. 
In unvaccinated cohorts of 20 years of age and older, a significant lower incidence rate of IPD was 
observed in the first year after introduction. The largest decrease in VT–IPD incidence (40%; 95% 
CI: 29–49%) was observed in the group 20–39 years of age comprising in large part parents of 
vaccinated infants46. Also, NVT–IPD (in this study defined as serotypes not included in PCV7 nor 
related to the seven serotypes included in PCV7) decreased significantly (20%; 95% CI: 1–35%) in 
this similar age group. However, more recent studies showed significant increases in IPD due to 
NVTs in the unvaccinated age groups limiting the indirect herd effect of the vaccine44,45,84,85, serotype 
19A increased rapidly (see also below), making it the most common serotype among all age groups 
in the USA84,86,87. Despite these increases in NVT–IPD, there are still significant reductions in overall 
IPD incidence (45%; 95% CI: 42–47%)84. 
 Several studies also provided more detailed epidemiological data on pneumococcal syndrome 
level44,45,84,85. Bacteremia without focus decreased significantly (p<0.001) among the adult age groups 
without significantly increasing incidence due to NVTs45,84. Also, a clear herd effect was shown for VTs 
causing meningitis and bacteremic pneumonia in adults with risk reductions of 80–90% (p<0.001)84. 
However, the herd effect of meningitis and partially also the herd effects for bacteremic pneumonia 
were counterbalanced by a substantial increase in NVT disease in 200744,45,84. 
 Indirect effects were also observed for groups with increased IPD risk. A US study showed that 
the incidence of VT–IPD in patients with HIV infections was reduced by 62% (95% CI: 53–70%) in 3 
years after the introduction of vaccination. However, an increase of 45% (p<0.001) was also observed 
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for NVT–IPD88. In addition some specified ethnic populations (e.g., native American Indians, Alaskan 
native population and the Australian Aboriginals) experience a much higher rate of IPD63-65. Before 
implementation of vaccination (1995–2000), Alaskan native children experienced an excess burden 
of disease compared with non–Alaskan native children with three–times higher annual incidence 
rates (403 vs 135 cases per 100,000 population annually from 1995 to 2000 for children aged <2 
years, respectively)63. During the PCV7 period a more than doubling (140%; 95% CI: 47to -200%) in 
the IPD incidence was seen in Alaskan native children due to NVTs, which largely limited the direct 
effect of vaccination on VT (-96%; 95%  CI: -100 to -86%)63. In Alaska Native adults, the increase in NVT 
disease leveled out or even increased the net–overall IPD incidence63. Also, the VT–IPD incidence 
decreased dramatically – similar to the Alaskan native population – in the Navajo Nation and the 
White Mountain Apache populations. However, in contrast to the Alaskan native population, the 
increase in NVT was only found significant in the adult White Mountain Apache population65 while 
in the Navajo population no significant change was observed at any age64. 
 After the introduction of vaccination in Canada, significant reductions in overall IPD were found 
in young children (6 months–4 years of age) and (most) adults groups72. Except for the age group 
containing 16–64 year old individuals no overall significant changes in IPD incidence due to NVTs 
was found. Similar results were found by Bettinger et al. who focused on children of less than 16 
years of age89. Similar to the USA, in Australia the incidence of IPD was also higher (three– to four–
times) among indigenous children aged less than 2 years compared with nonindigenous children of 
the same age before the introduction of PCV769,90. After the introduction of vaccination, significant 
overall decreases in IPD rates for all age groups (in both indigenous and nonindigenous groups) 
were observed, while NVT–associated disease incidence remained unchanged69. Rates in VT–IPD in 
indigenous children decreased less (78% between 2002 and 2006) than in nonindigenous children 
(91% between 2004 and 2005). It should be noted that vaccination of indigenous children was 
implemented 4 years earlier (2001) than routine infant vaccination (2005). 
Direct & indirect effects in European countries 
While at least 24 different European countries have recommended infant pneumococcal vaccination, 
country specific epidemiological data is limited or not yet available. The existing evidence for 
indirect effects on invasive and noninvasive disease for several countries is discussed below. 
 In France, vaccination was recommended in 2003 for all children at risk for infection and in 
2006 a routine vaccination program was implemented which resulted in an uptake of 44% in the 
same year. Most recent surveillance data showed a decline of 71% in VT–IPD incidence between 
2001/2002 and 2006 among children <2 years of age. However, an 85% increase in IPD cases due to 
NVTs resulted in a net decline of only 21% (95% CI:10–31%)73. While no significant changes in the 
incidence of meningitis were observed for other age groups the incidence of cases of pneumococcal 
bacteremia increased significantly in these age groups (p=0.013)73. Additionally, another study 
showed an overall decline in the number of meningitis cases of 28% (p<0.05) among children91. 
Although based on a small population, a much larger decrease in the incidence of meningitis was 
observed by Dubos et al. (82%, 95% CI: 52–95%)92. 







 In Spain, a risk based vaccination program was introduced in 2001 with gradually increasing 
region–specific coverage to approximately 50%74. Multiple regional reports from Spain showed 
geographical differences in the trends of IPD in children after PCV7 implementation. After 
implementation, no change in IPD incidence in children less than 5 years of age was observed in 
several different regions of Spain93-96. An increase (58%; 95% CI: 2–145%) in overall IPD was observed 
among children aged less than 2 years of age for the Barcelona region in the late PCV7 period97 while 
in the Basque region, a decrease was observed in the IPD rate (see Supplementary Table 2)98-100. Most 
of the Spanish studies do specifically report an increase in the incidence or proportion of IPD caused 
by NVT29,93,94,97,98,101. 
 In Barcelona, the overall incidence of IPD increased for both adults aged 18–64 years (49%; 
95% CI: 22–82%) and for adults aged 65 years and older (23%; 95% CI: -0.3–51%)74. These increases 
coincided with clonal expansion of NVTs among adults in Barcelona. Overall IPD due to VTs decreased 
significantly in adults above 65 years of age (37%; 95% CI: 7–57%) but not among adults 18–64 
years of age (-12%; 95% CI: -40–28%)74. The incidence of VT meningitis decreased nonsignificantly in 
adults by 45% (95% CI: -40–249%), whereas the overall meningitis incidence increased significantly 
(137%; 95%CI: 40–303%) owing to a significant increase of meningitis caused by NVT (214%; 95% CI: 
59–523%). 
 In Portugal, PCV7 became available in 2001. Although not included in an immunization 
program, the vaccine uptake for children (more than three doses) increased to 51% in the 2005 
birth cohort102. One study showed that after introduction of the vaccine the incidence of IPD did not 
change in children aged less than 1 year of age76. Another study found a significant reduction for 
VT–IPD among both children aged less than 5 years and adults (see Table 2)102. 
 In Germany, PCV7 vaccination was recommended for children at increased risk of infection in 
2001 (e.g., children with chronic heart and lung diseases). This resulted in a 8% uptake between 
2000 and 2003. In 2006, vaccination of all children was recommended, and combined with a 
catch–up program77. A significant reduction in IPD incidence was observed for children 2 years of 
age from 20.0 (95% CI: 19.1–20.9%) cases per 100,000 population in 1997-2003 to 11.0 (95% CI: 
9.3–12.9%) cases per 100,000 population in 2007–2008. By contrast, for children aged 24 years, a 
nonsignificant upward trend in IPD incidence was observed from 5.6 (95% CI: 5.3–6.1%) cases per 
100,000 population in 1997–2003 to 7.2 (95% CI: 6.1–8.4%) cases per 100,000 population in 2007–
2008. Furthermore, the incidence of NVT disease remained stable. 
 In Norway, an universal immunization program was introduced in 2006 and 2 years after the 
introduction, statistically significant reductions in VT–IPD were observed for all age groups, except 
for those aged 20–49 years. The largest decline was observed among children less than 5 years of 
age. Here, the incidence rate decreased from 26.89 cases/100,000 population to 1.36 cases/100,000 
population (Incidence Rate Ratio, IRR 0.05; 95% CI: 0.02–0.14)103. Similar increases in NVT–IPD were 
only significant for adults aged ≥65 years with a 22% higher incidence (IRR: 1.22 95% CI: 1.05–1.42). 
In the Netherlands, PCV7 vaccination was implemented in 2006. A recent study describing the 
impact of vaccination during the first two years after introduction of the immunization program, 
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showed that in children eligible for PCV7 vaccination of less than 2 years of age, the VT–IPD incidence 
decreased by 90% (95% CI 68%–97%)104. Furthermore, the incidence of NVT–IPD simultaneously 
increased by 70% (p=0.12), resulting in an overall decrease in IPD of 44% (95% CI: 7–66%). No such 
evident changes in overall IPD incidence were found for other age–groups. However, in addition 
to a smaller increase in NVT–IPD in children eligible for vaccination, recent unpublished data also 
suggest occurrence of herd–immunity in unvaccinated cohorts105. However it should be noted that 
the share of meningitis may be over–represented in this study. 
 In the UK, PCV7 was recommended for use in risk groups of children less than 5 years of age in 
2002. In 2006, vaccination was introduced into the routine childhood immunization program using 
a 2+1 dose schedule for infants combined with a catch–up campaign for children up to 2 years of 
age. National surveillance results from the Health Protection Agency (HPA) in the UK show a major 
absolute reduction in the number of IPD reports due to VTs among children less than 2 years of age 
from approximately 330 cases in 2005 to 40 cases in 2008. This reduction, however, was immediately 
followed by IPD increase due to NVTs in the same period (from 120 cases to 270 cases). Similar 
effects are present and identified in the cohort of children aged 2–4 years. Indirect protection effects 
in persons aged over 5 years were also observed. However, increases in IPD due to NVTs seem to 
completely counterbalance the decrease in IPD cases due to VTs (see Supplementary Table 1 for 
specific details)53. 
 In Denmark, vaccination was introduced in 2007 with the application of a 2+1 dose schedule 
combined with a two dose catch–up schedule. One year after the introduction of the Danish 
immunization program, the overall IPD incidence decreased from 55 to 24 cases per 100,000 (IRR: 
0.43; 95% CI: 0.29–0.62) in children aged <2 years, whereas the incidence of VT–related disease 
decreased by 80% (IRR 0.20; 95% CI: 0.09–0.38)82. Furthermore, this study also observed a decrease 
in the overall disease incidence of approximately 10% (IRR: 0.90; 95% CI: 0.84–0.97) in the population 
older than 2 years of age. In addition, a tendency to an increasing incidence of IPD among children 
2–4 years of age was observed. 
 In Austria, PCV7 vaccination has been recommended since 2003, but as it was only reimbursed 
for children at increased risk the coverage remained low at approximately 25% in 2007. Probably 
owing to the low coverage, the IPD incidence rate was not significantly lower after implementation 
of the vaccine. Nevertheless, the incidence of meningitis decreased significantly from 3.1 to 1.6 per 
100,000 (p<0.05) children less than 5 years of age. Furthermore, no significant increases in NVTs 
disease were observed83. 
Comparison between countries & populations 
Similar to the large reduction in VT–IPD in the USA, large reductions in European countries with 
high vaccine uptake (e.g., the Netherlands, Norway, Germany and the UK) have been observed in 
vaccinated cohorts. Initially, increases in NVT–IPD in the USA were low and nonsignificant for children 
less than 2 years of age46. In 2004, a significant increase (20%; 95% CI: 10–40%) in overall NVT–IPD 
was observed for children aged less than 5 years of age66, while more recent data show much higher 







increases for the same age84. Nevertheless, the absolute magnitude of this increase in the USA is still 
relatively small compared with the corresponding decrease in VT disease. Increases in NVTs have 
been observed in some European countries in the first 2–3 years after vaccination. For example, in 
the UK, a country with a high vaccination coverage, the number of incident cases due to NVT–IPD 
more than doubled in individuals less than 5 years of age in the third year after the introduction 
of PCV781,82. Despite lower vaccination coverage, increases in NVTs were also observed in France, 
Spain and Portugal73,74,76,102. Conversely, in Norway, Denmark, Germany and Austria (a country with 
a low vaccination coverage) the incidence rate of NVT–IPD in vaccinated cohorts remained quite 
stable77,82,83,103. Thus, the reported effect on the incidence of NVT–IPD is largely different between 
countries, even in countries with comparable levels of vaccine uptake. These differences may be 
explained by other factors that will be discussed later. 
 Similarly to the vaccinated cohorts, initial herd–protection benefits were observed for 
unvaccinated cohorts in the USA without increases due to NVTs46. However, more recent studies 
do show increases in NVT–IPD. In particular, large increases were found among some high–risk 
populations44,45,63,66,84,88,106, however, for other high–risk populations such increases were limited64,65.
The differences observed between high–risk populations may be related to factors such as the use 
of antibiotics (discussed later). Data regarding the indirect effects for European countries are scarce. 
Only few studies report data on unvaccinated cohorts and data on the elderly are rarely available. In 
the Netherlands and Germany, significant changes in overall disease incidence among unvaccinated 
cohorts were not observed77,105. Data from the UK show a clear herd–effect for individuals greater 
than 5 years of age, which is however, completely counterbalanced by an increase in NVT–IPD53. 
Large increases in overall IPD in unvaccinated cohorts are reported for Spain74,97, while for France 
small overall increases were seen for meningitis73. Finally, significant overall IPD decreases are 
reported for Norway and Denmark82,103. In Norway this was accompanied with a significant increase 
in NVT–IPD among elderly individuals 65 years of age or older103.
Possible explanation for the observed differences in pneumococcal epidemiology across 
countries 
The differences in (in–)direct effects are probably due to a combination of different factors. First, the 
serotype coverage largely differs between countries. For example, in the USA serotype coverage 
before routine vaccination was high at approximately 82% for young children68. In European 
countries, the coverage before vaccination was much lower and varied between 56% and 82% for 
studies included in this article (see Table 1). Also, in adults the serotype coverage was higher in 
the USA (55%) compared with European countries (approximately 35%)18. Another major difference 
between most European countries and the USA is that in Europe mild IPD cases in children are 
treated outside the hospital without blood culturing, whereas blood culturing is routine practice 
for all children with high fever in the USA62,66. In children less than 2 years of age, the incidence of 
IPD was estimated in the USA at 170–190 cases per 100,00046,61,62 while for this same age group in 
European countries the incidence was much lower with a mean incidence of 27 cases per 100,000 
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(ranging from 11.3 to 93 per 100,00062. Interestingly, the incidence of meningitis is essentially similar 
with 7.5–10 cases per 100,000 in the USA44,46,61 and 7–11 cases per 100,000 in Europe61. In contrast to 
bacteremia without focus, significant increases in the USA were observed for bacteremic pneumonia 
and meningitis in both vaccinated children and unvaccinated adults45,84. As the majority of the IPD 
cases in European infants are represented by meningitis, bacteremic pneumonia and bacteremia 
with focus, the reduction in IPD incidence in children in European countries after vaccination is 
more likely to be similar to the reduction in incidence of these specific diseases rather than to the 
overall IPD disease burden in the USA (of which a large share is due to bacteremia without focus). 
However, increasing blood culturing practices in European countries can also artificially increase the 
apparent incidence of the disease (discussed later). 
 Other potential differences that may have led to observed effects are the vaccine uptake, 
differences in immunization schedules, antibiotic use (discussed later)107,108, epidemiological 
conditions63,109, differences in pneumococcal nasopharyngeal carriage rates and age of first 
acquisition of pneumococcal colonization (which is related to the proportion and age of children 
attending day care centers110 vaccination schedules used (3+1 or 2+1) and initial inclusion of 
a catch–up program. With (initially) low vaccine uptake, both the direct and indirect impact of 
vaccination can be expected to be limited at first. By contrast, indirect effects would be expected 
to appear earlier if a catch–up program was implemented. Epidemiological conditions such as 
crowding, low indoor air quality and the frequency of comorbid conditions (such as chronic lung 
disease or HIV) increases the risk of IPD and also appears to increase the level of replacement IPD 
(also discussed later)44,45,63,64,66,84,88,106. Furthermore, reduced dose schedules might be less efficient in 
eliciting adequate antibody levels to prevent carriage compared to a full 3+1 dose schedule50,54,59,111.
Limitations of comparisons & other factors influencing IPD epidemiology 
There are many caveats for comparing the impact of pneumococcal vaccination between countries. 
Besides the potential vaccine impact, increased surveillance, changing practice in antibiotic 
prescribing and secular trends may also have confounded observed changes in pneumococcal 
disease epidemiology. 
 First, installation or intensified surveillance systems might have led to an increase in the number 
of reported isolates each year. Indeed, some studies did observe a temporal trend in more frequent 
blood culturing, especially in cases of bacteremia without focus97,102. For example, Muñoz–Almagro 
et al. report in their study a 531% (95% CI: 151–1487) increase in the rate of IPD due to NVTs among 
children less than 2 years of age in Barcelona, Spain97, despite a relatively low vaccine coverage 
(36% in 2005 and 47% in 2007). Although the authors did not show a significant increase in blood 
culturing practice (which might be due to the lack of sufficient power to show this difference), the 
incidence of pneumococcal occult bacteremia among children less than 2 years of age increased 
from 14.5 to 21.4 episodes per 100,000 population. This increase contributed by a substantial 
proportion to the overall increase in IPD112. Increasing surveillance may also have influenced the 
results as presented on the website of the Health Protection Agency in the UK81. 







 Second, antibiotic pressure might have influenced the distribution of specific serotypes causing 
replacement disease. Increasing disease incidence by drug–resistant clones of serotype 19A in the 
postvaccination period was observed in almost all countries included in this article. Nevertheless, in 
the prevaccination period increases due to serotype 19A have also been observed for both invasive 
and noninvasive pneumococcal disease76,107,108,113. This could lead to the theory that emergence of 
serotype 19A would mainly be attributable to antibiotic pressure112. However, a recent Norwegian 
study shows no change in the incidence of IPD (whole population) caused by penicillin–
nonsusceptible pneumococci–serotype 19A, despite a significant increase in overall incidence of 
serotype 19A103. Although the numbers in this study are small, this trend supports the hypothesis 
that an increase in the incidence of serotype 19A can also be attributable to vaccination rather than 
due to antibiotic pressure alone. The difference between this study and studies showing an increase 
in the prevaccination area could be related to the low antibiotic consumption and subsequently 
the low prevalence of antimicrobial resistance of S. pneumoniae in Norway. Another recent study 
suggests that in children who suffered from an invasive pneumococcal infection, the number of 
PCV7 doses received before they developed the invasive infection is positively correlated with the 
isolation of a serotype 19A86. Also arguing towards the effect of vaccination, Moore et al. showed that 
the IPD incidence due to penicillin–resistant serotype 19A and penicillin–nonresistant serotype 19A 
both increased after the introduction of PCV7 in the USA87. Finally, a recent randomized controlled 
study showed a positive association between a 2+1 dose PCV7 schedule and nasopharyngeal 
acquisition of serotype 19A during the first 2 years of life114. 
 Thirdly, secular trends in the distribution of pneumococcal serotypes are known to occur over 
time115. For example, in the USA between 1928 and 1998 the proportion of pneumococcal infections 
caused by the serogroups included into the 7 valent conjugate vaccine increased in children from 
53% to 87% and in adults from 15% to 59%115. Furthermore, early observational studies after the 
routine introduction of PCV7 in the USA also found a decrease in the incidence of NVT diseases that 
are not likely to be related to the seven serotypes included into the conjugated vaccine during the 
post vaccination period45,46. 
 Finally, the distribution of pneumococcal serotypes can change as different strains pass through 
a community. For example, clones of serotype 1 have frequently spread rapidly within local, 
community and national levels. In particular, in the case of a relatively small population size or in 
cases where the study area is limited, single geographical area fluctuations can have a large impact 
on the outcome112. 
Most common serotypes & serotype–specific characteristics 
Despite substantial differences between countries, the most important NVTs causing disease after 
the introduction of routine infant PCV7 vaccination seem to be 19A, 7F, 3, 22F, 10A, 33F, and 1. In 
the USA, serotype 19A is the most common serotype in the postvaccination area. Also, in European 
countries, 19A is an important postvaccination serotype116-118. The possible impact of antibiotic 
pressure and vaccination regarding the increase in serotype 19A was discussed previously. However, 
Chapter 2
32
other factors could also have influenced its emergence66,87. First, after serotype 6A, 19A was the 
second most common NVT causing IPD in children in the USA before PCV7 introduction61. Second, 
serotype 19A might be more invasive compared with other NVTs80,119,120. Finally, VT pneumococci 
may acquire a 19A capsule in order to escape the effects of the vaccine, by means of capsular 
switching74,121. 
 A clinically relevant concern of serotype replacement relates to the fact that shifts in serotype 
distribution of IPD may be accompanied by a change in disease severity and burden–of–illness79. 
Several studies suggest that there may be an inverse correlation between the invasive disease 
potential associated with a specific serotype and the frequency of detection of the specific serotype 
in carriage. The latter potentially implies that the most invasive serotypes and serogroups were 
the least commonly carried, while the most frequently carried are least likely to cause invasive 
disease80,119,122. For example, Brueggemann et al. showed in a meta–analysis that the serotypes 1, 5, 
and 7 versus 14 were 60–fold more invasive versus those with the lowest odds ratio (serotypes 3, 6A, 
and 15 versus 14)122. Furthermore, recent studies suggest that clones with a higher invasive disease 
potential, behave as primary pathogens, being more likely to cause disease in healthy (younger) 
individuals79,123,124. In contrast to this, serotypes with a lower relative risk of causing invasive disease 
primarily affect patients with an underlying disease and, therefore, behave more like opportunistic 
pathogens79,123,124. Interestingly, serotypes with the highest disease potential tend to have smaller 
capsule size and seem to cause milder disease (lower case–fatality) compared with serotypes with a 
lower invasive disease potential, which even holds true after correction for underlying patient and 
disease characteristics79,123,124,124-126. These findings were, however, not supported by a recent (smaller) 
German study that showed the highest case–fatality for serotype 7F in children127. Furthermore, two 
other studies concluded that invasive serotypes as a group were not significantly associated with 
a higher mortality rate84,128. This does not, however, not exclude the possibility of an association 
between individual serotypes and disease severity. 
Impact on the cost–effectiveness & applicability to different countries 
Assumptions regarding both serotype replacement and herd–immunity effects have a very large 
impact on effectiveness and cost–effectiveness outcomes that are used to support healthcare 
decisions on immunization programs. In European countries one of the main drivers for decisions 
on the introduction of a childhood vaccination program against S. pneumoniae are effectiveness 
and cost–effectiveness outcomes. Most cost–effectiveness outcomes for pneumococcal vaccination 
programs were driven by the inclusion of indirect protection benefits in unvaccinated cohorts. 
These indirect protection benefits were generally assumed to be similar to those observed in the 
USA43,47. In this article, we show that there are large differences between and even within countries 
and/or populations. These differences might represent ‘real’ differences but might also be caused 
by aforementioned confounding factors. The large indirect benefits as observed in the USA have 
not (yet) been observed in European countries. This probably relates to several factors, of which the 
most important might be the lower serotype coverage. The difference in the overall IPD incidence in 







children is largely due to the apparent difference in bacteremia without focus. As previously argued 
by Jefferson et al., the incidence of bacteremia without focus might be more influenced by the 
number of blood cultures than the number of infections62. The issue is whether these undetected 
cases, which are now likely to be prevented by vaccination in countries that introduced the vaccine, 
have profound beneficial effects. Although in terms of morbidity, mortality and costs, bacteraemia 
without focus is reportedly less severe compared with meningitis or bacteremic pneumonia, the 
incidence is much higher in children less than 5 years of age. Owing to the higher incidence, the 
potential prevention of these cases might have a considerable impact on epidemiological and 
cost–effectiveness outcomes. Nevertheless, before this can be included there is a need for more 
data regarding the incidence and costs related to bacteremia without focus. Similarly, in general 
the severity and costs related to nonbacteremic community–acquired pneumonia (CAP) and 
AOM are less compared with IPD, however, the incidence of these noninvasive diseases is much 
higher. Therefore, nonbacteremic CAP and AOM are important drivers of cost–effectiveness of the 
PCVs. In particular, for routine infant vaccination programs, the estimated efficacy against AOM 
is an important cost–effectiveness driver43, whereas the incidence and vaccine efficacy against 
nonbacteremic CAP has been shown to be one of the main cost–effectiveness drivers for a potential 
pneumococcal vaccine in the elderly129.
 New, increased valency vaccines are now available, which might limit the impact of the increase 
in serotype replacement due to increased serotype coverage of these new vaccines, at least during 
the first years after implementation. Before making a decision regarding the implementation of 
these new vaccines, most countries will again require new cost–effectiveness estimates. Taking into 
account the large differences observed between and even within countries, (cost–) effectiveness 
studies should be performed using country–specific epidemiological data. However, one also 
needs to be aware of the limitations that such country specific data might have, in particular 
observed trends in IPD might be biased by increased surveillance. If these country specific data 
are lacking, assumptions should be based on data from countries with similar epidemiology (e.g., 
serotype distribution) and other comparable characteristics (e.g., expected vaccine coverage and 
immunization program in terms of schedule and catch–up). All (cost–) effectiveness results should 
be interpreted in light of the country–specific disease epidemiology and with consideration of the 
effects of vaccination strategies that are per definition not directly generalizable between countries 
and can as such not be used for health policy decisions. 
DISCUSSION
Expert commentary 
Since its registration a decade ago, conjugated pneumococcal vaccines have been implemented 
in national pediatric immunization programs in more than 40 countries in both full (4–dose) and 
reduced 3–dose schedules. Despite its huge proven beneficial impact on VT–IPD reduction among 
infants, currently, a more extended and wider implementation is hindered by the observed changes 
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in pneumococcal epidemiology that are not yet fully understood. From a health–economical 
point of view, we have shown that major drivers of the economical benefits determining the 
cost–effectiveness of a pneumococcal vaccination program are the etiological fraction of the 
pneumococcal serotypes causing IPD covered by the vaccine versus those not covered by the 
vaccine, and the vaccine’s impact on these fractions in the vaccinated individual and on the 
transmission to other nonvaccinated populations. Post–marketing studies as presented in this article 
have clearly shown large differences in bacteremic pneumococcal epidemiology between the USA 
and Europe, but also between European countries and even regions within countries. Although 
the possible explanations might range from annual fluctuations to the antibiotic pressure and 
vaccination schedules implemented, it is clear that such incomparability renders one–size–for–all 
cost–effectiveness studies invalid. In our view, policy makers should therefore value the installation 
of valid surveillance systems to monitor the pneumococcal epidemiology and use their national 
data to best tailor the input for a cost–effectiveness model to their needs. 
Five–year view 
As only a limited amount of countries have introduced a national infant or childhood immunization 
program against pneumococcal disease, in the upcoming years many of the remaining countries 
are expected to introduce such programs. Countries that have not yet introduced any immunization 
program against S. pneumoniae can now choose from multiple vaccines, while countries that 
already introduced PCV7 previously should make a decision on whether or not to switch to vaccines 
of increased valency. Aside from the impact on the disease epidemiology, switching to one of the 
more valent vaccines might also have an impact on the infant pneumococcal vaccination schedule.
In the future, countries may not only need to make a decision on infant pneumococcal vaccination 
strategies but might also consider vaccination of the elderly with a pneumococcal conjugated 
vaccine; currently, the 13–valent pneumococcal vaccine is being evaluated for use in these elderly 
individuals. Although extension of the serotype coverage of the 10– and 13–valent vaccines might 
reduce the potential for disease caused by NVTs in both children and the elderly, it can still be expected 
that serotypes not included in the vaccine will emerge in time. Considering the immunogenicity 
issues, adding more serotypes to the conjugated vaccines seems impractical. Therefore, it might be 
necessary, depending on the level of serotype replacement, to revise the composition of the protein 
conjugated vaccines in the future. A next–generation pneumococcal vaccine, targeting conserved 
pneumococcal protein antigens that are found in all pneumococcal organisms rather than single 
serotypes, may overcome the problems of serotype replacement by targeting all pneumococcal 
organisms130. In the meantime it is important to continue IPD surveillance in order to identify the 
emergence of new relevant strains to direct the formulation of future conjugated vaccines. 
Supplementary data 
Supplementary data associated with this article can be found at: 
http://www.expert–reviews.com/doi/suppl/10.1586/erv.10.163







Financial & competing interests disclosure 
MHR was funded by an unrestricted grant from Wyeth (now part of Pfizer Inc.). CB received an unrestricted grant 
from GlaxoSmithKline. All authors received grants and/or honoraria from various vaccine producers, inclusive 
of both pneumococcal vaccines. The authors have no other relevant affiliations or financial involvement with 
any organization or entity with a financial interest in or financial conflict with the subject matter or materials 
discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, 
expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the 
production of this manuscript.
3




Several recently published European cost–effectiveness studies on the 7–valent pneumococcal 
conjugate vaccine (PCV7: Prevnar®) have included net–indirect vaccine benefits for non–vaccine 
protected groups into their studies, which might be too optimistic an approach given recent data. 
Net–indirect effects result from herd protection minus serotype replacement effects. In this study 
we analyze the impact of net–indirect effects in non–vaccine protected groups of 5 years of age and 
older with updated assumptions regarding epidemiologic data and health care unit costs. Without 
net–indirect benefits for non–vaccine protected groups included the cost–effectiveness ratio is 
estimated at €72,360 per QALY. In order to obtain cost–effectiveness ratios below the threshold of 
€50,000 per QALY – which is in the middle of the range that is often referred to in the Netherlands – 
the net–indirect protective effect should at least be 16% of which has been observed in the USA 
after the introduction of PCV7.








Several recently published European cost–effectiveness studies on the 7–valent pneumococcal 
conjugate vaccine (PCV7; Prevnar®) have included net–indirect vaccine benefits for non–vaccine 
protected groups in their analyses (indirect effects)131-134. Net–indirect effects result from herd 
protection minus serotype replacement effects. Net–indirect benefits were often extrapolated 
based on a specific observational study from the USA, after the introduction of PCV746. In particular, 
herd protection effects vastly outweighed any serotype replacements taking place. Inclusion of 
these indirect effects in elderly resulted in favourable cost–effectiveness ratios (CERs)133,134, or even 
in cost savings131,132. However, three years after the introduction of routine vaccination there is no 
overall reduction in IPD incidence observed in adults in any European country including Spain, 
France, and the UK73,81,97. This might be due to an increase in non–vaccine serotypes – offsetting 
the potential herd protection benefits – or due to that fact that only a few birth cohorts have been 
vaccinated yet, which might not be enough to reduce the transmission of disease in the community 
sufficiently. In this brief report, we show the impact of the inclusion of indirect effects in the cost–
effectiveness model and estimate the level of net–positive indirect effects needed (as a percentage 
of that observed in the USA) in order to label routine infant vaccination as cost–effective.
METHODS
Our static cohort model builds on our previously reported studies133,135. It was updated to include 
recent epidemiologic and resource use data79. For invasive pneumococcal disease (IPD: meningitis 
and bacteraemia), age–specific data regarding baseline disease risk, duration of hospitalization, 
case–fatality rates and the occurrence of sequelae were taken from a recently published Dutch 
study79. In our model it was assumed that sequelae could lead to neurological problems requiring 
life–time institutionalized care or lifetime special educations and to hearing problems, with 
corresponding high costs involved.
 National hospital and GP–registrations were used to estimate the age–specific incidences for 
acute otitis media (AOM) and community–acquired pneumonia (CAP). Both CAPs to be treated in 
GP–practices and CAPs requiring hospitalization were estimated separately as was done previously 
as well135.
 Vaccine efficacy for IPD was estimated at 97,4% for 7 serotypes included into the vaccine IPD, 
11.1% for hospitalized CAP, 6% for CAP treated by the GP and 7% against AOM, based on the Kaiser 
trial25,136,137. PCV7 was assumed to be effective after two doses of vaccination for the birth cohort 
analyzed (180,000 infants; corresponding to the size of the Dutch birth cohort). As the aim of this 
paper was to show the indirect effects in unvaccinated individuals due to routine vaccination of 
children we excluded serotype placement and herd protection effects for the followed cohort. The 
time horizon of our cohort analysis was 5 years, which justifies the use of a stable vaccine efficacy for 
IPD. For non–invasive disease it was conservatively assumed that children would be protected up to 
the second year of life138.
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 Indirect effects for those outside the vaccine–protected cohort were implemented in a sub–
module using straightforward proportional calculus on registered numbers of IPDs79. Three studies 
present data on the net–indirect effects (herd protection benefits minus serotype replacement) on 
IPD among non–vaccinated groups in the USA44-46. The most recent study was performed by Hsu et 
al., focussing solely on meningitis for all age groups44. In another study, detailed information was 
available on IPD for citizens aged 50 years and over45. Finally, a study performed by Whitney et al. 
describes the net–indirect effects on an aggregated level for all IPD together, but does present data 
from the age 20 and onwards46. The net–indirect effects assumed in our study for those outside 
the followed cohort (i.e., individuals aged 5 years and older) were based on Hsu et al. regarding 
meningitis, for all other IPD the findings of Whitney et al. were used for those aged 5–50 years 
(assuming that the effects in children aged 5–19 years are similar to those observed in individuals 
aged 20–40 years) and those by Lexau et al.45 for the age groups of 50 years and over. 
Table 1. Assumptions on the direct effects of PCV7 for the vaccinated cohort (those aged less than 5 years) 
and the indirect effect on those outside vaccine–protected cohort (those aged 5 years and older). Negative 
percentages indicate direct (those aged less than 5 years) or herd protection effects (those aged 5 years and 
older), positive percentages indicate serotype replacement (those aged 5 years and older).
Age category 0–4 5–17 18–39 40–64 65+ 
Meningitis
PCV7 serotypes -97% -8% -69% -62% -67%
PCV7 related typesa NA 0% -52% 39% -66%
Other types NA 1% 76% 68% -37%
Net–overall effect meningitisb -97% -2% -1% 6% -53%
Age category 0-4 5-19 20-39 40-49 50+
Invasive Pneumonia
PCV7 -97% -40% -40% -14% -48%
PCV7 related serotypesc/23PPVd NA -22% -22% -4% 11%
Other types NA -20% -20% -1% 26%
Net–overall effect pneumoniab 97% -29% -27% -4% -15%
Age category 0-4 5-19 20-39 40-49 50+
Bacteraemia
PCV7 -97% -40% -40% -14% -77%
PCV7 related serotypesc/23PPVd NA -22% -22% -4% -36%
Other types NA -20% -20% -1% -29%
Net–overall effect bacteraemiab -97% -29% -27% -4% -54%
a. Related serotypes for meningitis based on Hsu et al. 6A, 9A, 9L, 9N, 18A, 18B, 18F, 19B, 19C, 23A, 23B44.
b. Overall change after correction for Dutch serotype specific incidence data79.
c. Related serotypes for invasive pneumonia and bacteraemia for individuals aged less than 50 years based on Whitney et al. 6A, 
9A, 9L, 9N,18A,18B,18F,19A,19B,19C, 23A, and 23B46.
d. The 16 serotypes not included the PCV7 but yet in the 23–valent pneumococcal polyssacharide vaccine (1, 2, 3, 5, 7F, 8, 9N, 
10A, 11A, 12F, 15B, 17F, 19A, 20, 22F, and 33F) for those aged 50 years and older and all other types based on Lexau et al.45.
NA: Not Applicable







Table 1 summarizes the assumptions on the net–indirect effects. In this Table negative percentages 
indicate a relative decrease in the disease incidence and positive percentages indicate an increase 
(as compared to the pre–vaccination incidence; 2004–2006). To be conservative, when net–indirect 
effects are included we only assumed loss of utility and costs due to hospitalized IPD, so utility losses 
and costs related to sequelae were excluded. Also, we did not include net–indirect effects for non–
invasive pneumococcal disease due to lack of data on this issue.
 The main outcome measures were life years, quality–adjusted life years (QALYs) and costs. QALYs 
for IPD and non–invasive infections were taken from Melegaro et al.139, sequelae related utilities 
were based on two specific studies140,141. The analysis was performed from a societal perspective 
including both direct medical and indirect non–medical costs of production losses (measured 
using the friction cost method), all updated to 2008135,142. The costs of vaccination were assumed 
at €50 per dose including administration costs, which reflects the current price of PCV7 in the 
Dutch vaccination program. Given 3+1 dose schedule applied in the Netherlands, pneumococcal 
vaccination would cost €200 per infant. According to the Dutch guidelines, effects and cost were 
discounted at 1.5% and 4%, respectively142.
RESULTS
Without net–indirect effects being incorporated in the model, PCV7 is estimated to prevent 5778 
cases of non–invasive disease and 128 cases of invasive disease in the followed birth cohort over 
a period of 5 years, corresponding to a total gain of 292 life years or 422 QALYs. The total cost of 
vaccination is estimated at €34.2 million. Subtracting the cost savings on medical and non–medical 
costs from these vaccination costs, resulted in a net total cost of €30.6 million. Dividing the net cost 
by the number of QALYs or life years saved resulted in CERs of approximately €72,360 per QALY or 

























Figure 1. The cost–effectiveness ratio per QALY of as a function of varying the level of net–indirect effects 




We estimated that without the inclusion of net–indirect effects vaccination with a 4–dose schedule 
would approximately costs €72,360 per QALY gained or €104,790 life–year gained. Full inclusion of 
indirect effects would lower these cost–effectiveness ratios to €16,750 and €18,360 per QALY and 
life year, respectively.
 In the Netherlands, CERs above €80,000 certainly reflect unfavourable cost–effectiveness. 
Indeed 80,000 have been explicitly mentioned in this respect143. One other cut–off point that has 
been mentioned for the Dutch situation is €20,000 per life–year gained144. Certainly, CERs of less 
than €20,000 per life–year gained are considered favorable in the Netherlands. One might infer from 
these two cut–off points that assuming an implicit threshold of €50,000 per QALY in the Netherlands 
are not unreasonable.
In order obtain a CER for PCV7 below the implicit Dutch threshold of €50,000 per QALY, the net–
overall indirect effects should at least be 16% of those observed in the USA and above (as specified 
in Table 1)44-46. At this moment no overall decrease in the incidence in IPD incidence among those 
of 5 years older in any European country has been observed and it is obviously uncertain if this will 
happen in the future73,81,97. So at this moment it is uncertain if the Dutch PCV7 programme will be 
cost–effective in the future or not.
 We conclude that the exact assumption applied to indirect effects hugely determine cost–
effectiveness estimates for PCV7 vaccination. Future work should concentrate on explicitly 
modelling these indirect effects preferably using dynamic models which might be difficult due to 
the large number of relevant serotypes.
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Objectives: To update cost effectiveness estimates for the four dose (3+1) schedule of the seven 
valent pneumococcal conjugated vaccine (PCV7) in the Netherlands and to explore the impact 
on cost effectiveness of reduced dose schedules and implementation of 10 valent and 13 valent 
pneumococcal vaccines (PCV10 and PCV13).
Design: Economic evaluation comparing PCV7, PCV10, and PCV13 with no vaccination using a 
decision tree analytic model built from data in previous studies.
Setting: The Netherlands.
Population: A cohort of 180,000 newborns followed until 5 years of age. 
Main outcome measures: Costs; gains in life years and quality adjusted life years (QALYs); and 
incremental cost effectiveness ratios.
Results: Under base case assumptions—that is, assuming a five year protective period of the 
vaccine and no assumed net indirect effects (herd protection minus serotype replacement) among 
children aged over 5 years—vaccination with PVC–7 in a four dose (3+1) schedule was estimated 
to prevent 71 and 5778 cases of invasive and non–invasive pneumococcal disease, respectively, in 
children aged up to 5 years. This corresponds with a total net gain of 173 life years or 277 QALYs. 
The incremental cost effectiveness ratio of PCV7 was estimated at €113,891 (£98,300; $145,000) per 
QALY, well over the ratio of €50,000 per QALY required for PCV7 to be regarded as potentially cost 
effective. A three dose (2+1) schedule of PCV7 reduced the incremental cost effectiveness ratio to 
€82,975 per QALY. For various assumptions and including 10% of the maximum net indirect effects 
among individuals aged 5 years and over, PCV10 and PCV13 had incremental cost effectiveness 
ratios ranging from €31,250 to €52,947 per QALY.
Conclusions: The current Dutch infant vaccination programme of four doses of PCV7 is not cost 
effective because of increases in invasive disease caused by non–vaccine serotypes, which reduces 
the overall direct effects of vaccination and offsets potential positive herd protection benefits in 
unvaccinated individuals. The 10 valent and 13 valent pneumococcal vaccines could have better 
net health benefits than PCV7 through less replacement disease and increased herd protection. 
Both these effects could substantially reduce the incremental cost effectiveness ratio to possibly 
acceptable levels, if total programme costs can be lowered by reduced schedules, reductions in 
vaccine prices, or both.








Given the multitude of new vaccines available for introduction into national immunisation 
programmes, health economic modelling of various immunisation plans is becoming increasingly 
important in informing decisions on health policy. The decision to introduce the seven valent 
pneumococcal conjugated vaccine (PCV7) into the Dutch national immunisation programme for 
infants, for example, has in part been driven by cost effectiveness considerations11. The Dutch Health 
Council estimated the incremental cost effectiveness ratio of vaccination with PCV7 compared with 
no vaccination at €70,000 (£60,300; $89,200) and less than €20,000 per quality adjusted life year 
(QALY) in 2001 and 2005, respectively11. Crucial factors responsible for the change from a potentially 
unfavourable cost effectiveness ratio in 2001, exceeding €50,000 per QALY, to a favourable ratio 
in 2005 were the inclusion of data on observed herd protection effects in adults after nationwide 
implementation of PCV7 in the USA in 2000 and limited disease development caused by 
pneumococcal serotypes not present in PCV7 replacing pneumococcal serotypes eliminated by the 
vaccine (replacement disease)44-46.
 Next to direct effects on invasive disease in vaccinees, expected savings from herd protection 
were also part of health economic studies in other European countries that introduced PCV7 into 
their national immunisation programmes131-134,139,145. Both the four dose (3+1) vaccine schedule 
and the reduced three dose (2+1) schedule, as implemented in Norway and the UK78,81, are highly 
effective against invasive pneumococcal disease caused by vaccine serotypes. However, the 
net overall benefit of national immunisation programmes in many European countries has been 
reduced by increases in invasive disease caused by non–vaccine serotypes73,81,97,104. Importantly, in 
the first 18–30 months after the introduction of PCV7 in the Netherlands, France, and the UK, no 
overall reduction in invasive disease in non–vaccinees was observed73,81,104. 
 Given that both increases in invasive disease caused by non–vaccine serotypes and absence 
of herd protection may considerably affect the cost effectiveness of the current Dutch vaccination 
programme, we set out to update cost effectiveness estimates for the current four dose schedule 
of PCV7 by using recent data on epidemiology and resource use. Also, we investigate the cost 
effectiveness of reduced dose schedules and vaccine price reductions combined with the 
implementation of 10 valent and 13 valent pneumococcal vaccines (PCV10 and PCV13). 
METHODS
Model
We designed a decision tree analytic model structure that builds on our previously reported 
model133,135. Various data sources were used to populate our model; these included clinical trials 
and observational studies for effectiveness of pneumococcal vaccines, laboratory data for incidence 
and serotype distributions of pneumococcal disease, and registrations for resource use and costs. 
Figure 1 shows the disease model for the health effects of pneumococcal vaccination, including 
the possibility of subsequent pneumococcal disease such as non–invasive pneumonia, otitis media, 
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and invasive pneumococcal disease. Assumptions regarding both costs and quality of life are 
summarised in Table 1 and are more thoroughly discussed in  Appendix 1. In the analyses, a cohort 
of 180,000 newborns, representing the Dutch birth cohort, was run through the decision tree twice: 
once as a mainly vaccinated cohort (PCV7/PCV10/PCV13); and once as an unvaccinated cohort. The 
analytic time frame of the study was five years because vaccine effectiveness could not be assumed 
beyond five years. However, long term effects of invasive pneumococcal disease were extrapolated 
over the full lifetime of the individuals in the cohort (that is, until death or 100 years).
Table 1.  Parameters used in the economic model.
Mean or range Distribution References
vaccine Efficacy
IPD (all vaccine serotypes) 97.4% Lognormal (SD 0.044) 25
CAP (hospitalized) 11.1% Lognormal (SD 0.082) 136
CAP (general practitioner) 6.0% Lognormal (SD 0.032) 136
Acute otitis media 7.0% Lognormal (SD 0.011) 137
Case–fatality ratio (birth cohort)
Meningitis 9% Beta (3,32) 79
Pneumonia 0% N/A 79
Bacteraemia with focus 0% N/A 79
Bacteraemia without focus 9% Beta (2,21) 79
Respiratory infections 0% N/A Assumed
Case–fatality ratio (5 years and older)
Meningitis 9%–92% Beta (age dependent) 79
Pneumonia 0%–29% Beta (age dependent) 79
Bacteraemia with focus 0%–33% Beta (age dependent) 79
Bacteraemia without focus 9%–67% Beta (age dependent) 79
Respiratory infections 0% N/A Assumed
Direct costs (€)
Bacteraemiaa 1,091–27,318 Triangular (age dependent) 79,142
CAP 26–2,614 Triangular (severity dependent) 135,142,148
AOM 17–381 Triangular (severity dependent) 135,142,148
Special education (annual costs) 9,798–16,962 Triangular (age dependent) 135
Institutional care (annual costs) 39,583 Triangular (29,687; 39,583; 49,478) 142
Cochlear implantation 56,633 Triangular (42,475; 56,633; 70,792) 149







Table 1.  Parameters used in the economic model. (Continued)
Mean or range Distribution References
Indirect costs in (€)
IPDb 0–974 Triangular (severity dependent) 79,142
Non–invasive pneumonia (hospitalized)c 0–2529 Triangular (severity dependent) 79,142
Non–invasive pneumonia (general practitioner)b 115–315 Triangular (severity dependent) 135,142
AOMb 58–23 Triangular (severity dependent) 135,142
Total QALy detriment
Disabilityd 0.53 Beta (estimated) 140
bilateral hearing loss (first year)d 0.45 Beta (estimated) 139,141
Bilateral hearing loss cochlear deviced 0.18 Beta (estimated) 139,141
All other hearing lossd 0.09 Beta (estimated) 140
Hospitalized bacteraemiaf 0.0079 Beta (estimated) 139,150
Hospitalized meningitisf 0.0232 Beta (estimated) 139,150
Hospitalized CAPf 0.006 Triangular (0.001 ,0.006,0.01) 139
CAP treated at the general practitionerc 0.004 Triangular (0, 0.004,0.01) 139
AOMf 0.005 Triangular (0, 0.005,0.01) 139
Other parameters
Increase in non–vaccine serotype IPDg 100% Triangular (50%, 100%, 150%) 81,151f
Net–indirect effect for PCV10 and PCV13h 10% Triangular (0%, 10%, 30%) Assumedg
Discount rate health effects 1.5% N/A 152
Discount rate costs 4% N/A 152
a. Based on the average duration hospitalization (both IC and general hospitalisation days) and corresponding unit costs142. See 
also Appendix Table B for age specific hospitalisation costs
b. Indirect costs due to work loss of parents taking care of their children.
c. Indirect costs due to work loss of patient unable to work due to hospitalization. 
d. Per year.
e. Same QALY decrement was assumed for invasive pneumonia, bacteraemia with another focus and bacteraemia without a 
focus.
f. Per case.
g. See also Appendix 2 Indirect effects in the analysed birth cohort.
h. See also Appendix 3. Indirect effects for those aged 5 years and older. 
PCV7/10/13= 7/10/13–valent pneumococcal conjugated vaccine; IPD= invasive pneumococcal disease; AOM= acute otitis 
media.
Baseline disease risks
Surveillance data on the incidence and serotype distribution of invasive pneumococcal disease 
before national implementation of PCV7 were available for the period 2004–2006, including data on 
age, primary focus of infection, resource use, hospital admission, and outcome79,146. The case–fatality 
rate for meningitis and bacteraemia without focus in children was estimated to be 9% (Table 1)135, 
which is in line with the international literature131,139,147. Invasive pneumonia and bacteraemia with 
focus were assumed not to result in death in children135. 
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No vaccination  [+] 
Policy
Figure 1. Decision tree used in conjunction with the cohort of 180,000 newborns. The “No vaccination” arm is a 
clone of the “Vaccination of all healthy infants” arm (as represented by the + sign; risk differ between both arms). 
IPD= invasive pneumococcal disease.
 In our model, severe mental and physical handicap resulting from meningitis was assumed to 
occur in 13% of cases of pneumococcal meningitis in children, of which 50% would require special 
education and 25% intensive “round the clock” institutional care133. Jansen et al. found that hearing 
problems occurred in 32% of cases of meningitis, of which 50% were serious enough to require a 
cochlear hearing device135. Baseline risks for non–invasive pneumonia requiring hospital admission 
and for non–invasive pneumonia and acute otitis media treated in general practitioner practices 
were estimated from national hospital and general practitioner records, respectively (see Appendix 
Table A).
vaccine efficacies
Vaccine efficacy against invasive pneumococcal disease was assumed at 97.4% after two doses for 
all seven serotypes of pneumococcal disease covered by PCV7 (Table 1)25. This value seems to be 
a conservative estimate if one takes into account the fact that only one vaccine failure has been 
reported in the Netherlands in the first two years after introduction of routine infant vaccination in 
June 2006. Routine vaccination for infants in a 2+1 dose schedule was introduced in Norway in 2006, 
and similarly no vaccine failures had occurred up to June 200878,136. Protection against invasive disease 
was thus estimated to last for five years in the base case analysis136,153. Furthermore, in randomised 
controlled settings, the vaccine was shown to be effective against non–invasive pneumonia and 
otitis media in children136,137,154. For non–invasive pneumonia, efficacy of pneumococcal vaccination 
seems to increase with diagnostic certainty136.







 In our model, we applied the efficacy estimate of 11.1% for “clinical pneumonia and perihilar 
findings” to children admitted to hospital with the diagnosis of pneumonia in the Netherlands136.
This definition of pneumonia seems to best fit the types of pneumonias treated in Dutch hospitals. 
An efficacy of 6.0% was assumed for patients who visited a general practitioner and were diagnosed 
with pneumonia136. In two randomised studies, PCV7 was found to prevent 6.4% to 7.0% of all cases 
of acute otitis media136,136,155. The interpretation of these studies for the Dutch setting is hampered 
by several factors, including the fact that the causal micro–organism is not recorded in cases of 
otitis media in the Netherlands. In our model, we used an overall efficacy estimate of 7.0% for otitis 
media on the basis of the most recent data from the Kaiser Permanente trial137. Given evidence 
for the duration of protection against non–invasive pneumonia and recent US surveillance data, 
we assumed that vaccinated children were protected against non–invasive pneumonia and otitis 
media up to their second year of life, starting after the second dose of the vaccine79,138,154. 
 A vaccine efficacy of 97.4% against all serotypes included was assumed for PCV10 and PCV13, 
similar to the assumed efficacy of PCV7. In the absence of clinical data on the efficacy of PCV10 
and PCV13 against non–invasive pneumonia and acute otitis media, the efficacy of these two 
vaccines was assumed to increase proportionally with the increase in serotype coverage for invasive 
pneumococcal disease.
Indirect effects
As well as estimations of the direct effects, we also estimated indirect effects of vaccination in our 
model. We included in our base case analysis herd protection against invasive pneumococcal disease 
for children in the birth cohort not yet fully protected by the vaccine and for non–vaccinated children, 
assuming this protection would be as effective as vaccination (Table 2)81,104. We also increased the 
incidence of invasive pneumococcal disease caused by non–vaccine serotypes to 100% for the 
analysed birth cohort (that is, we doubled the incidence of invasive pneumococcal disease caused 
by non–vaccine serotypes) on the basis of surveillance data from early after national introduction 
of PCV7 in the Netherlands and the UK81,104. See Appendix 2 for a more in depth description of the 
assumptions for our estimation of indirect effects in the birth cohort.
 No serotype information for acute otitis media and non–invasive pneumonia is available in the 
Netherlands, and serotype replacement for these diseases may be assumed to be already included 
in the vaccine efficacy estimates in the first efficacy studies136,137,154. Therefore, we did not include an 
additional increase of non–vaccine serotype disease but also left out potential herd effects for otitis 
media and non–invasive pneumonia (see Appendix 2).
 We assumed in our base case analysis for PCV7 that no net indirect effect would exist for 
individuals outside the modelled cohort. This assumption was made because no reduction in the 
incidence of invasive pneumococcal disease has been observed after the introduction of routine 
vaccination with PCV7 for individuals 5 years of age or older and because the observed herd 
protection effect in the UK in the third year after introducing routine vaccination was completely 
countered by a rise in invasive pneumococcal disease caused by non–vaccine serotypes81. In this 
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respect, net indirect effects are defined as cases of invasive disease averted by herd protection 
minus invasive cases of replacement disease. 
Table 2. Serotype coverage and efficacy for direct effects and assumptions on indirect effects for the analysed 
birth cohort and the remaining population (those aged 5 years or older) for PCV7, PCV10, and PCV13
PCV7 PCV10 PCV13
Serotypes covered 4, 6B, 9V, 14, 18C, 19F, 23F + 1, 5, 7F + 3, 6A, 19A
Increase in IPD caused by non–vaccine serotypes in the 
analysed birth cohort (serotype replacement)
100% 100% 100%
Efficacy and level of herd protection against vaccine 
serotypes of IPD in the analysed birth cohorta
97.4% 97.4% 97.4%
Net–indirect effect in the remaining populationb 0% 10% 10%
a.  Herd protection was assumed for the entire birth cohort including those not yet (fully) protected by the vaccine (either too 
young to be vaccinated or those who received only a single dose of the vaccine) and non–vaccinated children (5% of a birth 
cohort for the Dutch situation) assuming a protection effect of 97,4% against vaccine serotype similar to the vaccine efficacy. 
b. Net–indirect benefits are defined as the benefits due to protection against invasive pneumococcal disease caused by vaccine 
serotypes minus the increase of invasive pneumococcal disease due to non–vaccine serotype. 
PCV7/10/13= 7/10/13–valent pneumococcal conjugated vaccine.
Net indirect effects may occur in the future, especially if serotype coverage is extended by a change 
from seven serotype vaccines to vaccines with broader serotype coverage79,104. Therefore, in the 
base case analysis for PCV10 and PCV13, a net indirect effect for invasive disease at 10% of the 
potential maximum was applied for those aged 5 years or older (see Appendix 3). In particular, the 
potential maximum was defined as prevention of all cases of invasive disease caused by serotypes in 
the vaccine and absence of any replacement disease. Net protective indirect benefits against otitis 
media and non–invasive pneumonia were not included in any of the analyses138. Given that there is 
much uncertainty about the development of indirect effects, these assumptions were varied over a 
wide range in the sensitivity analyses.
Outcome measures and cost effectiveness analysis
The simulation model tracks all the specific disease cases and the deaths, costs, changes in QALYs 
and life years, and indirect effects (herd protection and serotype replacement). We were able to 
determine the net costs and net life years and QALYs gained by summing all the costs, life years, 
and QALYs and calculating the differences for the evaluations with and without vaccination. The 
incremental cost effectiveness ratio was calculated by dividing the net costs by either life years or 
QALYs. Health effects and cost were discounted at 1.5% and 4% for time preference, respectively, 
according to the Dutch guidelines for cost effectiveness research152.
 Incremental cost effectiveness ratios for routine vaccination were calculated by comparing 
different vaccination schedules against no vaccination. Following recently published evidence 
on the efficacy of PCV7 in reduced dose schedules28,50, we investigated the effect of a three 
dose schedule (that is, 2+1) to test the effect of lower total vaccination costs (see  Appendix 4). 







We also forecasted the incremental cost effectiveness of potential shifts from PCV7 to pneumococ-
cal vaccines that include additional serotypes (that is, PCV10 and PCV13). 
 For PCV7, the estimated current cost of €50 per dose within the Dutch national immunisation 
programme was used133,135. For PCV13, the officially listed price of €68.56 was applied, with 
administration costs of €5.95 being added (total cost per dose €74.51)135. For PCV10, no officially 
listed price is available in the Netherlands. Given that we know the pricing of PCV10 in other 
countries is pessimistic compared with PCV13, we assumed the total cost per dose of PCV10 at the 
midpoint between PCV7 and PCV13 (that is, €62.25)156.
Scenario and sensitivity analyses
We performed univariate, threshold, scenario, and probabilistic sensitivity analyses. In the univariate 
sensitivity analyses, all relevant parameters were varied by 25% to explore the impact of each 
parameter relative to each other. One specific threshold analysis was performed in which the effect 
of the parameter on the incremental cost effectiveness ratio was investigated by varying the net 
indirect effects on individuals aged 5 years or older over a range of 0% to 30%. For the probabilistic 
sensitivity analyses, parameters were generated using Monte Carlo sampling, with outcome values 
generated by running the model 5000 times. Log normal, beta, and triangular distributions were 
used except for multinomial probabilities, where Dirichlet distributions were assumed (see Table 1 
for specific distributions).
RESULTS
Cost effectiveness of PCv7
In the base case analysis, the estimated burden of pneumococcal infection for a birth cohort followed 
for five years was 170,788 cases of acute otitis media and 19,385 cases of non–invasive pneumonia, of 
which 2645 cases would result in hospital admission (Table 3). Applying the base case assumptions, 
5372 cases of acute otitis media and 406 cases of non–invasive pneumonia would be prevented by 
vaccination with PCV7, corresponding to gains of 27 and 2 QALYs, respectively. Additionally, 188 
cases of invasive pneumococcal disease a year were estimated in children under 5 years of age: 
65 cases of meningitis; 45 cases of invasive pneumococcal disease; 38 cases of bacteraemia with 
focus; and 40 cases of bacteraemia without focus. In total, 71 cases of invasive disease would be 
prevented by vaccination with PCV7, corresponding to a total gain of 173 life years or 248 QALYs. In 
addition to the health gains, vaccination with PCV7 would also prevent approximately €2.2 million 
of direct costs and €0.4 million of indirect costs. Assuming a four dose schedule, the annual cost of 
vaccination is estimated at €34.2 million. Dividing the incremental costs by the incremental health 
benefits results in an incremental cost effectiveness ratio of €113,891 per QALY gained for PCV7. An 
incremental cost effectiveness ratio of less than €50,000 per QALY would be required for PCV7 to 
be regarded as potentially cost effective. Shifting from a 3+1 dose schedule to a 2+1 regimen could 
improve cost effectiveness of PCV7 to €82,975 per QALY (Table 4).
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No vaccination 170,788 19,385 188 2410 NA
PCV7 165,416 18,979 117 210 NA
PCV10 164,664 18,922 80 2260 NA
PCV13 163,912 18,865 38 2229 NA
Cases averted
PCV7 5372 406 71 0 NA
PCV10 6124 463 108 150 NA
PCV13 6876 520 150 181 NA
QALys gained
PCV7 27 2 248 0 277
PCV10 30 2 361 314 707
PCV13 34 2 470 384 891
Life years gained
PCV7 0 0 173 0 173
PCV10 0 0 255 312 566
PCV13 0 0 336 381 717
Direct savings (€ 1000s), excluding vaccination costs
PCV7 126 375 1,725  0 2226
PCV10 144 427 2,454 1398 4422
PCV13 161 479 3,181 1696 5518
Indirect savings (€ 1000s)
PCV7 320 74 46 0 440
PCV10 365 84 67 161 677
PCV13 410 94 93 202 799
a. Only net indirect effects against invasive pneumococcal disease were included in the model for individuals aged 5 years or 
older. For PCV7, no net indirect effects were included for individuals aged 5 years or older in the base case analysis.
NA= Not applicable; QALY= quality adjusted life years; PCV7/10/13= 7/10/13–valent pneumococcal conjugated vaccine; IPD= 
invasice pneumococcal disease.
Cost effectiveness of PCV10 and PCV13
Compared with no vaccination, vaccination with PCV10 would prevent 6124 cases of otitis media, 
463 cases of non–invasive pneumonia, and 258 cases of invasive pneumococcal disease, of which 
150 would be averted by net indirect effects in individuals aged 5 years and older. Overall these 
health benefits would result in a gain of 707 QALYs. Vaccination with PCV13 would prevent 6876 
cases of otitis media, 520 cases of non–invasive pneumonia, and 331 cases of invasive pneumococcal 
disease, resulting in a total gain of 891 QALYs. 












Without net–positive indirect effects for those aged 5 years and oldera 113,891b 99,151 91,705 
With 10% net–positive indirect effects for those aged 5 years and oldera 59,937 52,947b 50,042b
With 20% net–positive indirect effects for those aged 5 years and oldera  39,698 35,146 33,479
2+1–dose schedule
Without net–positive indirect effects for those aged 5 years and oldera 82,975 72,083 66,572 
With 10% net–positive indirect effects for adults and elderlya 43,070 37,891 35,743
With 20% net–positive indirect effects for those aged 5 years and oldera 28,101 24,718 23,488
Reduction in the cost of the vaccine (€50 per dose)c NAb 41,106 31,250
Excluding herd effects in the analysed birth cohort for IPDc 129,069 57,770 55,055
Including herd effects in the analysed birth cohort for non–IPDc 111,153 52,211 49,407
Higher utility lossesc,d 67,581 40,136 38,664
Exclusion of productivity losses (analysis from the health–care perspective)c 115,481 53,904 50,938
Efficacy against acute otitis media according to POET studyc,e 78,527 43,048 41,457
a.  Inclusion of net–positive indirect effects (herd protection against vaccine serotype disease minus non–vaccine serotype 
pneumnococcal disease increases). See also Appendix B.
b. Base–case scenario. 
c. Scenarios were calculated holding all other assumptions similar to the base–case analysis (no net–indirect benefits for PCV7 
and 10% for PCV10 and PCV13). 
d. Utilities reported by Prosser et al. were used for children aged up to 5 years old.157
e. Efficacy against acute otitis media was assumed to be 33.6%, as was shown for the precursor vaccine of PCV–10 by Prymula 
et al. 158
QALY= quality adjusted life years; PCV7/10/13= 7/10/13–valent pneumococcal conjugated vaccine; NA= Not applicable
Dividing the incremental costs by the incremental health benefits for the 10 valent and 13 valent 
vaccines produced incremental cost effectiveness ratios of €52,947 and €50,042 per QALY for PCV10 
and PCV13, respectively. A 2+1 dose schedule could reduce these incremental cost effectiveness 
ratios to €37,891 for PCV10 and to €35,743 for PCV13 (Table 4). A 25% reduction in the vaccine price 
of PCV10 and PCV13 to €50 per dose (the cost of PCV7) would reduce the cost effectiveness ratios 
to €41,106 and €31,250, respectively. Assuming both a dose (to three doses) and a price reduction 
(to €50 per dose), the cost effectiveness ratios for PCV10 and PCV13 would be as low as €29,013 and 
€21,654 per QALY, respectively.
Scenario and sensitivity analyses
Figure 2 shows the parameters that produced the largest variation in the cost effectiveness ratio 
for PCV7 when varied by 25%. Apart from vaccine efficacy against invasive pneumococcal disease, 
the most important determinants of the cost effectiveness of PCV were the total vaccination costs, 
the increase in invasive pneumococcal disease caused by non–vaccine serotypes, and the case 
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fatality rate for meningitis. In univariate sensitivity analyses for PCV10 and PCV13, generally similar 
but smaller changes in the incremental cost effectiveness ratio were observed. The changes were 
smaller because of the relative importance of indirect benefits in the unvaccinated population for 
PCV10 and PCV13. 
80,000 90,000 100,000 110,000 120,000 130,000 140,000 150,000 160,000 170,000 180,000
Vaccine efficacy against VT IPD
Total vaccination costs
Increase in NVT IPD
CFR for meningitis
CFR for bacteremia without focus
QALY loss: living with Cochlear  implant
Vaccine efficacy against AOM
QALY loss: AOM
QALY loss: disability
Cost effectiveness ratio (€/QALY)
Figure 2. Sensitivity analysis assumptions on base case cost–effectiveness ratio for PCV7. Parameters were 
varied with 25%. Black bars show the incremental cost–effectiveness ratio for a 25% decrease in the parameter 
varied, whereas the grey bars show the incremental cost–effectiveness ratio for a 25% increase (note that it was 
not possible to increase the vaccine efficacy). IPD= invasive pneumococcal disease; AOM = acute otitis media; 
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Net-indirect benefits
Figure 3. The effect on cost effectiveness ratios of varying the level of net indirect effect of vaccination for 
individuals aged 5 years or older. The horizontal dashed line shows the threshold at €50,000 per QALY. 
PCV7/10/13= 7/10/13–valent pneumococcal conjugated vaccine.







Figure 3 shows the impact of varying the level of net indirect effects of vaccination in individuals 
aged 5 years or over. At least 14% of the estimated net indirect effect would be needed in order to 
make PCV7 cost effective (that is, less than €50,000 per QALY). Several scenario analyses are displayed 
in Table 4, which again show the large impact of indirect effects and reduced dose schedules on the 
cost effectiveness of pneumococcal vaccination.
 Finally, Figure 4 shows cost effectiveness acceptability curves for six different scenarios. This 
figure clearly shows that administering PCV7 in a 3+1 dose schedule cannot be considered as cost 
effective compared with no vaccination. The incremental cost effectiveness ratios of PCV10 and 
PCV13 are likely to be more favourable than that for PCV7, yet still the total costs of vaccination 








































Figure 4. Cost effectiveness acceptability curves for base case vaccination schedules and for alternative scenarios 
for PCV7, PCV10, and PCV13. PCV7/10/13= 7/10/13–valent pneumococcal conjugated vaccine.
DISCUSSION
Our economic analysis indicates that the current national vaccination programme with PCV7 
in the Netherlands is not cost effective. As several papers suggest that lowering the number of 
doses from four to three will not affect the vaccine efficacy for the pneumococcal vaccine28,50,54,78, 
we investigated the potential impact of such reduced–dose schedules. Although a 2+1 reduced 
dose schedule could lower the total cost of vaccination and, therefore, reduce the incremental cost 
effectiveness ratio by approximately 30%, it is unlikely that universal vaccination with PCV7 will 
become acceptable on the grounds of cost effectiveness. 
 More favourable incremental cost effectiveness ratios were shown for PCV10 and PCV13, as long 
as net positive indirect effects for individuals aged 5 years or older were included in the analyses. In 
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particular, scenarios that used reduced total vaccination costs by using a 2+1 dose schedule showed 
that incremental cost effectiveness ratios would decrease down to €37,891 and €35,743 per QALY 
for PCV10 and PCV13, respectively. These ratios are likely to be considered as cost effective given 
various country specific thresholds.
Strengths and weaknesses
This is the first economic evaluation of national vaccination against pneumococcal disease that has 
included serotype replacement for the analysed birth cohort by using post–vaccination data81,104. 
We estimated the number of cases of invasive pneumococcal disease averted by vaccination and 
the increase in invasive pneumococcal disease caused by non–vaccine serotypes on the basis of 
the most recent data available79. Given the relatively small number of cases reported during the 
surveillance period of two years, our predictions regarding the increase of disease caused by non–
vaccine serotypes may have limited precision; however, they are based on the best data currently 
available. In particular, the estimated increase of 100% for invasive disease caused by serotypes 
not covered by PCV7 was based on national observational studies from the Netherlands and 
the UK79,81,104. On the one hand, this specific assumption may be too conservative. On the other 
hand, data from the UK show an ongoing increase in the cases of invasive pneumococcal disease 
caused by non–vaccine serotypes and no plateau has yet been reached in the third year after PCV7 
introduction, suggesting that the eventual increase in disease caused by non–vaccine serotypes 
might even be higher81. There are, however, some important differences between the Netherlands 
and the UK. In contrast to the Netherlands, the UK uses a reduced dose schedule of PCV7 at 2, 4, 
and 13 months. Also, the introduction of PCV7 in the UK was followed by a catch–up programme 
for all children aged less than 2 years. In the Netherlands, by contrast, vaccination was implemented 
without a catch–up programme. Several alternative scenarios regarding serotype replacement were 
explored in the sensitivity analyses, which showed that our conclusions regarding the incremental 
cost effectiveness ratios for all three vaccines were quite robust.
 In our base case analysis for PCV7, we assumed that there was no net indirect effect of 
vaccination for individuals outside the modelled birth cohort because no overall reduction in 
invasive pneumococcal disease in non–vaccinees has been observed in any European country, in 
contrast to the US73,81,104. The difference between results obtained in the US and those recorded 
in Europe may be partly explained by the 60% to 70% coverage of the seven vaccine serotypes 
in Europe, compared with the more than 80% coverage in the US18. This disparity leaves more 
room for replacement disease in Europe. Country specific differences in the circulating serotypes 
causing disease (inclusive of secular changes in time) could also contribute to the lower overall 
reduction of invasive pneumococcal disease in Europe compared with the US159. Furthermore, in 
the Netherlands, as in most parts of Europe, the baseline incidence rates of invasive pneumococcal 
disease in children are substantially lower than in the US and almost exclusively based on culture 
confirmed cases of children admitted to hospital55,79. Another potentially relevant difference in the 
introduction of PCV7 in the Netherlands compared with the US is the high vaccine uptake (>95%) 







among all newborns in the Netherlands for all four doses of the vaccination, which could potentially 
lead to more rapid development of replacement disease55.
 Potential net indirect effects in non–vaccinees were modelled using straightforward calculus. 
Ideally, the impact of pneumococcal vaccination should have been modelled using a so called 
dynamic transmission model, in which the transmission and carriage of S. pneumoniae is taken 
explicitly into account. However, because the transition dynamics of S. pneumoniae are complex 
and serotype dependent, and detailed data regarding these transmission dynamics are also quite 
limited, dynamically modelling all relevant serotypes of S. pneumoniae would be very complicated. 
For PCV10 and PCV13, a net indirect effect of 10% was included in the base case analysis. This 
estimate of indirect benefit may be conservative if compared with the much higher net indirect 
protective benefits observed in the US after implementation of routine vaccination with similar or 
lower vaccine serotype coverage44-46. 
 Furthermore, we did not include the benefits arising from the prevention of antibiotic 
resistance in our model because the impact of this inclusion is expected to be small given that 
penicillin resistance is less than 0.4% in the Netherlands79. Finally, similar to almost all previous cost 
effectiveness analyses for pneumococcal vaccination, our analytic time frame was equal to the 
assumed protection period, after which we assumed that health effects and costs would be similar 
in the vaccinated and unvaccinated group.
Comparison with other studies
The cost effectiveness of PCV7 is worse than that calculated in our previous studies and in other 
recent health economic studies131-135,139,147,160. This disparity is mostly because of the exclusion of herd 
protection effects and the inclusion of serotype replacement in our study. Other factors contributing 
to the worse incremental cost effectiveness ratio were the use of a lower death rate for invasive 
pneumococcal disease and lower indirect costs than in our previous studies133,135.
 Several recently published cost effectiveness studies included net vaccine benefits for 
unvaccinated adults and elderly people in their base case analysis131-134,160. These studies reported 
vaccination to be cost saving131,132 or at least cost effective133,134,160. The three studies that excluded 
herd protection in the base case analysis reported relatively unfavourable cost effectiveness ratios 
for PCV7 compared with other recommended infant vaccinations135,139,147. When we excluded the 
increase in invasive pneumococcal disease caused by non–vaccine serotypes but left all other 
assumptions the same as in the base case analysis, our results were similar to those of these three 
studies—that is, we found an unfavourable cost effectiveness ratio135,139,147.
Our cost effectiveness results show that the current vaccination schedule for PCV7 might be far more 
expensive per QALY gained compared with other routine infant vaccination programmes recently 
implemented, such as for human papilloma virus161, or with other vaccines that have not yet been 
implemented in a national programme in the Netherlands, such as hepatitis B162 and varicella10.
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Implications and future research
Administration of PCV7 at 2, 3, 4, and 11 months was introduced to the Netherlands as part of the 
national immunisation programme in 2006 partially on the basis of favourable cost effectiveness 
data. The current analysis shows unfavourable cost effectiveness of the PCV7 3+1 dose schedule 
because of increases in invasive disease caused by non–vaccine serotypes, which offset the herd 
protective benefits in individuals outside the analysed birth cohort. Although the cost effectiveness 
of PCV7 is unfavourable from a health economics point of view, it is favourable from a public 
health point of view—a significant decrease in cases of pneumococcal disease has occurred in 
the Netherlands over the past two years104. Switching to the 10 valent or 13 valent vaccine would 
extend the serotype coverage to a higher level than that currently achieved with PCV7, which might 
reduce the potential for disease caused by non–vaccine serotypes and increase the overall benefits 
in vaccinated children. 
 Herd protective effects are more likely to occur with broad vaccine coverage, rendering 
vaccination potentially cost effective. Vaccination would be particularly cost effective if a more valent 
vaccine is used in combination with dose reductions, price reductions, or both. Our paper should 
help guide future decisions to potentially reduce doses of pneumococcal vaccine or to shift from 
PCV7 to vaccines that cover additional serotypes. Further research should be directed to building 
a dynamic model to entangle and explicitly predict the indirect effects of disease replacement 
and herd protection on vaccine efficacy and thus further enhance the validity of cost effectiveness 
approaches applied to pneumococcal vaccination.
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Background: Community–acquired pneumonia and invasive pneumococcal disease are common 
among older people (ie, those aged ≥65 years). A new 13–valent pneumococcal conjugate vaccine 
(PCV13) is under study in the Netherlands.
Objective: The aim of this work was to model the cost–effectiveness of PCV13 vaccination among 
those aged ≥65 years in the Netherlands, both in the total population and in those at increased risk 
for pneumonia, for various levels of efficacy (30%–90%) assumed.
Methods: Our previously published cost–effectiveness model was updated to include age–specific 
epidemiologic data and health–care utilization and costs for a hypothetical cohort of adults aged 
≥65 years in the Netherlands. This cohort was followed twice—once as unvaccinated and once 
as vaccinated—over a time period of 5 years, with differences between both analyses reported. 
Outcome measures included costs, life–years gained (LYGs), quality–adjusted life years (QALYs), 
and incremental cost–effectiveness ratios (ICERs). All analyses were performed from a societal 
perspective.
Results: In the model, the ICER for vaccination remained below €80,000/LYG, except when the vaccine 
was assumed to protect only against bacteraemic pneumonia, with a relatively low effectiveness 
(40%) in combination with a high vaccine price (€65), and indirect effects of serotype replacement 
would largely offset the direct effect of vaccination. For various assumptions, introduction of 
widespread PCV13 vaccination (assuming a 60% efficacy against invasive and noninvasive disease 
because of vaccine serotypes, and a cost of €50 per vaccinated person) was associated with the 
ICERs varying from cost–saving to €50,676 per LYG.
Conclusions: In this model analysis of a hypothetical cohort in the Netherlands, vaccination 
with PCV13 might be considered cost–effective, both for the total population and for the high–
risk population aged ≥65 years, from a societal perspective, over a 5–year time horizon. The main 
limitation of this study was uncertainty regarding how great a proportion of pneumonia could be 
attributed to pneumococcal disease.








The annual incidence of community–acquired pneumonia (CAP) is estimated between 25 and 44 per 
1000 persons in noninstitutionalized patients in Western countries among those aged ≥65 years163. 
It has been estimated that 5% to 60% (depending on the diagnostic test used, geographic region, 
and health–care setting) of CAP can be attributed to Streptococcus pneumoniae163-165. In addition, S. 
pneumoniae is responsible for >50 cases of invasive pneumococcal disease (IPD) per 100,000 seniors 
in industrialized countries. 
 Although a 23–valent polysaccharide pneumococcal vaccine (PPV23) has been developed to 
prevent pneumococcal disease166, the evidence regarding its efficacy has been gathered primarily 
from nonrandomized, observational studies, and its effects on the occurrence of CAP have not 
been ascertained20,166. Therefore, in the Netherlands, PPV23 is recommended only for those with 
an increased risk of morbidity and mortality (eg, presence of diabetes mellitus or HIV infection) 
and not for routine use in everyone aged ≥65 years167. Consequently, <1% of those aged ≥65 years 
were vaccinated with PPV23 between 2004 and 2006, based on information from the University of 
Groningen prescription database. 
 In children, the 7–valent pneumococcal conjugate vaccine (PCV7) appeared to be effective 
against infection with vaccine serotype IPD, both in large vaccine trials and in surveillance studies25,66. 
Also, PCV7 has been effective in studies of CAP and acute otitis media137,154. Among those aged 
≥65 years, antibody responses after a single dose of PCV7 appeared to be similar to those seen 
in infants after the primary vaccination, which might imply a high efficacy against pneumococcal 
disease, although the antibody threshold needed for protection in older patients is unknown168. 
Furthermore, other studies concluded that an initial (double) dose of PCV7 was likely to elicit 
higher and potentially more effective levels of antipneumococcal antibodies than PPV23111,169,170. 
However, this response was not observed for all of the 7 serotypes common to the PPV23 and PCV7 
vaccines111,169,170. 
 Besides the possibility of greater efficacy against common serotypes, other possible advantages 
of PCV7 compared with PPV23 include the possibility of longer duration of protection by revaccination 
and the expected protection against pneumococcal CAP171. Based on these positive expectations, a 
large trial to determine the efficacy of a successor of PCV7, the 13–valent pneumococcal conjugate 
vaccine (PCV13), among 85,000 community dwelling adults aged ≥65 years was initiated in the 
Netherlands in 2008168. The primary objective of that trial is to establish the efficacy of PCV13 in 
the prevention of a first episode of vaccine serotype–specific CAP. The secondary objective is to 
assess the efficacy of PCV13 against first episodes of nonbacteraemic vaccine serotype–specific CAP 
and vaccine–serotype–specific IPD. However, in the process of implementing a new vaccine, there 
is also an increasing focus on economic aspects, particularly cost–effectiveness ratios. Especially 
in the case of PCV13, with relatively high costs per dose, cost–effectiveness considerations will be 
important; such considerations have already been important to the introduction of infant schedules 
for vaccination with PCVs172. A preliminary assessment of potential cost effectiveness is therefore 
Chapter 5
62
warranted, although definitive results will not be available until after completion of the previously 
mentioned clinical trial. In the mean time, it is important to estimate the desired efficacy of PCV13 
vaccination of older patients in relation to the price of the vaccine. The purpose of the current model 
analysis, therefore, was to estimate the cost–effectiveness (from the perspective of society) of PCV13 
vaccination among those aged ≥65 years in the Netherlands, both in the total population and in 
those at increased risk for pneumonia, given the assumption of various levels of efficacy (30%–90%). 
MATERIALS AND METHODS 
Structure of the decision model
Our general decision–tree analytic model structure built on our previously reported models (Figure 
1)47,133,135. In essence, the model distinguished between IPDs such as meningitis, bacteraemic CAP, 
and bacteraemia with and without focus, and nonbacteraemic CAP79. The model was updated to 
include age–specific epidemiologic data and health–care utilization and costs for a hypothetical 
cohort of adults aged ≥65 years in the Netherlands. The model distinguished between individuals 
without any specific underlying disease (ie, low risk) and those with underlying risk–elevating chronic 
conditions (ie, high risk) such as HIV, leukemia, or history of splenectomy79. This was necessary to 
enable modeling specific vaccination programs targeted at only those citizens at high risk, given 
that this group is likely to represent those with shorter life expectancy and lower quality of life173. 
 The cohort was followed twice—once as vaccinated and once as unvaccinated—over a time 
period of 5 years, with differences between both analyses reported. Epidemiologic parameters 
included the incidence of CAP, the incidence of IPD, hospitalizations, rates of visiting general 
practitioners, and fatality rates for IPD and CAP. In the model, vaccination was assumed to occur 
once at age 65 years. A hypothetical cohort of such individuals was followed over a 5–year time 
frame. Beyond 5 years, no vaccine efficacy was assumed, but long–term impact on life–years gained 
(LYGs), quality adjusted life–years (QALYs), resource use, and costs were extrapolated over the full 
lifetime of the individuals in the cohort (until death or age 100 years). For our analysis, therefore, 
health–economics data regarding individuals aged 65 and 69 years are crucial. Indirect effects (ie, 
effects in nontargeted age groups) may occur after the introduction of routine PCV13 vaccination; 
this was previously observed after the introduction of routine infant vaccination with PCV766,81. 
Furthermore, such indirect effects may have already occurred, given the earlier introduction of 
infant pneumococcal vaccination in the Netherlands in 2006.
 In our analysis, we compared the possible impact of routine vaccination with PCV13 with 
the current situation. As mentioned, in the Netherlands, the PPV23 is administered only to a few 
individuals at substantially increased risk of pneumococcal infection (eg, people suffering from 
asplenia, sickle–cell anemia, or liquor leakage), based on the recommendations of the Dutch Health 
Council174. Therefore, and because data regarding the effectiveness of PPV23 against IPD are limited, 
we excluded costs (both vaccination costs and costs associated with potentially prevented cases) 
and potential cases of IPD averted by PPV23 vaccination from our model. 



































Figure 1. Decision tree used in conjunction with the cohort model for a model analysis of the cost–effectiveness of 
13–valent pneumococcal conjugate vaccine in a hypothetical cohort of those aged ≥65 years in the Netherlands. 
Sequelae for meningitis were not included in base case analyses. IPD= invasive pneumococcal disease.
Epidemiologic parameters 
Pneumococcal surveillance data about the incidence and serotype distribution of IPD before 
national implementation of PCV7 vaccination for the period from 2004 through 2006 have been 
published, and include information regarding age, primary focus of infection, resource use, 
underlying conditions, and outcome79. In older subjects, many cases of IPD occur among those with 
an underlying condition (ie, asthma/chronic obstructive pulmonary disease, cardiovascular disease, 
diabetes mellitus, autoimmune disease, thyroid disease, malignancy, and immunocompromising 
conditions). According to these criteria, 52% of meningitis incidence, and 81% of other IPD 
incidence, occurred among those aged ≥65 years with an underlying condition. The fatality rate for 
IPD is displayed in Table 179. IPD, especially meningitis, may lead to long–term sequelae in children. 
However, the proportion of patients with meningitis is much lower among older individuals than 
among infants175. Because of this low share of meningitis and the occurrence of sequelae, as well 
as the absence of data regarding the treatment of meningitis in this population, we excluded 
the occurrence and impact of sequelae in the base–case analyses. Nevertheless, we explored the 
potential effect of its inclusion in sensitivity analyses using hypothetical figures (see following 
subsection). 
 Baseline risks for pneumococcal–related CAP requiring hospitalization were estimated from 
national hospital admission data (Table 1). Among those aged 65 to 69 years, 9% of all hospitalized 
CAP cases were caused by infection with S. pneumoniae. However, the causative microorganism 
was not identified in ~75% to ~80% of cases; therefore, it seems likely that the true proportion of 
cases caused by S. pneumoniae may be higher. In fact, findings in hospital–based studies suggested 
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that 5% to 60% of all hospitalized CAP cases were caused by S. pneumoniae13,163-165. To crudely 
correct for this, we assumed that in 35% of all hospitalized CAP cases, the causative agent would 
be S. pneumoniae. This assumption was also based on 3 Dutch studies that reported that 27% to 
38% of all hospitalized CAP cases were caused by S. pneumoniae13,176,177. However, this estimate is 
still likely to underestimate the true burden of S. pneumoniae, because the causative agent was 
unknown in ~40% of the cases. In sensitivity analyses, the share of CAP related to S. pneumoniae 
was varied across a wide range. From this same database of national hospital admissions178, the 
length of hospitalization due to S. pneumoniae CAP was available and subsequently inserted into 
our model. We assumed that only hospitalized patients would be at risk for death, because severe 
CAP cases would be referred to a hospital by a general practitioner or admitted to hospital by self–
referral (eg, by patient–initiated ambulance transportation to emergency department). A causative 
organism was reported for few (<5%) pneumonia deaths179. Therefore, we calculated fatality rates for 
hospitalized CAP patients based on the overall hospitalizations and number of deaths due to CAP in 
the Netherlands, and corrected these for the number of deaths due to bacteraemic CAP79,178,179. The 
estimated fatality rate of 2% for hospitalized nonbacteraemic CAP was low compared with other 
reported fatality rates180,181, but it was plausible, given that we were interested in relatively young 
elderly individuals (beginning at age 65 years) and that antibiotics and other rescue treatments 
were available. Furthermore, we noted that the overall mortality rate due to hospitalized pneumonia 
(noninvasive CAP and bacteraemic CAP together) was within the range (4%–29%) reported for CAP 
in the literature163. 
Table 1. Incidence, fatality rates, and costs for IPD and non bacteraemic CAP related to Streptococcus pneumoniae 
among those aged 65 to 69 years in the Netherlands.
Case fatality Incidencea
Mean direct costs 
per case, €
Mean indirect 
costs per case, €
Invasive pneumococcal disease
Meningitis 29% 3.4 15,255b 302
Bacteraemic CAP 14% 39 10,268 212
Pneumococcal bacteraemia with focus 33% 2 7,105 150
Pneumococcal bacteraemia without focus 43% 3 8,077 197
Noninvasive disease 
Pneumococcal CAP requiring hospitalization 2% 89c 5,194 173
Pneumococcal CAP requiring a GP visit 0% d 182e 17.1 6.50
a.  No. of cases per 100,000 elderly persons.
b.  Not taking sequelae into account.
c.  Assuming that in 35% of all hospitalized Pneumococcal CAP the causative micro–organism is S. pneumoniae (ICD–9–CM 
Diagnosis Codes 488–490were used). 
d.  Assumed. 
e   Assuming 20% of all CAP cases are due to S. pneumoniae.
IPD= invasive pneumococcal disease; CAP=community acquired pneumonia; GP=general practitioner







 Baseline risks for CAP–associated visits to a general practitioner (International Classification of 
Primary Care code R81) were taken from a national report indicating that the mean incidence of 
visits for CAP was 91 per 10,000 persons per year for individuals between the ages of 65 and 69 years 
in 2007 and 2008182. For CAP–associated visits to general practitioners, no information was available 
regarding the causative organism. Based on Woodhead164, we conservatively assumed that 20% of 
cases were related to S. pneumoniae. Serotype distributions for nonbacteraemic CAP were assumed 
to be similar to those observed for bacteraemic CAP. 
Sequelae not included in the base–case analysis 
IPD may lead to long–term sequelae, especially in the case of meningitis. In particular, hearing 
problems and paresis may occur79,175,183. In one specific scenario analysis, we included sequelae due 
to meningitis. Tetraplegia was assumed to occur in 1% of pneumococcal meningitis cases among 
those aged ≥65 years175, which would require lifelong admission to a nursing home. Hemiparesis 
was assumed in 6% of pneumococcal meningitis cases, resulting in a requirement of lifetime day 
care133,175. Furthermore, it was assumed that after a meningitis episode, 1% of patients would 
remain in a permanent vegetative state. Hearing impairment was assumed to occur in 15% of the 
cases175. Annual costs due to tetraplegia and hemiparesis were estimated at €81,540, based on the 
costs of intensive nursing–home treatment142. Annual costs due to a permanent vegetative state 
were estimated at approximately €154,000, similar to the cost previously calculated for children 
in a vegetative state184. Given that no data were available regarding costs associated with hearing 
impairment, such costs were not included.
vaccine efficacy, number of doses, duration of protection, and uptake 
In our base–case analysis, we assumed that a single vaccine dose would be sufficient to establish a 
stable vaccine efficacy over a period of 5 years comparable with what was assumed for the PPV23 
vaccination in previous cost–effectiveness analyses173,180,185,186(a single dose is also considered to be 
effective in children aged 2–5 years35). Furthermore, in the base–case analysis, we assumed that 
the vaccine would be equally efficacious in high–risk and low–risk individuals. In the absence of 
real clinical data, efficacy was assumed to range from 30% to 90%. Therefore, we explored different 
scenarios in which we assumed the vaccine efficacy would vary accordingly. Vaccination coverage 
was assumed to be 83% among high–risk older individuals and 65% among low–risk older 
individuals, similar to the vaccination coverage against influenza in the Netherlands187-189.
Indirect effects 
Similar to our previous model, we tried to adequately include estimations of indirect effects in our 
model. Indirect effects can be divided into herd–protection effects (ie, protection of unsuccessfully 
immunized and unvaccinated individuals because of reduced transmission of the pathogen) and 
serotype–replacement effects (ie, replacement disease caused by other pathogens)47. Indirect 
effects are likely to occur after the introduction of routine PCV13 vaccination in the older population 
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because both herd–protection and serotype–replacement effects occurred after the introduction 
of routine infant vaccination with PCV766,81. However, because vaccination coverage would likely 
be lower among older people than among infants, and because PCV13 offers broader serotype 
coverage than PCV7, it is difficult to predict what the indirect effects of PCV13 vaccination on the 
older population might be. Furthermore, indirect effects on older patients could also occur without 
the introduction of routine vaccination66. Several studies have reported herd–protection benefits 
for adults after the introduction of routine infant vaccination with PCV7; however, concomitant 
increases of nonvaccine serotypes were also observed (ie, serotype replacement) 73,74,81,103. In the 
United States, herd benefits in adults and the elderly seem to outweigh the serotype replacement66, 
but the scarce data available for European countries suggest that the net indirect benefit may be 
lower than it is in the United States, given that increases in nonvaccine serotypes seem nearly to 
counterbalance the decrease in vaccine serotypes73,74,81,103.  Switching from PCV7 to new 10–valent 
or 13 valent vaccines for use in national immunization programs could complicate predictions 
regarding indirect effects for older people. Finally, implementation of a vaccination program among 
the elderly could also influence serotype distribution in children, which could conversely influence 
serotype distribution among the elderly. All of these factors complicate the consideration of indirect 
effects.
 Because of the uncertainty surrounding the net indirect effects, we explored different scenarios 
in the base case. In scenario A, we did not include any indirect effects, given the current absence 
of specific data for those aged ≥65 years in the Netherlands or any other European country. This 
might be considered too optimistic a scenario from a cost–effectiveness point of view because we 
assumed no serotype–replacement or herd–protection benefits among older adults as a result of 
infant pneumococcal vaccination; such benefits might reduce the burden of disease among older 
people and decrease the potential burden of disease. In scenario B, we assumed that the current 
PCV7 infant vaccination program would increase the incidence of PCV7 nonvaccine serotype 
pneumococcal disease to 100%, with a corresponding decrease in PCV7 vaccine serotypes 
incidence, leaving the overall incidence unchanged43. Furthermore, given that the serotypes 
responsible for replacement are likely to be included in PCV13, we assumed that the 6 additional 
serotypes in PCV13 would reduce initial serotype replacement by 50%73,74,81,103. Also, in scenario 
B, we modeled an increase of 50% in nonvaccine serotype pneumococcal disease because of the 
introduction of routine vaccination of those aged ≥65 years. Scenario B might be considered too 
pessimistic because we included serotype replacement due to infant and elderly vaccination but 
did not include any potential herd protection benefits of elderly vaccination. 
Health care resource use and corresponding costs 
The analysis was performed from a societal perspective including both direct medical costs and 
indirect costs of production losses, all updated to 2008 (source: CPI: Central Bureau of Statistics 
for the Netherlands). Age specific resource use related to IPD were taken from Jansen et al.79, 
enabling estimation of direct costs (Table 1). Indirect costs related to IPD were taken into account 







for individuals who were unable to perform paid work because of hospitalization, although the 
impact of these costs is expected to be minimal given the age of the cohort (as only 6% of those 
aged 65 years and older still work 12 hours or more during a week) 142. For CAP, age–specific duration 
of hospitalization was available from the national hospitalization database. For CAP not requiring 
hospitalization, the costs of primary health care were included. The mean primary health care costs 
were estimated at €17.1, including the cost of a typical consultation with a general practitioner, 
antimicrobial treatment, and the pharmacist’s fee148. Treatment costs were based on official 
guidelines, recommending doxycycline for a period of 7 days190. 
LyG and QALy estimates 
We estimated the years of life lost using the remaining life expectancies, according to standard 
life tables180, calculated out over men and women to establish mean values. Life expectancy of 
those aged ≥65 years may differ between those with and without underlying conditions172. In 
particular, deaths from chronic diseases in conjunction with pneumococcal infection are likely to 
represent those who are more frail. Therefore, we included a mean 10% reduction in the potential 
LYGs for those aged ≥65 years with an underlying condition compared with standard life–table 
estimates, based on a method used previously191. To remain consistent with overall life expectancy, 
we correspondingly increased potential life expectancy by ~15% for the low–risk population. In 
addition to the cost per LYG, we also estimated the cost per QALY gained. General utility estimates, 
as well as utility estimates during an IPD episode, were taken from a previous cost–utility study 
by Sisk et al.192 that used conservative estimates for the general quality of life among older adults. 
During hospitalization for an episode of IPD, a utility of 0.2 was assumed. Subsequently, the QALY 
loss due to this episode was calculated by subtracting this utility loss from the mean age–specific 
utility (Table 2). The high and low–risk group definitions in the Sisk et al. study and in the present 
study were not identical, but they represent the best currently available estimates. In the absence of 
real data, utility decrements for CAP were not incorporated into the model. 
Table 2. Age–specific quality–adjusted life–year weight (QALYs) estimatesa.






a  Based on Sisk et al. 192
b  Low risk was defined as the absence of any specific underlying disease. High risk was defined as the existence of underlying 
risk–elevating chronic conditions such as HIV, leukemia, or history of splenectomy.
Chapter 5
68
Outcome measures and economic calculations 
Our main outcome measures were the efficacy and the costs of vaccination to determine whether 
routine PCV13 vaccination in the Netherlands would be cost effective. In the Netherlands, 
incremental cost–effectiveness ratios (ICERs) above €80,000 certainly reflect unfavorable cost–
effectiveness143. For LYGs, a threshold of €20,000 defines a situation in which cost–effectiveness 
would definitely be favorable in the Netherlands144. Based on these 2 thresholds, an implicit threshold 
of €50,000 per QALY for the Netherlands seems reasonable47. To calculate cost–effectiveness, the 
model keeps track of the number of IPD and CAP cases, QALYs, LYGs, and costs among the followed 
hypothetical cohort of 155,000 people aged ≥65 years (approximately the number of such people 
in the Netherlands). Dividing the net costs by either one of the health effects (LYGs and QALYs) 
defined the incremental cost–effectiveness ratio; these health effects and the costs of treatment 
were discounted according to the Dutch guidelines for cost effectiveness research at 1.5% and 
4%, respectively142. We investigated the impact of vaccination, starting with the most pessimistic 
scenario in which only protection against bacteraemic CAP was assumed. In subsequent analyses, 
we extended the protection to all vaccine serotype IPD and to CAP resulting in general–practitioner 
visits and hospitalizations.
Sensitivity analysis
To account for uncertainty in point estimates, we performed several sensitivity analyses. In contrast 
to PPV23, the conjugated vaccines do not cause hyporesponiveness (as observed after revaccination 
with PPV23)111,169. Furthermore, revaccination with the conjugated vaccine or the PPV23 after initial 
vaccination with a conjugated vaccine may be better tolerated than repeated doses of PPV23. 
Therefore, we explored a hypothetical situation in which a booster dose of either vaccine (PPV23 or 
PCV13) was administered 1 year after the initial PCV13 dose to double the protection period. After 
the booster dose, we assumed an extended efficacy against the serotypes included in the primary 
PCV13 dose and the PPV23 booster. Nevertheless, inconsistent results regarding the ability of PCV7 
to induce immune memory have been reported193. In 3 scenario analyses, the impact of less vaccine 
efficacy in high–risk older people was considered. It has been reported that influenza vaccines are 
less efficacious in high–risk older patients, so although this model analysis addressed a different 
vaccine, we explored a relative reduction of 10%, 20%, or 30% in vaccine efficacy among high–risk 
older patients compared with low–risk older patients, given that these groups are similar to those 
for whom influenza vaccination is recommended194. In a sensitivity analysis, we also explored the 
impact of the inclusion of meningitis sequelae (see previous subsection for details), the duration 
of protection after initial vaccination, varying the percentage of hospitalized CAP and general–
practitioner visits caused by S. pneumoniae, varying assumptions regarding the remaining life 
expectancy of the high–risk population (maintaining the same overall remaining life expectancy for 
the whole population), increasing the fatality rate related to CAP, applying different discount rates, 
and including QALYs rather than LYGs. Furthermore, all outcomes were shown with and without 
indirect effects (scenario A and scenario B, as previously described). 








Burden of disease 
Without vaccination, an estimated 358 cases of IPD were projected to occur among those aged 65 to 
69 years in the hypothetical cohort. Of these, 295 could be attributed to bacteraemic CAP, with the 
rest caused by meningitis (26 cases), bacteraemia with focus (11 cases), and  bacteraemia without 
focus (26 cases). The majority of these cases were projected to occur among individuals with an 
underlying condition. Regarding nonbacteraemic infections, 1387 general–practitioner visits and 
679 hospitalizations related to S. pneumoniae were estimated. The total number of deaths was 
estimated at 73, the number of life–years lost at 1083, and the corresponding loss of QALYs at 648.
Effect of efficacy and the vaccine price on the ICER
Figure 2 illustrates the effect on the ICER per LYG of varying the efficacy and the vaccine price. 
Figures 2A, 2C, and 2E correspond to scenario A (no indirect effects), whereas Figures 2B, 2D, and 
2F correspond to scenario B (indirect effects included). Furthermore, Figures 2A and 2B show the 
effect on the ICER assuming only vaccine efficacy against bacteraemic CAP; in Figures 2C and 2D, it 
was assumed that the vaccine was effective against all IPD, and in Figures 2E and 2F, an additional 
efficacy against CAP was assumed. 
 As shown in Figure 2, with increased efficacy (from 30%–90%), vaccination becomes more 
favorable. Without a net–indirect effect (Figures 2A, 2C, and 2E) vaccination is likely to be considered 
cost–effective. Even when the vaccine would only protect against bacteraemic CAP, vaccination 
may still be considered cost–effective because the ICERs remained below the informal threshold of 
€50,000/LYG. For example, assuming an efficacy of 30% against bacteraemic CAP and a total cost 
per vaccinated person of €50, the ICER was estimated at €49,300/LYG. Figures 2B, 2D, and 2F show a 
more pessimistic scenario in which serotype–replacement effects largely counterbalanced the direct 
effect of vaccination. However, when the vaccine was assumed to protect against all IPD, the ICERs 
still never surpassed the threshold of €80,000/LYG (above which an intervention is not certainly 
considered to be cost–effective), even when vaccine efficacy was estimated at 30%. Nevertheless, if 
the vaccine offered protection only against bacteraemic CAP with, for example, an efficacy of 40%, 
the vaccine price would have to remain lower than €65 to remain below the threshold of €80,000 
per LYG used. 
 We made similar graphs for the high and low–risk populations, which were almost similarly 
shaped (see Table 3 for comparison between the high–risk group and the total population); 
however, the ICER was lower for the high–risk population and higher for the low–risk population 
(data not shown). Cost–effectiveness estimates for different scenarios for the total population and 



















































































































































































































































Figure 2. The effect on the ICER of varying the vaccine efficacy and the vaccine price. Vaccine efficacy was not 
assumed to start at 0%. (A) No indirect effects, with the assumption of only vaccine efficacy against bactereamic 
CAP. (B) Indirect effects included, with the assumption of only vaccine efficacy against bactereamic CAP. (C) No 
indirect effects, with the assumption of vaccine efficacy against all IPD. (D) Indirect effects included, with the 
assumption of vaccine efficacy against all IPD. (E) No indirect effects, with the assumption of protection against 
all IPD and against nonbactereamic CAP. (F) Indirect effects included, with the assumption of protection against 
all IPD and against nonbactereamic CAP.
Sensitivity analyses
Table 3 shows several analyses for the total population and the high–risk population. We assumed 
an efficacy of 60% against both vaccine–serotype IPD and vaccine–serotype non–IPD. Again, all 







outcomes are shown with the inclusion of indirect effects (scenario B) and without the inclusion of 
indirect effects (scenario A). We combined this with a cost of €50 per vaccination. Similar to what 
was observed in Figure 2, Table 3 shows that the inclusion of net–indirect effects (scenario A vs B) 
affected the ICER. Calculating the projected costs per QALY instead of the cost per LYG increased 
the ICER by 70% to 80%. This was due to the relatively lower quality of life of the elderly, particularly 
those with an underlying condition. A booster dose given in the second year was projected to 
coincide with more favorable ICERs, especially when PPV23 would be given as a booster because 
of low vaccine price, combined with an efficacy assumed to be similar to that of a PCV13 booster. 
Obviously, decreasing the duration of protection would increase the ICER, and increasing the 
duration of protection would decrease the ICER. 
Table 3. Incremental cost–effectiveness ratios (€/QAY) in the base case, sensitivity, and several scenario analyses. 









Base case 8,505 4,723 18,432 12,243 
Per QALY 14,416 8,547 31,055 22,152 
2 year duration of protection 27,931 20,393 50,676 37,969 
10 year duration of protection 722 Cost saving 5,810 2,125 
Booster dose (after 1 year) of PCV13 and 10 years protection 7,976 4,717 17,740 12,475
Booster dose (after 1 year) of PVV and 10 years protection† 4,258 1,461 11,583 7,134 
Inclusion of meningitis sequalae 6,820 3,550 17,334 11,488 
10% of the GP visits related to S. pneumoniae 8,520 4,739 18,447 12,259 
40% of the GP visits related to S. pneumoniae 8,477 4,692 18,402 12,212 
25% of the unspecified hospitalized CAP related to S. pneumoniae‡ 10,500 6,584 21,212 14,701 
45% of the unspecified hospitalized CAP related to S. pneumoniae‡ 6,754 3,096 16,002 10,101 
10% lower vaccine efficacy in high–risk elderly 9,793 6,025 20,575 14,389 
20% lower vaccine efficacy in high–risk elderly 11,315 7,652 23,111 17,071 
30% lower vaccine efficacy in high–risk elderly 13,139 9,745 26,159 20,518 
5% case fatality due to hospitalised CAP 6,527 3,587 14,058 9,284 
7.5% case fatality due to hospitalised CAP 5,537 3,024 11,894 7,830 
Discount rate of 3.5% for both costs and LYGs 10,357 5,668 22,524 14,818 
No discounting 6,750 3,543 15,139 9,942 
No indirect costs 8,754 5,008 18,684 12,531 
* In scenario A, only direct effects were included. In scenario B, indirect effects were also included. It was assumed that the 
current 7–valent infant vaccination program would increase the incidence of nonvaccine serotype pneumococcal disease to 
100%, with a corresponding decrease in vaccine serotype incidence, leaving the overall incidence unchanged. 
† No efficacy was assumed for those 10 serotypes not included in PCV13.
‡  In the base case, it was assumed that 35% of all hospitalized CAP cases were caused by infection with S. pneumoniae.
PPV= 23–valent polysaccharide pneumococcal vaccine; CAP = community–acquired pneumonia.
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The percentage of primary–care visits related to S. pneumoniae had virtually no impact on the ICER; 
the costs related to a primary–care visit were relatively low, and mild pneumonia cases were not 
assumed to result in mortality. In contrast, the share of S. pneumoniae related to hospitalized CAP, 
and the fatality rate related to hospitalized CAP, had a much larger impact on the ICER in the model 
analysis. A lower vaccine efficacy for the high–risk population increased the ICER of the high–risk 
group by 18% to 106%, depending on the decrease in efficacy, but the ICER of the total population 
(including both low and high–risk elderly) was less sensitive for this variation. Applying a similar 
discount rate of 3.5% for both costs (4% in the base case) and health effects (1.5% in the base case) 
to correct for time preference increased the ICER by >20%, whereas not discounting costs or health 
effects decreased the ICERs to a similar extent. Exclusion of indirect costs, or assumption that a 
larger share of the CAP–related general–practitioner visits were related to S. pneumoniae, had a 
negligible impact on the ICER.
DISCUSSION 
The burden of pneumococcal disease is high among the elderly and, in particular, among those 
considered to be at high risk for pneumococcal infection163. In this model analysis, we present 
several scenarios to estimate the potential cost–effectiveness of PCV13 for routine use among those 
aged ≥65 years in the Netherlands. Our results suggest that even in the most pessimistic scenario, 
vaccination of this population is likely to be cost effective. Despite the fact that we assumed a 10% 
shorter life expectancy for high–risk people aged ≥65 years, we projected that vaccination of high–
risk elderly people would be more cost–effective than vaccination of all elderly people, given that 
the majority of cases occur in high–risk older people.
 Sensitivity analyses revealed that apart from vaccine efficacy and the vaccine price, incidence 
and fatality rate related to CAP had the greatest impact on ICER. We estimated the share of S. 
pneumoniae related to CAP hospitalizations at 35%, which might well be an underestimate. 
The literature reports shares up to 60%163-165, which would further improve the estimated cost 
effectiveness of PCV13. Future improvements in diagnostics could change understanding of the 
true burden of disease, given that current diagnostic tests lack sensitivity for the identification of the 
bacterial etiology of CAP195. Furthermore, we estimated the fatality rate due to nonbacteraemic CAP, 
because a causative organism is reported for relatively few pneumonia deaths. We used general 
CAP mortality data as a proxy for pneumococcal CAP fatality rates. Because pneumococcal CAP 
is considered to be more severe than general CAP196,we may have underestimated the effect of 
vaccination on both costs and health effects. Our model results suggest that variation in vaccination 
costs would have a substantial impact on the ICER. If, in the future, PCV13 were used for both routine 
infant and routine elderly vaccination, it might be possible to reduce vaccination costs because 
mass quantities of the vaccine would be marketed. In addition, the costs of vaccination could be 
further decreased if the vaccine could be administered concomitantly with the influenza vaccine 
without compromising immunogenicity or producing interactions or adverse events. Our model 
probably provides adequate and mutually consistent estimates for both the high–risk and the 







general population of those aged ≥65 years because we corrected the estimated life expectancy 
among those with underlying diseases79. We neglected the beneficial effect that vaccination would 
have on antimicrobial resistance, further adding to the fact that, in the Netherlands, resistance to 
antibiotics has traditionally been very low79. In other countries with higher levels of resistance, 
vaccination could result in slightly more favorable outcomes. We also chose to exclude all costs and 
health effects associated with long–term meningitis sequelae in the base–case analyses, because 
detailed data regarding costs and quality of life were not available for the elderly population. Finally, 
we included indirect costs due to paid work in our model. However, because this model considered 
those aged ≥65 years,  this had only a  limited impact on the ICER. We did not include unpaid work 
such as housekeeping and taking care of grandchildren, which one might expect in this older 
age group. Inclusion of these indirect costs, if valued monetarily, would further improve the cost–
effectiveness outcome. 
 Our model has several limitations. We did not include quality–of–life effects in our base–case 
analysis because specific data regarding CAP were not available, and because the appropriateness 
of the data that were available for IPD was questionable. Furthermore, we did not include any 
possible adverse effects of vaccination because severe reactions to the conjugated vaccines have 
not yet been observed and because adverse events have mainly consisted of mild local reactions35. 
However, full information about the safety of the use of PCV13 in those aged ≥65 years is still lacking. 
We also did not include vaccination costs and possible health effects for individuals receiving PPV23 
because adverse events would probably consist mainly of mild local reactions that would not 
require a doctor visit. Because our outcome measure was the cost per LYG, it was not possible to 
include potential QALY decrements related to these local reactions. Also, we assumed no additional 
primary care visits, and no additional costs were assumed for mild adverse events. As mentioned, 
vaccination coverage for PPV23 is very low in the Netherlands20. Nevertheless in other countries, 
routine vaccination with PCV13 might be more cost–effective (assuming no efficacy of PPV23) or 
less cost–effective (assuming a high efficacy of PPV23) depending on the efficacy of PPV23. 
 The impact of CAP requiring a general–practitioner visit was limited in our model, mainly because 
we only assumed that such a case would have costs without any reduction in the quality–of–life. This 
was assumed because no specific quality–of–life data were available for the elderly population, and 
because we assumed that severe CAP cases would be referred to a hospital. However, its inclusion 
would only have further improved our ICERs. 
CONCLUSIONS
In this model analysis of a hypothetical cohort in the Netherlands, vaccination with PCV13 might be 
considered cost–effective, both for the total population and for the high–risk population aged ≥65 
years, from a societal perspective, over a 5–year time horizon. The main limitation of this study was 
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Objective: To estimate the cost effectiveness of vaccinating people with high risk conditions against 
invasive pneumococcal disease (IPD) using the 13 valent pneumococcal conjugate vaccine (PCV13).
Design: Economic evaluation using a cohort model from the perspective of healthcare providers.
Setting: England.
Participants: People aged 2 years and older at increased risk of IPD due to chronic kidney disease; 
splenic dysfunction; HIV infection; a compromised immune system; chronic heart, liver, or respiratory 
disease; or diabetes.
Main outcome measure: Costs, gains in life years and quality adjusted life years (QALYs), and 
incremental cost effectiveness ratios (ICERs).
Results: Increasing indirect protection resulting from the infant PCV13 programme means that the 
burden of disease preventable by targeting high risk groups will diminish in time. Under base case 
assumptions—that is, no overall impact on non bacteraemic pneumonia in high risk groups and 
assuming the high risk vaccination programme would be launched two to three years after the 
infant programme—the ICER was estimated to be more than £30,000 (€37,216; $48,210) per QALY 
gained for most risk groups. If, however, the vaccine does offer protection against non–bacteraemic 
pneumococcal pneumonia or the vaccine was introduced concomitantly with the infant PCV13 
programme then vaccinating high risk people would (more) likely be cost effective. Sensitivity 
analyses showed that the cost effectiveness was particularly sensitive to assumed herd benefits and 
vaccine efficacy estimates.
Conclusion: Under base case assumptions it is unlikely that a pneumococcal vaccination programme 
aimed at risk groups could be considered cost effective. Uncertainty could be substantially reduced 
by establishing the effectiveness of the PCV13 against non–bacteraemic pneumococcal pneumonia, 
particularly in at risk groups.








People with certain clinical conditions such as immunocompromised patients and those with 
chronic heart or lung disease are at increased risk of  invasive pneumococcal disease (IPD) and 
related mortality197. To prevent disease among these high risk groups many countries recommend 
vaccination with the 23 valent polysaccharide vaccine (PPV23), which has been available since 
the 1980s. Nevertheless, the efficacy and duration of protection of this vaccine is limited, and the 
antibody response to revaccination is reduced20,21. The use of conjugated pneumococcal vaccines 
could potentially overcome the limitations of PPV23. In children the seven valent pneumococcal 
conjugate vaccine (PCV7) has been shown to be highly effective in preventing IPD caused by vaccine 
related serotypes198. Data on the efficacy in adults, elderly people, and high risk groups are, however, 
scarce, with most studies focusing on immunogenicity rather than on efficacy21. The limited data 
on efficacy that are available suggest that pneumococcal conjugate vaccines are effective in 
preventing IPD (and possibly pneumonia) in adults and children infected with HIV, a group in whom 
PPV23 is ineffective199,200. As the pneumococcal conjugate vaccines are more expensive, there is a 
need to assess whether the use of these vaccines is justified. Such an assessment is complicated by 
the interaction (at a population level) between a targeted risk based programme and vaccination 
of children. The introduction of the PCV7 in the infant immunisation programme led to a dramatic 
decline in incidence of IPD due to vaccine serotypes in all age groups (including those in risk groups)40.
However, these decreases were partly offset by a simultaneous increase in disease caused by non–
vaccine serotypes, reducing the impact on overall IPD36.
 In the infant programme in the United Kingdom, as elsewhere, PCV7 has recently been replaced 
by PCV13. This higher valency vaccine covers six additional serotypes, including the key replacement 
serotypes 19A and 7F. Similar herd effects for the additional serotypes, as observed for the seven 
serotypes included in the PCV7 after its implementation, can be expected in time. However, high 
risk groups could potentially still benefit from the faster and greater effects of direct vaccination 
with PCV13 compared with waiting for the indirect benefit from the herd immunity against the 
vaccine serotypes generated by the infant programme.
 We estimated the effectiveness, costs, and cost effectiveness of vaccinating high risk groups in 
England using PCV13, taking into account that herd benefits of the current infant PCV13 programme 
will diminish the potential impact of a specific programme for high risk groups over time.
METHODS
We estimated the costs, health benefits, and cost effectiveness of vaccination of high risk groups 
with PCV13 on top of the current risk based vaccination programme with PPV23. This was done 
because the existing PPV23 programme is likely be continued despite the potential introduction 
of a risk based PCV13 programme. In addition our risk estimates for pneumococcal disease were 
estimated in the current situation in which a risk based PPV23 programme is already in place (albeit 
with a low uptake of vaccination).
 As infants are already vaccinated with PCV13, we restricted our analysis to high risk patients aged 
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2 years and older. The perspective was from that of the National Health Service, as recommended in 
the United Kingdom9.
Model and population
We developed a cohort model to determine the cost effectiveness of vaccinating specific high risk 
groups with PCV13. Groups included in this analysis were based on a recent study among patients 
admitted to hospital in England with culture confirmed IPD, which compared the prevalence of 
clinical risk factors in the general population with that in patients admitted to hospital with IPD40. 
The study sample comprised 22,298 patients admitted to hospital between April 2002 and March 
2009 with an admission record in the hospital episode statistics database for England that could be 
linked with the dataset of the national IPD laboratory held at the Health Protection Agency40.
 In the current analysis we differentiate between people who are immunocompromised, such 
as those with HIV, asplenia, or splenic dysfunction or who respond poorly to the vaccine, such as 
people with chronic kidney disease; and those in immunocompetent risk groups such as patients 
with chronic heart, liver, or respiratory disease and people with diabetes40.
 The analytical time frame of the study was until 2021 (we assume that after this time the 
additional benefits of vaccination would be negligible). However, we extrapolated the long term 
effects of IPD over the full lifetime of the participants in each cohort—that is, until death or 100 
years.
Incidence of IPD and mortality risks
Using the most recent data available we estimated age group and risk group specific incidences. 
Firstly, we calculated age specific incidences of IPD for the general population, including cases 
confirmed by polymerase chain reaction and culture from the epidemiological year 2009–10 (in this 
paper we refer to epidemiological years, which run from July to June, unless stated otherwise)36. 
These incidences were subsequently used to estimate the incidence of IPD in high risk people using 
the prevalence of clinical risk factors among the general population and the prevalence among the 
linked patients admitted to hospital with IPD40. From the same databases we estimated the age 
specific share of meningitis and empyema to the total IPD burden to allow the inclusion of specific 
costs related to these outcomes. We also obtained age group and risk group specific case fatality 
ratios for IPD from this same study40.
Invasive pneumococcal disease sequelae
Invasive pneumococcal disease may lead to long term sequelae, especially in the case of meningitis. 
We obtained the risk of different types of sequelae from a recent meta–analysis201. As patients can 
have multiple sequelae, we assigned all possible combinations on the basis of the prevalence of the 
individual conditions and reweighted them such that the overall risk to develop any sequela was 
equal to the pooled prevalence of 31.7% as estimated by the meta–analysis. We obtained the losses 
in overall quality adjusted life years (QALYs) using the most severe QALY weight in the combination.








To assess whether to include an effect of PCV13 on non–bacteraemic pneumococcal pneumonia 
in the base case we looked at the impact of PCV7 on the overall incidence of non–bacteraemic 
pneumonia in high risk children. For this we obtained the number of episodes of non–specified 
pneumonia (ICD J18.X, mentioned in any diagnostic code) and the number of deaths for the same 
cases (within 30 days of admission) for the years 1997–98 up to 2009–10 (data from 2002–03 to 
2009–10 were used for deaths) from the hospital episode statistics database in children aged less 
than 5 years. Next, we divided individual cases into risk or non–risk groups based on the same ICD 
codes (see Appendix 9) as used for IPD, and we calculated incidences. An interrupted time series 
analysis showed that the incidence of pneumonia requiring admission to hospital in non–high risk 
children aged less than 5 years (that is, those eligible for vaccination) was significantly reduced 
after the introduction of PCV7, whereas the incidence in high risk children of the same age was 
not significantly reduced (see Appendix 1). Based on the striking difference between risk and non–
risk groups, and the additional uncertainty about the contribution of Streptococcus pneumoniae to 
non–bacteraemic pneumonia, particularly in high risk children, we decided not to include an overall 
impact on non–bacteraemic pneumonia in the base case analysis for the high risk groups. We did, 
however, explore the potential impact of including an effect against non–bacteraemic pneumonia 
in specific analyses. For this we used the data on age specific incidence for all cause pneumonia 
for the year 2010 from hospital episode statistics and projected these forward assuming the same 
incidence as in 2010. Next we assumed that S pneumoniae would be the causal agent in 42% of the 
patients in high risk groups admitted to hospital with non–bacteraemic pneumonia on the basis of 
the results of the two most recent UK studies available202,203. We then assumed that the contribution 
of the vaccine serotypes to pneumococcal pneumonia would decline in line with the herd effect of 
the infant vaccination programme on IPD.
Indirect effects
In virtually all countries the introduction of PCV7 was followed by a large reduction in IPD owing to 
vaccine serotypes in vaccinated and unvaccinated age groups, with the indirect benefits in some 
age groups partially offset by a concomitant increase in IPD due to non–vaccine serotypes198. This 
was also the case in the United Kingdom in which PCV7 was introduced in September 2006 with a 
vaccination schedule of 2, 4, and 13 months, and catch–up vaccination for children aged up to 2 
years36. In April 2010, PCV13 replaced PCV7 in the infant vaccination programme.
 To predict the future decrease in IPD due to vaccine serotypes in unvaccinated age groups, 
we divided the serotypes into those covered by PCV7 and those included in the PCV13 but not 
in PCV7. In both cases we used age group specific (2–4, 5–14, 15–44, 45–64, and >64 years) UK 
data on incidence of vaccination before and after the introduction of PCV7. The prevaccination 
period included the incidence data for the years 2000–06, whereas the post–vaccination period 
included data up to four years after the introduction of the vaccine (2006–10). Using the age group 
specific annual incidence (adjusted for underlying trends in case ascertainment) we fitted a Poisson 
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regression model adjusting for the population size to predict the future reduction in cases of IPD 
due to the vaccine serotypes (see Appendix 2).
 We consequently used the predicted annual decrease in vaccine serotypes to predict the 
incidence of the additional serotypes (except for serotype 3, see below) in PCV13—that is, we 
assumed that the herd effects for the additional serotypes in this vaccine would be similar to those 
observed for the serotypes in PCV7  after the introduction of the routine infant PCV7 programme 
in 200640. The only difference was that we delayed the herd effects for the six additional serotypes 
in PCV13 by one year as the introduction of the infant PCV13 programme  was not combined with 
a catch–up programme. This assumption is supported by the most recent data from the Health 
Protection Agency, which show no indication of any herd effect yet in people aged 5 years and 
older, 15 months after implementation of the routine infant PCV13 programme204. Furthermore, in 
the Netherlands, where the PCV7 programme was launched without a catch–up, herd effects were 
not observed in the first year after implementation in contrast with the United Kingdom105.
 We did not include serotype replacement effect in the model as we assumed that it would not 
affect the incremental cost effectiveness ratio (ICER) because changes in IPD due to non–vaccine 
serotypes are expected to be the same irrespective of the implementation of the risk group 
programme.
vaccine efficacy, number of vaccine doses, duration of protection
Although the efficacy of PCV7 in healthy infants is well established, the available data for risk groups 
and adults is scarce, with most studies reporting data on immunogenicity rather than efficacy21. 
Data on the efficacy of PCV13 is limited204; the current licence for the use in infants and children from 
6 weeks to 5 years of age and adults aged 50 years and over was based on immunogenicity rather 
than efficacy data35 (see Appendix 3 for an overview of available data).
 Considering the limited data available, we carried out a formal elicitation of expert opinion 
on vaccine related variables to construct a probability distribution that represents the experts’ 
knowledge and uncertainty205. The objectives of the elicitation were to estimate the efficacy 
of PCV13 (against IPD and non–bacteraemic pneumococcal pneumonia) and the duration of 
protection after one dose of the vaccine (as in the base case analysis) or two doses of the vaccine. 
Importantly, recent data from our group show that the serotype 3 component of PCV13 seems to 
be ineffective against IPD caused by this serotype206. Therefore, in the model we also assumed no 
protection against disease or carriage for serotype 3.
 Specific details on the method of elicitation can be found in Appendix 4. Briefly, we asked 
five members of the Pneumococcal Subcommittee of the Joint Committee on Vaccination and 
Immunisation to give an estimate of the PCV13 vaccine efficacy for risk groups based on the available 
PCV7 efficacy data and immunogenicity data of both the PCV7 and PCV13. We used the estimates 
to create distributions for vaccine effectiveness using the Sheffield elicitation framework205. Final 
distributions can be found in Table 1.







Life years and QALy estimates
As the life expectancy between the general population and high risk groups differs172,209, we 
calculated specific background mortality for people at high risk (and for the general population for 
validating purposes). Data were gathered from the Royal College of General Practitioners database 
(including 0.8 million patients; more than 1% of the UK population) over a period of six years (2005 
to 2010). We grouped the patients by risk factor (based on Read codes mapped to ICD–9 codes) 
and calculated the number of person years and deaths in the high risk group. Using these data we 
calculated background mortality (see Appendix 5). We also calculated the mortality for non–risk 
groups and validated these against life tables from the Office for National Statistics210. 
 In addition to life years gained we also calculated QALYs gained by vaccination. For patients 
admitted to hospital for IPD, we used losses in QALYs of 0.0079 per case for bacteraemia and 0.0232 
per case for meningitis150. We assumed that non–bacteraemic pneumococcal pneumonia resulted 
in a QALY loss of 0.006 per case43. In addition to acute losses in QALYs, we also linked specific losses 
in QALYs to the sequelae due to meningitis based on a Dutch study140 (see Table 1 for specific losses 
in QALYs).
Costs
All costs are reported in pounds sterling at 2009–10 prices. Where necessary we inflated these using 
the hospital and community health services pay and price index211. As the perspective was from 
that of the healthcare provider, we included only direct costs. We used recommended procedures 
to estimate the costs for patients admitted to hospital with IPD. The NHS healthcare resource group 
software was used, which combines procedure codes and ICD–10 diagnostic codes to output the 
most relevant healthcare resource group code. We subsequently assigned these codes a cost from 
the National Schedule of Reference Costs for NHS trusts. As the patients included in our analysis are 
all high risk, we included only those for which it was likely that the IPD episode was the main cause 
for admission to hospital—defined as those patients who had a primary diagnostic code related to 
an IPD code (see Appendix 6). Table 1 displays the costs and probabilities related to IPD. The costs 
of hospital admission for non–bacteraemic pneumococcal pneumonia were based on reference 
costs for pneumonia. We used the weighted average costs based on the number of non–elective 
admissions for pneumonia without complications (NHS reference costs code WADZ11C). Patients 
who had meningitis without sequelae were assumed to have a single outpatient appointment after 
discharge; we obtained the cost of treatment and care for patients with sequelae after meningitis 
from a previous cost effectiveness analysis139.
 The total cost per PCV13 dose was estimated at £56.61, consisting of the price of the vaccine 
(£49.10) and administration costs (£7.51).
Chapter 6
82
Table 1. Variables used in economic model
Variables Expected value Distribution Reference
Age specific incidence See Appendix 8 NA See methods
Odds of IPD* Age and risk group dependent* Log normal 40, see methods
Case fatality ratio† Age and risk group dependent† β 40, see methods
Share of meningitis in total burden of IPD 3–8% (age dependent) Fixed See methods
Share of empyema in total burden of IPD 1–5% (age dependent) Fixed See methods
vaccine efficacy against invasive pneumococcal disease‡
High risk immunocompetent:
 Aged <65 years 0.71 β (α 2.1, β 0.863) See methods
 Aged ≥65 years 0.63 β (α 2.01, β 1.19) See methods
High risk immunocompromised:
 Aged <65 years 0.53 β (α 1.59, β 1.41) See methods
 Aged ≥65 years 0.43 β (α 1.21, β 1.62) See methods
vaccine efficacy against non–bacteraemic pneumococcal pneumonia ‡
High risk immunocompetent:
 Aged <65 years 0.46 β (α 1.88, β 2.19) See methods
 Aged ≥65 years 0.40 β (α 1.47, β 2.2) See methods
High risk immunocompromised:
 Aged <65 years 0.33 β (α 1.24, β 2.55) See methods
 Aged ≥65 years 0.27 β (α 1.27, β 3.47) See methods
Waning immunity (per year)§
High risk immunocompetent:
 Aged <65 years 0.11 See methods See methods
 Aged ≥65 years 0.25 See methods See methods
High risk immunocompromised:
 Aged <65 years 0.24 See methods See methods
 Aged ≥65 years 0.26 See methods See methods
Prevalence of sequelae after meningitis
Deafness 0.08 β (mean 0.08 SE 0.03) 201
Mild hearing loss 0.21 β (mean 0.21 SE 0.02) 201
Seizures and hydrocephalus 0.07 β (mean 0.07 SE 0.02) 201
Spasticity or paresis 0.09 β (mean 0.09 SE 0.01) 201
Cranial nerve palsy 0.12 β (mean 0.12 SE 0.04) 201
Quality adjusted life year losses
Hospital admission for meningitis 0.023 β (mean 0.023 SE 0.031) 43, 150
Hospital admission for bacteraemia¶ 0.0079 β (mean 0.079 SE 0.083) 43
Hospital admission for non–bacteraemic 
pneumonia
0.006 Normal (mean 0.006 SD 
0.0015)
43, 150







Table 1. Variables used in economic model (Continued)
Variables Expected value Distribution Reference
Quality of life weights
Deafness 0.81 β (mean 0.81 SE 0. 028) 140
Mild hearing loss 0.91 β (mean 0.91 SE 0.015) 140
Seizures 0.83 β (mean 0.83 SE 0.015) 140
Hydrocephalus 0.62 β (mean 0.62 SE 0.021) 140
Spasticity or paresis 0.67 β (mean 0.67 SE 0.023) 140
Cranial nerve palsy 0.67 β (mean 0.67 SE 0.023) 140
Costs (£)
Case of meningitis** 6509 Normal (mean 6509 SD 405) See methods
Case of empyema** 7538 Normal (mean 7665 SD 444) See methods
Short hospital stay for other IPD** 825 Normal (mean 839 SD 3.93) See methods
Case with long stay for other IPD:
 With excess days in hospital** 8977 Normal (mean 9129 SD 142) See methods
 Without excess days in hospital** 3022 Normal (mean 3073 SD 19) See methods
Admitted to hospital for pneumonia 661 Normal (mean 672 SD 168) See methods
Chance of  long  hospital stay for IPD 0.61 β (α 5075 β 8257) See methods
Chance of excess days during  long stay 
for IPD
0.46 β (α 2328 β 5075) See methods
Lifetime costs after meningitis:
 In first year 6591 Log normal (mean 8.7 SD 0.4) 139
 In subsequent years 203 Log normal (mean 8.7 SD 0.4) 139
Outpatient follow–up for meningitis 382 Log normal (mean 5.2 SD 0.4) 139
Cost of PCV13 49.10 Fixed 207
Administration costs 7.51 Fixed 207
Other variables
Herd effect due to infant vaccination See Appendix2 Normal See Appendix 2
Life expectancy among high risk groups See Appendix 2 NA See Methods
Discount rate for costs and health effects 3.5% NA 208
* Odds ratio of IPD comparing risk groups to non–risk groups. Specific odds ratios can be found in Van Hoek et al.40
† Age specific case fatality ratios can be found in Van Hoek et al.40
‡ After single dose during first year of vaccination. Efficacy estimates do not apply for serotype 3 (see method section)206. 
Estimates of vaccine efficacy after two doses are listen in Appendix 4.
§ Annual waning factor was calculated by using the experts estimation of vaccine efficacy during first and third year after 
vaccination using annual exponential decay of immunity.
¶ Same quality of life year decrement was assumed for invasive pneumonia, bacteraemia with focus, and bacteraemia without 
focus.
** Mean costs were sampled from a normal distribution with a mean equal to the log normal mean and standard deviation equal 
to the standard error of the log normal mean.
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Scenario and sensitivity analysis
We carried out univariate, threshold, scenario, and probabilistic sensitivity analyses. In the univariate 
sensitivity analyses, relevant variables were based on the 5% and 95% quantiles to explore the 
impact of uncertainty around each variable. A threshold analysis was done in which we varied 
the vaccine price to investigate the effect on the ICER. In specific scenario analyses we explored 
the impact of changes in vaccine efficacy, vaccine waning, delaying the herd effect of the infant 
PCV13 programme, assuming life expectancy of the general population (rather than using the life 
expectancy of people in high risk groups), and the effect of discounting.
 For the probabilistic sensitivity analyses, we generated variables using Monte Carlo sampling, 
with outcome values generated by running the model 5000 times using Latin hypercube sampling. 
When quantitative data about uncertainty around variables were available we used log normal 
and β distributions (see Table 1 for specific distributions). When only a single point estimate was 
available, we assumed a normal distribution with a coefficient of variation of 0.25. For all the 
sensitivity analyses it was assumed that the vaccination programme would be launched in 2012–13 
(two to three years after the infant programme).
Outcome measures and cost effectiveness analysis
The simulation model tracks the incidence of IPD and non–bacteraemic pneumococcal pneumonia, 
the number of deaths, costs, QALYs, and life years. We calculated the net costs, life years gained, 
and QALYs by summing all the costs, life years, and QALYs and calculating the differences for the 
evaluations with and without vaccination. The ICER was calculated by dividing the net costs by 
either the life years gained or QALYs gained. Health effects and cost were both discounted at 3.5% 
according to the UK guidelines208. In the analyses we compared the possible impact of vaccination 
using PCV13 with that of the current situation. Currently, adults aged more than 65 years and people 
in at risk groups aged 2 years or more are recommended to be vaccinated with PPV23212; however, 
uptake of the vaccine is relatively low, especially in those aged less than 65 years (see Appendix 7)40. 
We assumed that PCV13, would be used in addition to PPV23.
 Finally, we assumed that the uptake of PCV13 would be similar to the annual influenza 
programme in the United Kingdom, at 34.5% in the age group 2–16, 53.6% in the age group 16–
65, and 72.4% in the age group 65 and older213 and that vaccination with PCV13 would be offered 
irrespective of previous vaccination with PPV23.
RESULTS
Invasive pneumococcal disease incidence, vaccine efficacy, indirect effects, and life expectancy
Among high risk groups the highest incidence of IPD was in young people infected with HIV and 
the lowest in those with chronic heart disease, diabetes, or splenic dysfunction (see Appendix 8 
for estimated incidence of IPD among high risk groups). Table 1 shows the estimates for vaccine 
efficacy based on the elicitation of expert opinion and the estimated costs associated with different 







types of IPD. Appendix 2 presents the Poisson regression for IPD due to vaccine serotypes after the 
introduction of PCV7. Finally, appendix 5 shows the life expectancy for people in high risk groups.
Total burden in high risk groups
Without a vaccination programme based on risk groups, but taking into account the likely herd 
effects of the infant PCV13  programme, the model predicts that from 2012–13 to 2020–21 about 
1333 cases of IPD due to vaccine serotypes would occur in people at high risk. This corresponds to 
a total loss of about 5900 life years or 6200 QALYs (undiscounted). The herd impact of the infant 
PCV13 programme  is large; preventing an additional 6200 IPD cases due to vaccine serotypes 
corresponding to an additional 30,400 QALYs lost compared with a continuing infant PCV7 
programme.
Table 2. Total burden of IPD due to vaccine serotype (undiscounted) over nine year period (2012–13 to 2020–21) 
in people at high risk.
Variables
Cases of IPD due to 
vaccine serotypes
Deaths Life years QALYs
Without high risk vaccination and without herd protection 
benefits of PCV13*
7522 1895 34,251 36,579
Cases prevented by the herd effects  of the  infant PCV13 
programme†
6189 1538 28,397 30,382
Without high risk vaccination and with herd effects of 
additional six serotypes in PCV13
1333 357 5854 6197
With high risk group vaccination (including herd effects of 
infant programme)‡
927 247 4033 4274
Averted burden by high risk vaccination (incremental 
effects)§
406 110 1821 1923
* Only including herd effect due to serotypes included in PCV7 (excluding herd effect due to the six additional serotypes 
included in PCV13.)
† Herd effects due to the additional six serotypes in PCV13 based on incidence after vaccination with PCV7 (see methods and 
Appendix 2).
‡ Vaccination uptake to be assumed similar to that of annual influenza uptake (see methods).
§ Numbers may not add up owing to rounding.
Budget impact
A risk based vaccination programme would require 4.1 million vaccine doses (assuming the same 
vaccine uptake as the annual influenza vaccination programme), resulting in a total cost of around 
£233m (of which £202m is attributed to the vaccine and the remainder to administration costs). 
Focusing on specific high risk groups, in whom vaccination would be most cost effective, could 
reduce the costs substantially. For example, vaccinating people with chronic liver disease would 
result in a total net cost of £4.6m. Furthermore, Table 3 also shows the impact on budgets of 
assuming a higher coverage among all risk groups (80% uptake) and the impact assuming the same 
annual coverage as for the PPV23 (see Appendix 7). If coverage is no higher than that achieved by 









programme (base case)* 80%
Similar to annual
PPV23 programme†
Any risk group 233 290 17.8
Splenic dysfunction 6.3 8.9 0.35
Chronic respiratory disease 34.1 41.5 2.80
Chronic heart disease 116 1411 9.60
Chronic kidney disease 71.5 83.4 6.40
Chronic liver disease 4.64 6.4 0.24
Diabetes 59.2 75.2 4.15
Immunocompromised 17.9 24.0 1.12
Infected with HIV 0.37 0.54 0.01
* Annual influenza coverage 34.5% in 2–15  year olds, 53.6% in 16–65 year olds, and 72.4% in those aged ³65 years213. Sum 
of costs of separate risk groups are higher than total costs of any risk group as people may have more than one underlying 
condition.
† Annual uptake 4.1% in 2–15 year olds, 1.5% in 16–65 year olds, and 7.2% in those aged ³65 years). See Appemndix 7.
Cost effectiveness
The base case analysis (excluding a possible impact against non–bacteraemic pneumococcal 
pneumonia) assumed it would be possible to start vaccinating at risk groups in the epidemiological 
year 2012–13. Using a threshold of £30,000 for a willingness to pay for a QALY gained208, only 
vaccination of patients with chronic liver disease (Table 4) would be deemed cost effective. People 
infected with HIV was the second most favourable at risk group, with an ICER of £61,200 per QALY 
gained. Vaccinating all other at risk groups would not be considered cost effective, with an ICER of 
more than £80,000 per QALY gained.
Impact of time on cost effectiveness
The expected indirect benefits as a result of the infant vaccination programme limit the direct effect 
of targeting high risk groups. As a result the cost effectiveness of vaccinating at risk groups decreases 
over time as indirect benefits accrue. If a programme targeted at high risk groups had been initiated 
in 2009–10, then vaccinating immune compromised people and people with chronic respiratory 
disease and HIV infection could also be deemed cost effective (ICER of ≤£30,000 per QALY). Figure 1 
shows the impact of time on the ICER for the years 2009–10 up to 2015–16.
Sensitivity analyses
Table 4 shows the impact on the ICER of assuming an overall impact on non–bacteraemic pneumonia. 
If included, even vaccinating the whole group at increased risk of IPD might be considered cost 
effective, with an ICER of £17,500 per QALY. Figure 2 shows the maximum costs of vaccination for it 







to be considered cost effective. These costs will decrease with a decreasing net effect of the vaccine 
in time. In the base case (no overall impact on non–bacteraemic pneumonia) the vaccine costs have 
to be reduced for all risk groups, except for patients with chronic liver disease, to consider a risk 
group programme to be cost effective.
Table 4. Incremental cost effectiveness ratios (ICERs) in £/QALY per risk group assuming vaccination will be 






Any risk group 183,680 17,503
Splenic dysfunction 1,204,091 37,686
Chronic respiratory disease 90,243 14,832
Chronic heart disease 161,063 16,043
Chronic kidney disease 493,682 22,641
Chronic liver disease 20,324 10,825
Diabetes 269,750 18,459
Immunocompromised 90,720 24,296
Infected with HIV† 61,239 28,144
*  Assuming no overall impact on non bacteraemic pneumonia in high risk group.
† When the assumption was made that life expectancy of people infected with HIV would be similar to high risk 
immonocompetent people,43 44 ICERs were estimated at £54 409/QALY in base case analysis and at £25 717/QALY when an 
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Figure 2. Maximum costs per vaccinee (including costs of vaccine and administration) to consider risk group 
vaccination cost effective (ICER of ≤£30,000 per QALY)
Table 5. Result of scenario analyses on the incremental cost effectiveness ratio (£/QALY) for those risk groups 












Base case 183,680 90,243 20,324 90,720 61,239
No herd effects due to any serotypes in 
PCV13 *
37,687 18,061 2848 20,059 10,059
No herd effects due to six additional 
serotypes in PCV13 †
46,903 22,715 3529 25,259 12,404
No herd effects due to serotypes 1 and 5† 74,882 36,122 6496 41,115 25,181
Herd effect of infant PCV13 programme 
delayed by two years
128,603 63,257 13,369 63,301 39,452
Vaccine price 25% reduced 143,564 70,390 15,772 70,720 47,342
Vaccine price 25% reduced and no 
administration costs
119,021 58,244 12,987 58,484 38,840
No waning immunity 141,999 69,927 17,013 65,107 45,181
No discounting 120,495 60,164 11,570 59,730 34,484
Life expectancy of normal population 163,070 79,937 18,446 81,036 50,331
Double vaccine dose 308,886 153,053 34,429 143,581 97,066
15% higher incidence of invasive 
pneumococcal disease
159,550 78,302 17,586 78,691 52,880
Assuming PCV13 to be effective against 
serotype 3
150,326 73,331 17,620 74,099 54,099
* No further reduction as from 2009–10 for all serotypes included in PCV13.
† 20% less herd effects could be achieved when serotypes 1 and 5 were not assumed to provide herd protection and 80% less 
herd effects could be achieved when six additional serotypes included in PCV13 would not provide any herd effect compared 
with maximum herd effect (for example, total eradication of all serotypes included in PCV13) calculated by using specific 
incidence data on serotype for 2009–10 and projecting forward.







 The results of the scenario analyses (Table 5) and the univariate sensitivity analysis (Fig 3) show 
that the predicted herd effects of the infant programme and vaccine efficacy have a large impact on 
the ICERs. For instance, if there are no herd effects resulting from the additional types now included 
in the infant vaccination programme then the cost effectiveness of targeting all high risk groups 
would be reduced from over £180,000 to around £47,000 per QALY gained. 
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Figure 3. Result of the univariate sensitivity analysis. Variables were changed over their 5% and 95% quantiles, 
with exception of share of meningitis and empyema, which were varied by 50%. Incidence was altered by 
varying odds of IPD in those with risk factors compared with those without. Bar for lower vaccine efficacy are 
cut–off for all at risk groups except immunocompromised patients. Please note that the scales of the figures vary. 
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Other important factors were the price of the vaccine, the risk and age group specific incidence, and 
the case fatality ratio. Also, the scenario analysis showed that the additional benefits of a second 
dose were outweighed by the doubling of the costs. 
Probabilistic sensitivity analysis
Figure 4 shows the cost effectiveness acceptability curves for the risk groups in whom the ICER was 
less than £100,000 per QALY. It is clear that if the vaccine does not offer protection against non–
bacteraemic pneumococcal pneumonia then only vaccinating patients with chronic liver disease is 
likely to be considered cost effective, but by assuming an overall impact against non–bacteraemic 
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Figure 4. Results of probabilistic sensitivity analysis. 
DISCUSSION
Although herd effects of the infant vaccination programme will indirectly protect high–risk 
individuals in time, the burden of preventable, pneumococcal disease will remain high during the 
first years after the introduction of the infant PCV13 programme.
 Vaccinating all groups at high risk of IPD with PCV13 would have a large impact on budgets, 
therefore targeting specific high risk groups may be more attractive although this would require 
general practitioners to identify subgroups among those at increased risk. Our analysis shows 
that unless PCV13 also offers protection against non–bacteraemic pneumococcal pneumonia, 
vaccination is unlikely to be considered cost effective for most at risk groups. The assumptions about 







vaccine efficacy and effectiveness, and in particular that against non–bacteraemic pneumococcal 
pneumonia, had a large impact on our results, and a great deal of uncertainty surrounds these 
estimates. Although evidence from randomised controlled trials would be preferable to expert 
opinion, by the time results are available168 the potential benefits of vaccinating high risk groups are 
already largely limited by the expected herd effects.
Strength and weaknesses of the study
This is the first economic evaluation of vaccination against pneumococcal disease in specific high 
risk groups using PCV13. The two most influential variables on the outcome were the assumed 
herd protection benefits from the infant pneumococcal vaccination programme and the vaccine 
effectiveness against non–bacteraemic pneumococcal pneumonia.
 Dynamic models have been used to predict the herd effects of the infant vaccination 
programme but their reliability critically depends on the structure and underlying assumptions, 
such as vaccination coverage, difference in case–carrier ratios between serotypes, and the level of 
competition between vaccine serotypes and non–vaccine serotypes in carriage209,214. Hence any 
such model predictions are subject to considerable uncertainty. Therefore we decided to predict 
the future herd effects by using Poisson regression models, assuming that the decrease in the 
additional serotypes (with the exception of serotype 3) would be similar to those observed after 
the introduction of the PCV7. Nevertheless, the herd effect for the six additional serotypes in PCV13 
might be different from those in PCV7 owing to differences in carriage, transmissibility, and the 
potential to cause disease80,120. We also assumed that the herd effects would be similar among high 
risk and non–high risk groups, as this was previously also observed for IPD due to serotypes in 
PCV740. However, as the less invasive serotypes primarily affect people at high risk and the additional 
serotypes included in the PCV13 are the more invasive, people at high risk might benefit less from 
herd effects compared with healthy people215. This may also explain the failure to find a reduction in 
non–bacteraemic pneumonia in children at high risk compared with healthy children.
 Another key assumption was the vaccine efficacy against IPD and non–bacteraemic 
pneumococcal pneumonia. The main reason for not including an effect against non–bacteraemic 
pneumococcal pneumonia in the base case analysis was that the time series analysis did not show 
any measurable effect on admissions due to pneumonia in high risk children eligible for vaccination 
with the PCV7, whereas a significant reduction was observed in non–high risk children of the same 
age. This might be explained by different pathogens (viral or bacterial) causing pneumonia in high 
risk populations and for those with pneumococcal pneumonia, a different serotype distribution in 
high risk compared with low risk people. As we had the ability to analyse our surveillance data 
by whether patients had comorbidities, which would seem essential for deciding on a risk based 
vaccination programme, our assumption of the effectiveness against non–bacteraemic pneumonia 
differs from two previous analyses129,216. We do, however, also note that the effect of being in an at 
risk group on increasing the risk of IPD is more noticeable in children than in adults40, which might 
mean that our assumption of lack of a direct effect of PCV13 on non–bacteraemic pneumonia in 
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adults may be conservative199, yet consistent with the BMJ guidelines for economic evaluations40,217.
 Finally, we note that the impact of non–bacteraemic pneumococcal pneumonia was high in our 
analysis despite a relatively low vaccine efficacy being used in combination with a relatively high 
waning rate (Table 1).
 The cost effectiveness of vaccination depends heavily on the probability of developing disease. 
In our analysis this was based on the observed odds of IPD in risk groups compared with those not 
in risk groups and the absolute incidence of non–risk group related disease. One of the caveats of 
the risk factor study was that patients were attributed to risk groups on the basis of the presence 
of specific discharge codes. Some of the risk groups might not have been consistently recorded. 
The odds for people with asplenia were low in the study, with no obvious increased probability of 
developing disease, resulting in unfavourable ICERs. Although this might be explained by successful 
prophylaxis by antibiotics or polysaccharide vaccine, it is possible that people with asplenia were 
poorly recorded. Therefore the cost effectiveness of some of the described risk groups might have 
been underestimated, although sensitivity analyses showed that our conclusions remained valid 
when we increased the incidence. Also, the future incidence of pneumococcal disease due to vaccine 
serotypes may be affected by changes in the epidemiology of viral respiratory tract infections, such 
as happened with pandemic A/H1N1 2009 influenza218. This caused a noticeable increase in IPD in 
the age groups with the highest incidence of H1N1 infection218, and, given the overlap between 
the risk groups for influenza and IPD, selective vaccination of high risk groups PCV13 might help 
mitigate the effects of future increases in such viral infections.
Comparison with other studies
This is the first cost effectiveness analysis of PCV13 focusing specifically on people at increased risk 
for IPD. As far as we know, two other studies have focused on the cost effectiveness of vaccinating 
non–infant populations129,216. A main difference is that these studies focused on older adults (>50 
years216 and 65 years129), whereas our study specifically focused on risk groups of people aged 2 years 
and older. Both these studies showed that for these specific age groups a vaccination programme 
could be considered cost effective, whereas we in the base–case analysis conclude that a vaccination 
programme is unlikely to be considered cost effective. The main driver for this difference is that in the 
base case analysis we assumed that PCV13 would not have an overall impact on non–bacteraemic 
pneumonia. This difference was further driven by the assumption that PCV13 would not be effective 
against serotype 3, as early data from England and Wales suggests that this component of PCV13 
does not seem to provide direct protection to vaccinated people206. However, this assumption was 
based on a few cases of invasive disease due to this serotype in children in England and Wales and 
future data are necessary to answer the outstanding question on the efficacy of this serotype.
 Other differences between our study and these two age based studies are that we had detailed 
data on the risk of disease, the life expectancy of high risk populations, and specific costs per 
IPD episode available, all based on primary data as opposed to estimates from the literature or 
databases. Furthermore, compared with the Dutch study we were able to explicitly take herd effects 







into account for the unvaccinated population as recent data has become available that could be 
used for the prediction of these effects36.
 We showed in the current study that these herd effects have a major impact on cost effectiveness. 
It is desirable that specific cost effectiveness studies from a European perspective become available 
to guide decision making in European countries rather than using cost effectiveness estimates from 
the United States. Previous decisions to introduce the infant pneumococcal vaccination programmes 
in European countries largely relied on herd immunity estimates from the United States that were 
subsequently shown not to be applicable elsewhere3.
Implications and future research
We found that the cost effectiveness of a PCV13 risk group based programme will mainly depend 
on the time of using the vaccine and its effectiveness, in particular against non–bacteraemic 
pneumococcal pneumonia. Since most countries have replaced PCV7 with PCV13, herd effects 
are likely to decrease the burden of preventable pneumococcal disease over time rendering any 
additional preventive efforts less cost effective. If PCV13 does protect against non–bacteraemic 
pneumococcal pneumonia in high risk groups the programme may be cost effective if introduced 
early enough before the full effect of herd immunity is manifested, or if the expected herd immunity 
effect is less than expected. Policy makers may prefer to delay any decision about the use of PCV13 
in high risk groups until the results of the trial currently being done in the Netherlands to assess its 
efficacy against non–bacteraemic pneumonia in elderly people are available168. However, such a 
wait and see policy would possibly reduce the need for the additional vaccination effort. Another 
option for governments to consider would be sharing the risk with the manufacturer; on the 
basis of the uncertainty around the cost effectiveness a price reduction could be negotiated that 
remains valid until the data on efficacy become available. The implementation of a risk based PCV13 
programme in the United Kingdom has been considered by the UK Joint Committee on Vaccination 
and Immunisation, with the final decision being not to introduce such a programme largely 
dependent on the outcome of our study219. As many other European countries lack the various high 
quality epidemiological data sources available in the United Kingdom or lack the statistical power 
owing to their population size to conduct their own analyses this study will also provide them with 
important evidence. Specific cost effectiveness ratios cannot directly be extrapolated from England 
to other countries but we believe that the general conclusion is informative for those countries that 
introduced PCV13 around the same time and have a similar uptake of vaccination. Some European 
countries are, however, already recommending PCV13 for at risk groups or adults. For example, in 
Austria and Greece PCV13 is recommended for those aged 50 and older220,221, whereas in France, 
parts of Germany, and Italy the vaccine is being recommended for (specific) risk groups222,223.
 Finally, we note that in addition to considerations about cost effectiveness, decision makers 
need to estimate carefully the possible uptake of vaccination, considering the potentially large 
impact on budgets of a risk based PCV13 programme.
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Objective: The primary objective of this meta–analysis was to estimate the prevalence of adult 
community–acquired pneumonia (CAP) caused by Streptococcus pneumoniae in Europe, adjusted 
for possible independent covariates. 
Methods: Two reviewers conducted a systematic literature search using PubMed on English–
language articles that involved human subjects with CAP during the period from January 1990 to 
November 2011 across European countries. A mixed–effects meta–regression model was developed 
and populated with 24,410 patients obtained from 77 articles that met the inclusion criteria. 
Results: The model showed that the observed prevalence of S. pneumoniae in CAP significantly 
varies between European regions even after adjusting for explanatory covariates, including patient 
characteristics, diagnostic tests, antibiotic resistance, and health–care setting. The probability of de-
tecting S. pneumoniae was substantially higher in studies that performed more frequently a diag-
nostic PCR assay compared to all the other diagnostic tests included. Furthermore, S. pneumoniae 
was more likely to be confirmed as the cause of a CAP in studies with ICU patients as compared to 
those with hospital or community treated patients. 
Conclusion: This study provides estimates of the average observed prevalence of S. pneumoniae, 
which could be used for projecting the health and economic benefits of pneumococcal immuniza-
tion.








Community–acquired pneumonia (CAP) is a common disease, with an annual incidence of 5 to 11 
cases per thousand adults in Europe and Northern America224. Streptococcus pneumoniae is generally 
accepted to be the most common cause of CAP163,164,225. There is, however, no consensus regarding 
the prevalence of S. pneumoniae in CAP, and estimates vary from 5% to 60% between different 
studies163,164,225. This may either reflect a true difference or, rather, a difference in confirmation rates.
Two earlier reviews, which focused on the causative agents of CAP, suggested that the frequency 
of S. pneumoniae differs between countries225 and health–care settings164. However, large variations 
between studies within the same setting and country were observed, suggesting that these 
differences could be more related to the study methodology than to real differences164. Another 
factor which might have impacted the findings of the previous reviews is that the investigators also 
included studies in which radiographic confirmation of pneumonia was not an inclusion criterion. 
As a consequence, part of the study patients can be expected to have had respiratory tract infections 
other than pneumonia, or entirely other conditions, and the respiratory pathogens detected in 
those cases might not be relevant to describe the relative contribution of S. pneumoniae in CAP226.
 It is important to have a reliable estimate of the share of S. pneumoniae in the total burden 
of CAP, especially now that the results of a clinical trial estimating the efficacy of the 13–valent 
conjugated pneumococcal vaccine (PCV13) in the elderly are pending and the country–specific 
health and economic impact of this vaccine will largely depend on the share of S. pneumoniae in 
CAP129,168.
 The primary objective of this meta–analysis is to estimate the average etiological fraction of S. 
pneumoniae in CAP while controlling for potential sources of heterogeneity attributed to regional, 
health care settings, and other differences.
METHODS
Search strategy and selection criteria
We used PubMed (www.pubmed.com) to search for original study reports during the period between 
January 1990 and November 2011 on the etiology of CAP among adults using the following search 
terms: ”Pneumonia” [MAJR] AND (“etiology” [Subheading] OR “epidemiology” [Subheading]) AND 
(“Pneumonia, Bacterial” [MH] OR “Pneumonia, Viral” [MH] OR “microbiology” [Subheading] OR “virology” 
[Subheading] OR “Streptococcus pneumoniae” [MH]) AND (“Adult” [MH] OR “aged” [MH]) AND (“Journal 
article” [PT] NOT “meta–analysis” [PT] NOT “review” [PT] NOT “guideline” [PT]). We limited the articles 
to the English language. To ensure that articles actually dealt with the most accurate diagnostic 
definition of CAP, studies in which the CAP diagnosis was not confirmed with a new or increased 
infiltrate on a chest radiograph were excluded. Furthermore, we excluded (1) case reports, editorials, 
reviews, and letters without original data; (2) studies which focused primarily on pneumonia related 
to sources other than the community; (3) articles that included only specific patient groups such as 
patients with COPD; (4) studies performed during the 2009 influenza pandemic; (5) clinical trials; 
and (6) studies which did not report the fraction of CAP being caused by S. pneumoniae. 
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 After applying these inclusion and exclusion criteria, the titles of all potentially eligible articles 
were independently reviewed by two investigators (MHR and EH). Articles were excluded from 
further review only if both investigators agreed on one or more reasons for exclusion. If a study 
was not excluded on the basis of the title, the study abstract was reviewed independently by both 
investigators. Subsequently, all articles judged to meet the inclusion criteria based on the reviewed 
abstract were retrieved for further evaluations. After reviewing the entire text of the retrieved 
papers, only those that met all inclusion criteria were included in the analysis and the relevant data 
were extracted (see below).
Data Extraction 
Two reviewers independently extracted the total number of CAP episodes and the number of CAP 
episodes in which S. pneumoniae could be detected. A CAP episode was assumed to be caused 
by S. pneumoniae if it was detected in a normally sterile site, in the nasopharynx, or in sputum. 
We also recorded the type of diagnostic tools applied and distinguished them between culture, 
serological or PCR tests, or more invasive sampling methods. Culture tests were subdivided into 
those performed on either sputum or blood. Serological tests were separated into tests performed 
on urine and those performed on blood and sputum. More invasive sampling methods included 
trans–thoracic needle aspirations and bronchoscopic techniques.
 Further, the following study–specific data were extracted: health–care setting, country and 
time period, age (mean or median if the mean is not reported), gender distribution, percentage of 
included patients with COPD and patients with severe immunosuppression (including patients with 
organ transplants, HIV/AIDS, chemotherapy and chronic corticosteroids use of >20mg/day). The 
health–care setting was divided into three distinctive groups: (1) cases managed in primary care; 
(2) cases admitted to hospital; and (3) cases admitted to the intensive care unit (ICU). Four different 
geographical regions were defined based on the United Nations geoscheme (North, East, South, 
and West)227.
 Also, country–specific antibiotic use and resistance of S. pneumoniae to antibiotics might have an 
impact on the observed prevalence of the respiratory agents228. To take antibiotic use into account, 
we used the defined daily dose of outpatient antibiotics (antimicrobials for systemic use, ATC Group 
J01) per 1,000 inhabitants as reported by Muller et al for the year 2002229. Since only reimbursement 
data were available for Spain, we corrected the number of doses upwards to correct for the fact that 
over–the–counter antibiotic use in Spain stands at around 30% 228. The S. pneumoniae–specific level 
of antibiotic resistance was based on the percentage of penicillin non–susceptibility using 2010 
data of the antimicrobial resistance surveillance in Europe230 and other sources for Switzerland231 
and Greece232. Although shifts in the use of antibiotics and related resistance might occur, it has 
been shown that antibiotic use and resistance in the selected countries remained quite stable over 
time228-230,233. 








In order to synthesize the collected evidence, we used a meta–regression model framework for 
binomial outcomes234. Given the large expected true variation of prevalence between studies, we 
decided to use a mixed–effects instead of a fixed–effects meta–regression framework235. In this 
specification, we assumed that the covariate–adjusted log odds of an S. pneumoniae–induced CAP 
is not constant but varies randomly across studies. We further assumed that the additional, study–
specific random effects follow a normal distribution with zero mean and variance σ2Study. It was also 
assumed that the measure of association between the log odds of an S. pneumoniae–induced CAP 
and countries is random and normally distributed with mean zero and variance σ2Country. Additionally 
to these random effects, the model was corrected for a number of study–and country–specific 
covariates which were incorporated as fixed effects. From the full set of covariates we sub–selected 
those that significantly improved the fit of the model. We fitted a variety of models with different 
covariates included and compared their goodness of fit using the Akaike information criterion (AIC) 
in order to arrive at the final set of covariates236,237. 
 Missing values in the covariates used were handled through multiple imputation238,239. We 
created twenty–five imputed datasets, in each of which every missing value was replaced with 
a plausible value estimated through a regression model. Next, the meta–regression framework 
described above was applied for every dataset. The results were subsequently synthesized for 
statistical inference. All statistical analyses were implemented using the statistical software R (version 
2.13.2) 240. We additionally used the “mi”, “lme4”, and “meta” R packages for the implementation of 




Of the 3,738 original citations, we excluded 3,290 (88%) based on a review of the titles (Figure 
1). Of the remaining 448 selected studies, 277 were excluded after reviewing the abstract. After 
reviewing the entire text of the remaining 171 studies 73 met eligibility criteria. In addition to the, 73 
studies included by the initial search term, four more were identified by scanning of references and 
subsequently added, resulting in a total of 77 included studies13,176,177,202,203,226,242-312. Several studies 
reported data separately for health–care settings. These studies were, therefore, split into setting–
specific “sub–studies” in this analysis. 
Study characteristics
The characteristics of the 77 selected studies are presented in Table 1. Of all (sub–) studies included, 
the majority reported cases admitted to hospital (n=60), 17 were available for cases admitted to the 
ICU, and 14 for cases managed in the primary care. A total of 24,410 patients were included with 
an average age of 62.1 years, with 62.3% being male. Most of the studies originated from Southern 
Europe, with Spain being the most frequently represented country. No studies were found for 
Eastern Europe. In Figure 2, the crude proportion of S. pneumoniae per country is presented. 
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Table 1. Basic study characteristics of the (sub–) studies included into the mixed–effects logistic regression$.
First author and 
reference













Ewig et al242 1999–2000 Germany Western Hospital 68 62 3.7
Ewig et al286 1985–1993 Germany Western Hospital 51 67 3.7
Kruger et al287 2002–2007 Germany Western Community 62 55 3.7
Kruger et al287 2002–2007 Germany Western Hospital 62 55 3.7
Steinhoff et al288 1991–1992 Germany Western Hospital 57 62 3.7
Blanquer et al290 1985–1986 Spain Southern Community 41 70 29.8
Blanquer et al290 1985–1986 Spain Southern Hospital 60 70 29.8
Briones et al291 2000–2004 Spain Southern Hospital 66 64 29.8
Valencia et al292 1996–2003 Spain Southern Hospital 79 69 29.8
Valencia et al292 1996–2003 Spain Southern ICU 79 75 29.8
Cilloniz et al279 1996–2008 Spain Southern Community 66 63 29.8
Cilloniz et al279 1996–2008 Spain Southern Hospital 66 63 29.8
Cilloniz et al279 1996–2008 Spain Southern ICU 66 63 29.8
Falco et al280 1988–1989 Spain Southern Hospital 56 100 29.8
Falguera et al281 1997–2000 Spain Southern Community 51 57 29.8
Garcia–Ordonez et al282 1996–1998 Spain Southern Hospital 76 58 29.8
Garcia–Vazquez et al283 2003–2003 Spain Southern Hospital 63 66 29.8
Garcia–Vidal et al284 1995–2005 Spain Southern Hospital 65 68 29.8
Gomez et al285 1991–1994 Spain Southern Hospital 58 67 29.8
Gutierrez et al303 1999–2001 Spain Southern Community 57 63 29.8
Gutierrez et al303 1999–2001 Spain Southern Hospital 57 63 29.8
Lorente et al304 1996–1998 Spain Southern Hospital 62 61 29.8
Martinez Moragon et al305 2003–2003 Spain Southern Hospital 73 45 29.8
Menendez et al306 1996–1997 Spain Southern Hospital 62 63 29.8
Molinos et al307 1991–1994 Spain Southern Hospital 58 79 29.8
Molinos et al308 2003–2004 Spain Southern Hospital 67 68 29.8
Sopena et al309 1994–1996 Spain Southern Hospital 54 73 29.8
Pachon et al310 1985–1987 Spain Southern ICU 57 67 29.8
Pareja et al311 1989–1991 Spain Southern Hospital 57 67 29.8
Querol Ribelles et al312 2000–2003 Spain Southern Hospital 71 71 29.8
Rello et al293 1991–1992 Spain Southern ICU 72 65 29.8
Rello et al294 1993–1999 Spain Southern ICU 61 79 29.8
Rello et al295 1988–1990 Spain Southern ICU 45 76 29.8
Riquelme et al296 1993–1994 Spain Southern Hospital 79 67 29.8
Ruiz–Gonzalez et al297 1993–1994 Spain Southern Hospital 51 62 29.8
Ruiz–Gonzalez et al297 1993–1994 Spain Southern Community 51 62 29.8
Sorde et al298 2007–2008 Spain Southern Hospital 64 67 29.8
Torres et al299 1984–1987 Spain Southern ICU 53 77 29.8
Zalacain et al300 1997–1997 Spain Southern Hospital 76 63 29.8
Howard et al202 1999–2000 UK Northern Hospital NS NS 3.1
Lim et al203 1998–1999 UK Northern Hospital 65 51 3.1
British Thoracic Society301 1987–1987 UK Northern ICU 54 57 3.1
Venkatasan et al302 1987–1988 UK Northern Hospital NS 52 3.1
Woodhead et al273 1988–1989 UK Northern Hospital NS 55 3.1
Boersma et al176 1987–1989 Netherlands Western Hospital 59 64 2.0
Boersma et al274 1988–1992 Netherlands Western Hospital 52 60 2.0
Bohte et al177 1991–1993 Netherlands Western Hospital NS 58 2.0
Endeman et al275 2004–2006 Netherlands Western Hospital 63 62 2.0







Table 1. Basic study characteristics of the (sub–) studies included into the mixed–effects logistic regression$. 
(Continued)
First author and 
reference













Holloway et al276 NS–1991 Netherlands Western Hospital 58 60 2.0
Templeton et al277 2000–2002 Netherlands Western Hospital NS 71 2.0
Templeton et al277 2000–2002 Netherlands Western ICU NS 71 2.0
Van der Eerden et al13 1998–2000 Netherlands Western Hospital 64 54 2.0
Vegalin et al278 1992–1996 Netherlands Western ICU 64 61 2.0
Fantin et al264 1995–1997 France Western Community 52 50 27.6
Fantin et al264 1995–1997 France Western Hospital 52 50 27.6
Georges et al265 1987–1995 France Western ICU 63 66 27.6
Leroy et al266 1987–1992 France Western ICU 63 63 27.6
Leroy et al266 1993–1994 France Western ICU 61 68 27.6
Moine et al267 1987–1989 France Western ICU 58 74 27.6
Paganin et al268 1995–2000 France Western ICU 55 84 27.6
Renaud et al269 2002–2003 France Western Community 71 64 27.6
Renaud et al269 2002–2003 France Western Hospital 71 64 27.6
Laurichesse et al270 1998–1999 France Western Hospital 67 53 27.6
Blasi et al271 1991–1993 Italy Southern Community 42 52 9.2
Blasi et al271 1991–1993 Italy Southern Hospital 42 52 24.4
Cosentini et al272 1992–1993 Italy Southern ICU 68 64 9.2
Farina et al251 1999–2000 Italy Southern Hospital NS NS 9.2
Guglielmo et al252 NS –1995 Italy Southern Hospital 63 62 9.2
Michetti et al253 1991–1992 Italy Southern Community NS 43 9.2
Michetti et al253 1991–1992 Italy Southern Hospital NS 70 9.2
Burman et al254 1982–1984 Sweden Northern Hospital NS 52 3.8
Johansson et al255 2004–2005 Sweden Northern Hospital 61 51 3.8
Ortqvist et al256 NS –1987 Sweden Northern Hospital 62 43 3.8
Stralin et al257 1999–2002 Sweden Northern Hospital 0 53 3.8
Hohenthal et al258 1999–2004 Finland Northern Hospital 50 52 14.2
Jokinen et al259 1981–1982 Finland Northern Community 49 58 14.2
Jokinen et al259 1981–1982 Finland Northern Hospital 49 58 14.2
Beovic et al260 1999–2001 Slovenia Southern Community 45 62 15.5
Socan et al261 1996–1997 Slovenia Southern Hospital 57 50 15.5
Melbye et al262 1988–1989 Norway Northern Community NS 46 15.5
Holm et al226 2002–2003 Denmark Northern Community NS 58 3.6
Kirk et al249 1995–1996 Denmark Northern Hospital NS 44 3.6
Ostergaard et al250 1988–1993 Denmark Northern Hospital 65 46 3.6
Leesik et al263 1996–1998 Estonia Northern Hospital 56 77 1.6
Genne et al248 1999–2000 Switzerland Western Hospital 68 57 9.3
Janssen et al247 1988–1989 Switzerland Western Hospital 85 36 9.3
Muller et al246 2002–2005 Switzerland Western Hospital 67 63 9.3
Muller et al245 2006–2008 Switzerland Western Hospital 73 59 9.3
Marques et al243 2004–2006 Portugal Southern ICU 63 74 14.7
$  When studies reported data separately for different healthcare settings, they were split into different sub–studies.
*  When average age and sex was not provided across different health settings, the overall average corresponding estimates 
were used instead.
#  The level of S. pneumoniae antibiotic resistance was based on the percentage of penicillin non–susceptibility using the Clinical 
and Laboratory Standards Institute (CLSI) , the European Committee on Antimicrobial Susceptibility Testing (EUCAST), and 























Reporting same data as other studies n=39
Not reporting etiologic share of S. pneumoniae n=15
Focusing on other countries than EU countries n=11
Xray conformation was not an inclusion criteria n=6
Evaluation of specific test  n=7
Focusing on a specific population n=6
Other reasons n=14
Excluded n=277*
Non European country n=164
Pneumonia not acquired in the community n=20
Case reports n=16
Specific population (e.g. COPD patients) n=7
Test validation studies  n=14
S. pneumoniae not included n=7
Other reasons n=41
Clinical trials n=8
* Multiple reasons per paper were possible, only one was 
selected
Additional studies 
found by scanning  
references
n=4
Figure 1. Flow diagram for the selection of studies.
Figure 2. The country–specific, crude proportion of Streptococcus pneumoniae as a causative agent for 
community acquired pneumonia (CAP). Numbers of episodes per country: Germany (1783), Spain (12,804), UK 
(605), Netherlands (1318), France (2480), Italy (897), Sweden (892), Finland (688), Slovenia (325), Norway (19), 
Denmark (545), Estonia (439), Switzerland (1,464), Greece (88), Portugal (76).








We identified 24,423 CAP episodes in 24,410 patients (patients could have more than one episode), 
of which 4,714 (19.3%) were attributed to S. pneumoniae. Figure 3 presents the unadjusted, study–
specific proportions of S. pneumoniae as the causative agent for CAP, together with the proportions’ 
confidence interval (CIs). 
Mixed–effects meta–regression
The results of the final model, in which country and study were estimated as random–effects 
parameters and the rest of the covariates as fixed–effects parameters, are presented in Table 2. 
This model assumes as baseline a study with average proportion of blood cultures, urine serology, 
blood or sputum serology, and PCR tests. Additionally, this baseline study is assumed to originate 
from a Northern European country with average antibiotic resistance and with CAP episodes that 
were managed in primary care. Hence, the estimated odds of an S. pneumoniae–caused CAP for a 
study with baseline characteristics was 0.176, which corresponds to a probability of 0.15. The model 
also showed that, in studies in which the percentage of blood cultures, urine serology, blood or 
sputum serology, or PCR tests increased, the likelihood of detecting S. pneumoniae also significantly 
increased with the highest increase observed for PCR tests (odds ratio 2.49; 95% CI: 1.39–4.46). 
 Compared to studies with CAP episodes managed in primary care, the odds of S. pneumoniae 
being the cause of a CAP was 1.45 (95% CI: 1.19–1.77) times higher in studies with episodes treated 
in the hospital and 2.33 (95% CI: 1.80–3.02) times higher in the ICU. The odds of detecting S. 
pneumoniae as the cause of CAP in studies from Western and Southern Europe were almost two 
and three times smaller, respectively, compared to studies conducted in Northern Europe, where 
S. pneumoniae was the most frequently observed, independently of the percentage of diagnostic 
testing, [Western Europe: 0.57 (95% CI: 0.32–1.00); Southern Europe: 0.40 (95% CI: 0.2–0.80)]. 
Illustratively, a study with baseline characteristics but originating from Southern Europe is expected 
to identify S. pneumoniae as the causative agent in 6.5% of the CAP episodes (since (0.176*0.397)/
(1+0.176*0.397)=0.065) .
 The estimate of the variance for the study–and country–specific random effects indicated that 
there was significant heterogeneity among the estimates that was not captured through the fixed–
effects covariates. The inclusion of both study–and country–specific random effects significantly 
improved the goodness–of–fit of the model. 
 Sputum culture and invasive detection techniques did not have a significant impact on the 
model or contributed to a better fit of the model to the study data, according to the AIC. Antibiotic 
resistance also did not significantly affect the probability to detect S. pneumoniae, after inclusion of 
the random–effects term for per–country variations. However, antibiotic resistance was deemed as 
being useful for the fit of the model and was, therefore, included in the analysis.
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Figure 3. Forest plot showing the unadjusted proportion (with 95% confidence intervals) of Streptococcus 
pneumoniae as the causative agent for community–acquired pneumonia (CAP). CAP cases reported for different 
health settings are reported separately across studies. 
Table 2. Mixed–effects meta regression model results.
Odds ratios Lower CI bound Upper CI bound p–value
Fixed effects estimates
Intercept1 0.176 0.113 0.274 <0.001
Region
   Western Europe 0.565 0.32 0.998 0.048
   Southern Europe 0.397 0.198 0.797 0.009
Health Care Setting 
   Hospital 1.451 1.191 1.769 <0.001
   ICU 2.334 1.804 3.021 <0.001
Blood culture (%) 1.782 1.002 3.17 0.048
Urine serology (%) 1.987 1.283 3.077 0.002
PCR (%)2 2.491 1.39 4.464 0.002
Blood or sputum serology (%) 1.836 1.114 3.023 0.017
Antibiotic resistance (%) 1.021 0.995 1.047 0.115
Random–effects estimates        
σ2Study  0.185      
σ2Country  0.094      
1Baseline study characteristics: region: Northern Europe; health care setting: primary care; average proportions of blood culture, 




In this analysis, we showed that the observed prevalence of S. pneumoniae in adult CAP significantly 
varies between studies conducted in different European regions, even after correcting for effect 
modifiers, including diagnostic tests used, antibiotic resistance, and health–care setting. The 
probability of detecting S. pneumoniae was also substantially higher in studies that performed more 
frequently a diagnostic PCR assay compared to all the other diagnostic tests included. Furthermore, 
S. pneumoniae was observed less frequently in studies with CAP cases treated in the community as 
compared to those with cases treated in the hospital or in the ICU. 
 In contrast to earlier review studies on this topic, we approached the analysis of the observed 
frequency of S. pneumoniae among pneumonia cases through a mixed–effects meta–regression 
framework164,225. In this respect we not only accounted for the influence of various covariates on 
the observed prevalence of S. pneumoniae, such as the health–care setting, diagnostic tests used, 
and antibiotic resistance, but we also corrected for other study and country specific unobserved 
parameters that might also have an impact on this share. This correction revealed that significant 
unobserved variation exists among countries as well as across studies, regarding the observed share 
of S. pneumoniae in CAP.
 The finding that this share differs across health–care settings was also noted previously by 
Woodhead164, although this was accompanied with the remark that individual studies showed a 
wide variety in the frequency of detecting S. pneumoniae. Our findings agreed with those observed 
by Woodhead, but through the use of a meta–regression model and the inclusion of more recent 
studies, we were able to confirm significant differences that were independent of other covariates. 
 One of the limitations of the previous reviews was that they did not exclude studies in which a 
radiographic confirmation of pneumonia was not an inclusion criterion. Without a chest radiograph, 
a CAP diagnosis cannot be made with certainty226. Similar clinical signs and symptoms can also be 
caused by non–infectious diseases such as congestive heart failure or atelectasis246. Therefore, and 
because the interpretation of clinical assessments are prone to inter–observer variability, we only 
included those studies in which this was an inclusion criterion.
 Our meta–analysis showed that in studies in which the percentage of invasive techniques or 
sputum culture increased, the likelihood of detecting S. pneumoniae did not significantly increase. 
This finding for invasive testing might be counterintuitive but can be attributed to the underreporting 
of the proportion of patients tested with this invasive method. In particular, almost all included 
studies report that invasive tests were performed, but the majority did not report the proportion 
of the patients tested. In most studies, the use of invasive techniques is likely to be limited to a few 
patients, as invasive sampling methods for lower respiratory secretions are impractical. This limited 
the accuracy of the estimate of the impact of invasive tests on detecting S. pneumoniae. A sub–
analysis in the studies that reported the fraction of invasive testing revealed that the percentage 
of invasive tests performed had a significant, positive impact on the study’s detected fraction of S. 
pneumoniae in CAP (data not shown).







 Of course, our study also has some limitations, which can be divided into those related to health–
care setting, populations, epidemiological, study methodological, and model–related factors164. 
Our model showed that S. pneumoniae was more likely to be prevalent in CAP cases treated in the 
ICU as compared to those treated in the hospital or in the community. We do, however, note that 
admission criteria for hospitalization or ICU admission might differ between hospitals and countries 
and may not always reflect severity. For example, in Spain, many patients seek medical care directly 
from the emergency service of the hospital rather than after a visit to a primary care physician281. 
Nevertheless, some of the country variation on the detection of S. pneumoniae is expected to have 
been captured through the country–specific random–effects parameter. 
 Secondly, factors related to the population, such as antibiotic therapy, vaccination status, 
immunosuppression, and comorbid conditions, might impact the share of S. pneumoniae 
detected. We tried to obtain as much information on the included studies as possible in order to 
be able to correct for these factors. For example, we obtained information on the proportion of 
immunosuppressed patients and patients suffering from COPD. However, the fit of the model was 
best when these factors were excluded. This might be explained by the fact that different definitions 
of ‘immunocompromised’ among studies were used or that specific data were just not reported. 
Additionally, the country–specific random–effects term used in the model might have corrected 
for enough across–country variation, constituting these variables as redundant. Furthermore, to 
minimize heterogeneity between studies we decided to exclude clinical trials as patients enrolled 
in these studies differ from those encountered in daily clinical practice. Considering the long time–
span of studies included into the model, we were unable to include PPV23 or influenza vaccination 
status, as country–specific vaccination coverage over time are not abundantly available. The impact 
of PPV23 vaccination is probably small as the uptake, the efficacy and the duration of protection of 
PPV23 are limited20,21. Although the influenza vaccine does not protect directly against pneumococcal 
pneumonia, viral infections may pave the way for pneumococcal infections32. We based the level of 
antibiotic resistance on recent antimicrobial resistance surveillance data230. Resistance levels may 
change over time, but we note that the resistance patterns of the most recent EARSS report230 are 
very similar to the earliest EARSS report using data from 1999–2001233.
 Thirdly, epidemiological factors may change the share of S. pneumoniae cases. For example, the 
time of year might impact the frequency of S. pneumoniae detected. Most of the studies included 
in our analysis had a time span of over a year, which might have been long enough to capture the 
short–term seasonal effects. 
 Fourthly, methodological factors such as comprehensiveness of sample collection and 
microbiological investigation performed are important164. We explicitly took this into account by 
correcting for both the type of microbiological investigation performed, as well as for the frequency 
at which these tests were performed. As previously noted by Woodhead some studies did not 
explicitly state the percentages of actually performed tests164. 
 Finally, a limitation of our analysis is the inability to accurately estimate the true prevalence of S. 
pneumoniae among CAP cases. The main reason for this is that the applied tests cannot detect the 
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true fraction of S. pneumoniae among the CAP cases, and, hence, the S. pneumoniae prevalence, due 
to their limited sensitivity and specificity. It is expected that there will be an undetected fraction of S. 
pneumoniae due to false negative tests, i.e., low sensitivity. However, this undetected fraction might 
be partly compensated by the false–positive tests, i.e., low specificity. 
 Recently, the European Commission extended the indication of PCV13 to adults aged 50 years 
and older to prevent invasive pneumococcal disease caused by S. pneumoniae. While there is 
currently no indication for non–invasive pneumonia, clinical trial data will become available soon168. 
Recent cost–effectiveness studies have shown that, next to the vaccine efficacy, the proportion 
of non–bacteraemic pneumonia due to S. pneumoniae is one of the key determinants of cost–
effectiveness129,313. Our current study might, therefore, support the decision– making process of the 
introduction of PCV13129,313.
 In conclusion, our study provides estimates of the average observed prevalence of S. 
pneumoniae, which could be used for projecting the health and economic benefits of pneumococcal 
immunization.
Part II
Costs and effectiveness of extended 
vaccination strategies against pertussis
8




The aim of this study was to investigate the optimal pertussis booster vaccination strategy for the 
Netherlands. A realistic age–structured deterministic model was designed. Assuming a steady–state 
situation and correcting for underreporting, the model was calibrated using notification data from 
the period 1996–2000. Several sensitivity analyses were performed to explore the impact of different 
assumptions for parameters surrounded by uncertainty (e.g. duration of protection after natural 
infection, underreporting factors, and transmission probabilities). The optimal age of an additional 
booster dose is in the range of 10–15 years, and implementation of this booster dose will reduce 
both symptomatic and asymptomatic infections, although the incidence of symptomatic infections 
in older age groups will increase. The impact of the different assumptions used in the model was in 
general limited. We conclude that over a wide range of assumptions, an additional booster dose can 
reduce the incidence of pertussis in the population. 








Bordetella pertussis is a bacterium that causes the highly contagious respiratory disease pertussis, 
also known as whooping cough. Despite widespread vaccination, infection with pertussis remains 
endemic even in countries with high vaccination coverage314-317. Moreover, there has been a 
resurgence of pertussis in many countries during the past decade, particularly in adolescents and 
adults314,317-320. For example, in the Netherlands a clear increase in the incidence of pertussis was 
apparent from 1996 onwards despite a consistently high vaccine uptake315,318. Although infections 
in adolescents and adults are less severe than those in infants and young children, the increasing 
incidence in adolescents and adults is still a major concern because adolescents and adults are 
identified as important sources of transmission to young infants who are not yet vaccinated or 
only partially vaccinated321-323. Therefore, the addition of immunization strategies to the current 
childhood immunization programme should be considered not only to reduce the disease burden 
in adolescents and adults but also to prevent transmission of the infection to infants. Indeed, several 
countries (e.g., Australia, France, USA) have already incorporated adolescent booster doses into 
their national immunization programmes324,325. However, other countries such as the Netherlands, 
have not implemented adolescent or adult booster immunization programmes even though such 
programmes would potentially reduce the transmission of B. pertussis and potentially lower the 
incidence of pertussis in infants323,326,327. Therefore, the impact of additional booster dose(s) at later 
age(s) should be explored. 
 Mathematical models can be used to investigate, for example, the optimal age(s) of vaccination 
or the impact of different levels of uptake of the vaccine. During the last 10 years several studies 
have modelled the potential impact of additional booster doses328-332. Nevertheless, specific 
drawbacks make them inappropriate to use for decision making. For example, most studies did 
not (i) take into account underreporting (for adults), (ii) explore the impact on the epidemiological 
outcome of transmission–related parameters, or (iii) use contact rates based on ‘real life’ contact 
patterns. Also, our previous work had these limitations329. We have attempted to overcome these 
limitations through the use of a realistic age–structured deterministic model, programmed within 
an environment allowing for high–speed model runs, to determine the optimal vaccination strategy 
for reducing the number of infections in the population, and to explore the impact of different 
assumptions for parameters surrounded by uncertainty. 
MATERIALS AND METHODS 
Several analyses were performed to explore the impact of introducing different types of booster 
immunization programmes to the current Dutch vaccination strategy in which acellular vaccine 
formulations are used and infants receive three doses at the ages of 2, 3 and 4 months and booster 
doses at 11 months and 4 years. In particular, we focused on the optimal age of implementing a 
single additional booster vaccination. However, we also investigated other potential vaccination 
strategies to reduce the burden of disease in the youngest age groups such as providing a booster 
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dose every 10 years. Base–case, sensitivity and scenario analyses were performed. The base–case 
analysis represented the most plausible assumptions (described below) and was subsequently used 
as a baseline against which all other scenarios and sensitivity analyses were assessed. The dynamic 

















































Figure 1. Graphical representation of the possible pathways within the model. The solid compartments 
represent the different pertussis epidemiological states. Solid arrows represent the flow between these states. 
Dashed lines and compartments represent events and pathways associated with vaccination.
Model structure 
A schematic overview of the deterministic model used to assess the impact of various booster 
vaccination strategies against pertussis is shown in Figure 1, where mutually exclusive compartments 
represent the different epidemiological states of the disease and the arrows represent possible flows 
of individuals between the different states. Note that the underlying structure of the model is the 
same as our previously published stochastic model329. In the model all infants are born susceptible 
and then face age–specific risks of acquiring a pertussis infection as a result of contact with an 
infectious person. As shown in Figure 1, the model distinguished between three types of infections: (i) 
infections in immunologically naive individuals (henceforth called primary infections); (ii) infections 
in individuals whose immune system has been primed by vaccination or infection (breakthrough 
infections, sometimes known as ‘recidive’ infections); and (iii) asymptomatic infections (note that all 
primary and breakthrough infections were assumed to be symptomatic). 
 Individuals were assumed to be fully immune (i.e. immunity against transmission and disease) 
to subsequent infections following either vaccination or recovery from primary infection. Because 
of waning of immunity, these individuals will become partially immune (i.e. immunity against 
disease only). Partially immune individuals can acquire the pathogen but will not become ill and 
only experience asymptomatic infections (and transmit the pathogen). However, partial immunity 
also wanes with time. As a result, partially immune individuals will again become susceptible. These 
susceptible individuals are at risk of acquiring breakthrough infections, which were assumed to 







be less severe than primary infections because the immune system had previously been primed. 
Furthermore, we assumed that partially immune and susceptible individuals can re–acquire full 
immunity as a result of contact with the pathogen through either vaccination or subsequent 
infection.
Disease characteristics 
Although the duration of the infectious period is not precisely known and is likely to vary between 
individuals, it has been suggested to be dependent on the severity of the disease329. Based on expert 
estimations (see de Vries et al329), we assumed the average infectious period for individuals with 
primary infections, breakthrough infections, and asymptomatic infections to be 4 weeks, 3 weeks, 
and 1 week, respectively (see Table 1 for specific parameter values used)329. 
 Similar to the duration of the infectious period, the duration of immunity after a natural infection 
is not precisely known. However, a recent review suggested that immunity after a natural infection 
wanes after 4–20 years333. Based on these data, we assumed in the base-case analysis that immunity 
after natural infection wanes after 12 years on average, with individuals being fully protected for 2 
years and partially protected for 10 years. 
vaccine characteristics and vaccination schedules 
Until 2001, the vaccination schedule in the Netherlands consisted of four doses (currently at ages 
2, 3, 4 months and a booster at age 11 months) of the whole cell pertussis vaccine within the 
combination of diphtheria, tetanus and polio vaccine. From 2001 onwards, an additional acellular 
booster vaccination was given to 4–year–old children. Starting in 2005 the pertussis component in 
the combination vaccine was changed from the whole cell to an acellular vaccine. The efficacy of 
the whole cell pertussis vaccine was estimated at 89%315,334-336. Based on clinical trial data, we also 
assumed that the vaccine efficacy after vaccination in the first year, after booster vaccination at age 
4 years38,337, and after adolescent booster vaccination would be 89%338-340. 
 In the model the vaccination scheme was divided into three parts: (i) the vaccinations 
administrated in the first year (including the first booster dose at age 11 months); (ii) a second 
booster dose at age 4 years; and (iii) potentially a third booster dose at age 12 years. After vaccination, 
we assumed that the fraction of the population, defined by coverage multiplied by efficacy, is 
effectively protected precisely after 4 months. Using a recent estimate for duration of immunity 
after vaccination with either whole cell or acellular vaccine of 4–12 years333, we assumed that the 
immunity acquired by vaccination would be for 8 years, where individuals were fully and partially 
protected for 2 and 6 years, respectively. Note, that the duration of full immunity after vaccination 
is identical to the duration after natural infection, while the duration of partial immunity is 4 years 
shorter after vaccination compared to natural infection.
 Based on the actual pertussis vaccination coverage of the Dutch national immunization 
programme, we applied a vaccine uptake of 96% for the three infant doses and the two booster 
doses (at ages 11 months and 4 years). Vaccine coverage of 70% was assumed for the adolescent 
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booster dose(s), which is much lower than the coverage for infants but is still higher than the uptake 
achieved in girls with the more controversial human papillomavirus vaccine in the Netherlands 
(50%). In the sensitivity and scenario analyses the vaccination coverage was varied over a much 
wider range. 
Force of infection
The force of infection (FOI) is the rate at which susceptible individuals will be infected within a given 
time period. Age–dependent FOIs were estimated by using a method developed by van Boven et 
al.336 (see Supplementary material). The main advantage of this method is that it is able to take 
different types of infection and waning immunity into account in a consistent manner336. 
Table 1. Epidemiological Data
Variable
Parameter
(see also Figure 1)
Base–case value
Annual birth cohort NA 100,000/75
Force of infection λ (a) Age dependent (see Supplement Figure 1)
Rate of recovery from primary infection ρ1 13.0 (yr
–1)
Rate of recovery from breakthrough infection ρ2 17.4(yr
–1)
Rate of recovery from asymptomatic infection ρ3 52.1 (yr
–1)
Rate of loss of full immunity after primary infection σn1 0.50 (yr
–1)
Rate of loss of partial immunity after vaccination σn2 0.17 (yr
–1)
Rate of loss of full immunity after vaccination σv1 0.50 (yr
–1)
Rate of loss of partial immunity after breakthrough infection σv2 0.10 (yr
–1)
Fraction effectively protected by vaccination V(a)a Age dependent
Vaccination coverage first 4 doses NA 0.96
Vaccination coverage booster at 12 years of age NA 0.7
Vaccine efficacyb NA 0.89
a  (a) = age.
b  We assumed that a certain fraction of the population (coverage ´ efficacy) is effectively protected precisely after 4 months for 
vaccinated infants and after 4 years for the first booster. The age of protection after the third booster was dependent on the 
age at which this dose was administered. 
 Because an additional booster dose at age 4 years was introduced in 2001, we assumed an 
endemic equilibrium from 1996 to 2000. For this period, average age–specific incidences were 
calculated based on case notification data after correction for underreporting341,342. Previously, it 
was estimated that the incidence of pertussis including very mild and asymptomatic cases in the 
Netherlands was more than 600 times higher than the notified cases for children and adults342. In 
particular, these age–specific Dutch ratios of underreporting were used to correct the number of 
notified cases342. We note that in reality there was probably no endemic equilibrium from 1996 
to 2000341. Once the FOIs were estimated these were subsequently used to calculate age–specific 
transmission coefficients. The transmission coefficient denotes the probability that a contact 







between a susceptible individual of a specific age and an infectious individual of a specific age leads 
to transmission. Since the transmission coefficients (β) can be expressed as a function of the number 
of infectious individuals at a given point in time, the contact function and FOIs, the transmission 
coefficients can be calculated once the age–specific FOIs are known. The contact function represents 
the number of contacts between an individual in one specific age group with an individual in 
another age group per unit of time. We applied the contact function for respiratory diseases in the 
Dutch population estimated by Wallinga et al.343. We assumed that the transmission probability 
would increase with severity of disease and assigned transmission probabilities of 1, 0.7, and 0.05 for 
primary (β primary), breakthrough (β breakthrough) and asymptomatic (β asymptomatic) infection, 
respectively329 . 
Population 
Simulations were performed for a population of 100,000 individuals with a uniform age distribution 
(i.e. the age groups were equally sized). The population was divided into 86 age groups, represented 
by 1–month groups for the first year (0–11 months) and 1–year groups subsequently (1–74 years). 
The total population size remained constant because newborns entering the model were equal 
to individuals leaving the model from death (at the age of 75). To mimic reality, the model was 
started at the steady state of the 1996–2000 endemic period (t=-5 to -1) with a booster vaccination 
at age 4 years implemented in 2001 (t=0). Additionally, we assumed in the base–case analysis that a 
booster dose at age 12 years would be implemented in 2011 (t=10) and the impact of this booster 
vaccination on pertussis incidence and prevalence in the population was assessed over a time 
period of 35 years. All vaccinations were assumed to be administered at the start of a new year. 
Sensitivity analysis and scenario analysis 
In the base–case analysis we used the most plausible parameter assumptions. However, as many 
parameters are surrounded by some level of uncertainty, we performed several sensitivity analyses 
to explore the impact of this uncertainty on the epidemiological outcome (Table 2a). To explore the 
impact of vaccination coverage of the booster dose, coverage was varied over a range of 50–90% 
by increments of 10%. In addition, the impact of applying an alternative contact function based on 
data provided by Mossong et al.344 was explored. The advantage of using the data of Mossong et al. is 
that it is more recent; however a disadvantage is the much smaller sample size compared to the data 
of Wallinga et al.343. Furthermore, the transmission probabilities of the different types of infections, 
the duration of protection after natural immunity, and the duration of infectiousness were varied333. 
Finally, as the real incidence of pertussis is surrounded by uncertainty, especially in adolescents and 
the elderly, the impact of lowering the underreporting factor by 25% or 50% was also investigated. 
In addition, scenario analyses were performed for several other vaccination strategies (Table 2b) 
including varying the age of the third booster dose between 5 and 35 years, using a combination 
schedule in which both adolescents (third booster dose) and adults (fourth booster dose) were 
vaccinated, and giving repeated booster doses every 10 years starting at age 10 years. 
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Table 2a. Sensitivity analyses performed on the base–case analysis
Base Case Sensitivity Analysis
Variation in the coverage of the booster dose 70% 50% to 90% (10%)
Contact function Based on Wallinga et al. Based on Mossong et al.
Different transmission probabilities 
βprimary(a) : β residive(a) : βasymptomatic(a)
1: 0.7: 0.05 1; 1; 0.05 
1; 0.7; 0 
1; 0.7; 0.10 
Duration of protection after natural infection 12 (2+10) in years 8 (2+6) in years
16 (2+14) in years
Duration of infectiousness for primary, breakthrough and 
asymptomatic infections (in weeks) 
4, 3, 1 2, 2, 1
3, 3, 1
Reducing the estimated underreporting factors 0% 25% 
50%
Table 2b. Scenarios (Variations on base–case analysis)
Scenario´s Age booster(s) (in years)
Current situation (without adolescent booster dose) N.A.
Base Case 12 years
Age of the first booster dose (adolescent vaccination) Between 5 and 35 yearsb
Combined adolescent (1 dose) and adult immunization (1 dose)a Third booster dose between 10 and 18 years and fourth 
booster dose between 18 and 35 yearsb
A booster dose every 10 years starting at the age of 10 until age 
60 years
10, 20, 30, 40, 50, 60, 70b
a  All possible combination were investigated (applying a minimal period between the doses of at least 5 years, and assuming 
the youngest age at which a adolescent booster dose would be 10 years).
b  A step size of 1 year was used.
RESULTS 
Base–case analysis 
The estimated impact of the implementation of two vaccination strategies, childhood boosters 
alone (at t=0) and childhood boosters in combination with an adolescent booster vaccination (at 
t=10), on primary, breakthrough and asymptomatic pertussis infections is shown in Figure 2 (note 
that not all of the axes start at 0). The additional adolescent booster dose resulted in reduction of all 
types of pertussis infections with the relative decrease being most apparent for primary pertussis 
infections. 
 Although a decrease in overall infection was observed, the impact of the adolescent booster 
dose largely differed between age groups (Table 3). The largest absolute reduction and the largest 
relative reduction in infections were observed for children (6–12 years) and adolescents (13–19 
years). Furthermore, although the total number of symptomatic infections declined as a result of 
the adolescent booster vaccination, the incidence in the older age groups increased, illustrating an 
age shift induced by the adolescent booster dose. 
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Figure 2. Pertussis incidence per 100,000 population per year applying base–case assumptions. The solid 
lines show the current situation after implementation of the booster dose at age 4 years (at t=0). The situation 
regarding adolescent vaccination after t=10 is represented by the dotted lines. Note that the y–axis does not 
start at 0 in all graphs.
Table 3. Total number of infections per age category per 100,000 population over a time period of 25 years (from 
t=10 [third booster dose] up to t=35 in model simulated time)
Age group in years 0 1–2 3–5 6–12 13–19 20–39 40–59 60–74 Total
Primary infections, booster at 
4 years only (current approach)
1,851 403 10,512 3,999 1,628 8.55 0.00 0.00 983
Primary infections, booster at
 4 and 12 years 
1,750 381 9,982 3,332 798 9.47 0.00 0.00 821
Averted primary infections 101 21.9 529.2 667 830 –0.92 0.00 0.00 163
Averted primary infections (%) 5.5% 5.4% 5.0% 16.7% 51.0% –10.7% 0.00 0.00 16.5%
Breakthrough infections booster 
4 years only (current approach)
14.9 205 23,735 119,028 155,022 72,358 63,766 85,427 79,918
Breakthrough infections booster at 
4 and 12 years 
14.1 194 22,586 92,150 120,404 75,338 65,107 85,998 75,399
Averted breakthrough infections 0.8 11.1 1,149 26,879 34,617 –2980 –1342 –572 4519
Averted breakthrough infections (%) 5.5% 5.4% 4.8% 22.6% 22.3% –4.1% –2.1% –0.7% 5.7%
Asymptomatic infections booster at 
4 years only (current approach)
441.0 1,106 95,114 197,164 598,860 788,746 817,111 554,833 617,331
Asymptomatic infections booster at 
4 and 12 years
416.9 1,045 90,155 156,964 554,735 776,179 808,193 548,523 602,269
Averted Asymptomatic infections 24.1 60.9 4,959 40,200 44,124 12,567 8,919 6,310 15,062
Averted Asymptomatic infections (%) 5.5% 5.5% 5.2% 20.4% 7.4% 1.6% 1.1% 1.1% 2.4%
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Sensitivity analysis for base–case 
The impact of the different sensitivity analyses on the total number of infections is shown in 
Figure 3. Overall incidence of all infections decreased with increasing coverage of the adolescent 
booster vaccine at age 12 years (Figure 3a). Furthermore, with increasing coverage, more primary 
and asymptomatic infections were averted in generally all age groups, while the shift in age of 
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Figure 3. Results of the sensitivity analyses of the base–case scenario (as described in the Methods section and 
Table 2). (a) The impact of varying the uptake of the booster dose between 50% and 90% (70% in the base–case); 
(b) the impact of using different transmission coefficients; (c) the impact of assuming a different duration of 
protection after natural infection; (d) the impact of reducing the infectious period; (e) the impact of applying the 
contact function is reported by Mossong et al. is shown; (f ) the impact of lowering the underreporting factor. 
Note that the y–axis does not start at 0 in any of the graphs.
 Varying the transmission coefficients for the different types of infection resulted in a similar 
post–vaccination endemic equilibrium (Figure 3b). However, in the period between implementation 
of the booster dose and reaching the post–vaccination steady–state incidence (sometimes referred 
to as the post–honeymoon period), assumptions on the transmission coefficients, particularly for 
asymptomatic cases, had the most impact on overall pertussis incidence. For example, assuming 







that asymptomatic cases do not transmit infection resulted in stronger annual fluctuations in the 
incidence of breakthrough and asymptomatic infections, whereas assuming that asymptomatic 
cases were more infectious than in the base–case analysis resulted in equilibrium being reached 
earlier. 
 Changing the duration of partial immunity after natural infection also did not have a considerable 
impact on the overall post–vaccination endemic equilibrium (Figure 3c). However, the incidence 
of break–through and asymptomatic cases differed substantially when the overall duration of 
protection was varied. The post–vaccination endemic equilibria for breakthrough and asymptomatic 
infections (per 100,000) were 4400 and 22,840 cases, respectively, assuming 6 years of partial 
protection, and 2360 and 24,660, respectively, assuming 14 years of protection. Nevertheless, the 
relative change in the number of cases was similar regardless of the duration of protection because, 
within the methodology used, the pre–vaccination pertussis incidence also differed proportionally 
to the post–vaccination endemic incidence. Shortening the infectious period for primary and 
breakthrough cases had almost no impact on the relative decrease of pertussis cases (Figure 3d). In 
terms of absolute cases it was estimated that for the scenario when the infectious period for both 
primary and asymptomatic cases was set at 3 weeks, <0.34 cases per 100,000 population could be 
averted compared to the base case, where this was 0.46 cases per 100,000 population when the 
infectious period was reduced to 2 weeks. 
 Using the contact function of Mossong et al.344 instead of the contact function of Wallinga et al.343, 
resulted in the prevention of slightly more asymptomatic cases, although slightly less breakthrough 
infections were averted resulting in an overall similar endemic equilibrium (Figure 3e). As expected, 
reducing the estimated underreporting factors resulted in lower total numbers of infections and 
in lower age–specific estimates of FOIs (Figure 3f, Supplementary Figure S1). Surprisingly, more 
pertussis cases were averted when the correction factor for underreporting was reduced by 25% 
compared to the base case, while slightly less cases were prevented when this factor was reduced 
by 50% compared to the base case. 
Scenario analyses 
The impact of varying the age of the third booster dose is shown in Figure 4. The optimal age of 
administering the third booster dose for the prevention of symptomatic cases was around 10 years, 
while the optimal age for the prevention of asymptomatic cases was around 12 years. The impact of 
adding a fourth booster was limited (data not shown). Nevertheless, the most effective combination 
strategy for the prevention of symptomatic cases would be an additional childhood booster dose 
at age 10 years and an adult booster dose at age 20 years. However, the optimal strategy for the 
























Age (in years) of third booster dose
16 years of protection
Base-case analysis (12 years of protection)
Figure 4. (a, b) Graphs showing the impact of varying the age of the third booster dose on the average number 
of symptomatic pertussis cases (solid lines) or asymptomatic pertussis cases (dashed lines) per age category per 
100,000 populations over a time period of 25 years after the introduction of a third booster dose (t=10 in model–
simulated time). Horizontal lines represent the number of symptomatic cases (solid lines) or asymptomatic cases 
(dashed lines) without a third booster dose; (a) The impact on children aged <3 years ; (b) the impact on the total 
number of infections in the population.























Age (in years) of third booster dose
no underreporting indirect
Underreporting reduced by 25%
Underreporting reduced by 50%
Figure 5. Pertussis incidence per 100,000 population per year showing the effect of a booster dose every 10 
years (dashed–dotted line) compared to impact of the current situation (dashed line), the current situation 
combined with a potential single adolescent booster dose at age 12 years (dotted line, base–case analysis), and 
two additional booster doses at the ages of 10 and 20 years (solid line).
DISCUSSION 
We have presented a realistic age–structured deterministic pertussis model, able to optimally 
use the scarce data on FOI and age–dependent fractions of symptomatic and notified cases. We 
have shown that, over a wide range of variations, an additional booster dose can reduce both the 
incidences of symptomatic and asymptomatic pertussis cases in the population. Furthermore, we 
propose that the optimal timing for the third booster dose in the Netherlands is between the ages 
of 10 and 15 years and that the optimal vaccination strategy would be a booster dose every 10 years. 
Notably, our results confirmed the epidemiological findings of a previous stochastic model in 
showing similar trends with respect to the prevention of pertussis cases and the induction of age 
shifts after the introduction of an additional adolescent booster dose329. 
 The impact of applying different assumptions on the overall disease burden were limited, 
although some assumptions (e.g., the duration of protection of natural protection) did change 
the ratio of asymptomatic and breakthrough cases. Surprisingly, the impact of an additional 
booster dose on the total reduction of pertussis cases was larger when the underreporting factors 
was reduced by 25% from base–case level, while slightly fewer cases could be averted when the 
underreporting factors was reduced by 50% from base–case level. A possible explanation is that the 
infection pressure is so high in the base–case analysis that the impact of an additional booster dose 
will have only limited herd effects in the other unprotected individuals. More herd immunity effects 
may be observed if the FOI is lower (i.e. 25% or 50% lower underreporting), while on the other hand 
fewer cases can be prevented when the initial incidence is lower (50% lower underreporting). 
 Several recent modelling studies used a dynamic model to estimate the effect of additional 
booster doses on the epidemiology of pertussis326,328-332. Most of these studies used estimates for FOI 
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that were based on incidence data from England and Wales before the introduction of widespread 
vaccination. We used a method developed by van Boven et al.336 to estimate specific Dutch FOIs 
which allowed waning of immunity and different types of infection to be taken into account. As a 
result, the FOI estimates of this study, corrected for age–specific underreporting and occurrence 
of asymptomatic infections, were consistently higher and of different shape than those previously 
reported326,328,330-332. 
 Our model has a number of limitations. First, the method used to estimate the FOI assumed that 
the population is in endemic equilibrium during the period 1996–2000. Although we are fully aware 
that this assumption does not reflect reality, we believe that it still represents the best approach 
currently available and that deviations from the steady state would not relevantly change the 
findings and conclusions. Second, the estimated incidence during this period and the underlying 
underreporting factors are uncertain. Our estimates of the incidence of infection are higher than 
estimated previously by de Melker et al. for the period 1994–1996. This is because we used the 
incidence numbers of notified cases from 1996 to 2000 and increased these with age–specific 
underreporting factors from 1994 to 1996. As data from 1996 showed that the incidence was about 
six times higher compared to 7 years previously, our incidence estimates increased about sixfold345. 
As a result our model predicts that, on average, the entire population will be infected every 3 to 4 
years, of which 88% will be asymptomatic. Nevertheless, as discussed above, when a lower overall 
incidence was applied, the number of averted cases increased when the under-reporting rate was 
lowered to 25% while only a slight decrease in the number of averted case was observed when the 
underreporting rate was lowered to 50%.
 Similar to all previous modelling studies investigating the impact of additional pertussis 
booster doses326,328-330,332 we did not include maternal immunity. Indirect evidence from before 
the introduction of widespread vaccination indicated that maternal antibodies provided some 
protection against mortality during the first month of life346. However, surveillance data after the 
introduction of widespread pertussis vaccination no longer show this relation between maternal 
antibodies and protection against pertussis346. Furthermore, as there is no serological correlate of 
protection for pertussis it is not possible to estimate the proportion of infants born with a protective 
level of maternal antibodies346. Therefore, we decided not to include maternal immunity in our 
model. 
 We used equally sized cohorts assuming a type 1 mortality, rather than the actual age distribution 
of the Netherlands. It has been argued in the literature that this approximation represents a valid 
approach for developed countries347. 
 Last, it should be noted that an economic evaluation of our analyses in order to judge the 
attractiveness of the different strategies from the cost effectiveness perspective is warranted. The 
most cost effective strategy may certainly differ from the most optimal vaccination strategy (i.e. a 
booster dose every 10 years), in terms of primary and/or total cases averted. Thus, an economic 
evaluation, using the epidemiological results reported here, will be the next step in the evaluation 
of potential additional pertussis vaccination strategies in the Dutch context.







 In conclusion, we designed an age–structured deterministic pertussis model with rapid 
simulation runs, which was used to explore the impact of various parameter assumptions and 
pertussis booster vaccination strategies on pertussis epidemiology. We showed that the optimum 
age of an additional booster dose is between ages 10 and 15 years, while the optimal vaccination 
strategy is a booster dose every 10 years. A sensible strategy representing a compromise between 
these two approaches may be booster vaccinations at 10 and 20 years. 
Supplementary data 
Supplementary data associated with this article can be found at: 
http://journals.cambridge.org/ hyg.
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The aim of the current study is to estimate the epidemiological and economical consequences of 
several extended pertussis booster vaccination strategies and to explore the impact of parameters 
surrounded by large uncertainty on the cost–effectiveness. 
 We developed an age structured transmission dynamic model to evaluate the impact of 
programs targeting (i) adolescents or adults using a single booster dose, (ii) a combination of 
adolescent and adult vaccination, and (iii) an every 10 years booster dose.
 The base case analysis, that is a single adolescent booster administered at the age of 12 years, 
resulted in a reduction of pertussis infections. However, due to an increase in the number of 
symptomatic infections in adults, the benefits in terms of QALYs gained and costs saved in children 
were partly offset. Despite these negative indirect effects in the adult population, administering 
an additional booster dose could still be considered cost effective with an ICER of €4,200 per QALY 
gained. Combining an adolescent booster dose at the age of 10 (most cost–effective age for a single 
adolescent booster dose) with an adult (18–30 years) booster dose always resulted in favorable 
ICERs (<€10,000/QALY). Finally the every 10 year booster dose resulted in an ICER of €16,900 per 
QALY. The impact of different assumptions regarding the disease epidemiology, disease–related 
parameters, and vaccination program–related issues was limited.
 To conclude, we show that extended pertussis booster vaccination strategies are likely to be 
considered as cost–effective. 








Pertussis, or whooping cough, is a contagious respiratory tract disease primarily resulting from 
infection with Bordetella pertussis. Pertussis continues to be a public health concern even in 
countries where a high vaccine coverage for infants and children is achieved37. In the past decade, 
an increase in the incidence has been observed in many developed countries combined with a shift 
in the incidence towards older age groups which may be related to increased awareness, changes in 
disease susceptibility and vaccine characteristics, shifting demographics, and genetic variations348. 
Although pertussis is more severe in infants and young children, the increasing incidence in 
adolescents and adults is a major concern as adults are an important source of transmission to 
infants, and infection in adults causes significant morbidity and high costs349-351. Therefore, extended 
immunization strategies targeting adolescents and adults should be considered. Several countries, 
including Australia, Canada, France, and Germany, have already incorporated adolescent booster 
doses into their vaccination programs37. The current Dutch pertussis vaccination schedule consists 
of three primary doses given at 2, 3, and 4 months and two booster doses given at 11 months and 
at the age of 4 years. An additional third booster dose could reduce the incidence of pertussis in 
the population328,329,352. However, next to the effectiveness of such programs, also the economical 
consequences of such programs should be taken into account, i.e., can such programs be considered 
cost–effective?
 Several studies evaluated the cost–effectiveness of extended pertussis vaccination strategies, 
but most of them used static models353. However, as pertussis is a transmissible infectious 
disease, a dynamic model is required to fully take into account the transmission of the disease in 
the population15. Up to now, only two studies have used dynamic models to estimate the cost–
effectiveness of extended pertussis vaccination schedules328,329. Although both studies provide 
plausible insights, they cannot be used for current decision making in the Netherlands. Firstly, 
because the only study that did focus on the Netherlands was unable to investigate the impact of 
multiple vaccination scenarios and the impact of different assumptions for parameters surrounded 
by uncertainty (e.g., duration of protection after natural infection, underreporting factors) due to 
long computational times329. Secondly, the other study focused specifically on the USA with limited 
options for transferability to other settings. In particular, whereas various vaccination scenarios 
were analyzed, no transmission related parameters were varied, underreporting for adults was not 
taken into account, and contact rates were not based on ‘real life’ contact patterns328.
 Therefore, the aim of the current study is to estimate the cost–effectiveness of several extended 
pertussis booster vaccination strategies and to explore the impact on the cost–effectiveness of 
different assumptions surrounded by uncertainty. 
METHODS
In this study we compare the current Dutch pertussis vaccination programme (with doses provided 
at 2, 3, 4 and 11 months and 4 years) with different extended vaccination strategies. In the base–
Chapter 9
130
case (1), representing the scenario in the Netherlands discussed by the Dutch Health Council, we 
explored the impact of a third booster dose provided at the age of 12 years. In addition to this, we 
also explore the following strategies:
1.  a single (third) booster vaccination with a different timing (between the ages of 5 and 30);
2.  a combination of an adolescent booster dose at the age when (1) is most cost–effective with an
  adult (18–30 years) booster dose (fourth booster dose); and
3.  a booster dose every 10 years starting at the age of 10 until the age of 60 years. 
Our model (programmed in Berkeley Madonna: R. I. Macey & G. F. Oster, UC Berkeley, CA, USA) 
consists of two parts: a dynamical transmission dynamic model used to predict the epidemiological 
impact of the different strategies and an economic analysis, which is integrated into the transmission 
model, allowing rapid analyses of the economic consequences of epidemiological trends. The 
epidemiological model and the economical data are described in details in the following section.
Epidemiological model structure
We used an age–structured transmission dynamic model to predict the impact of the extended 
pertussis programs as presented previously329,352. Briefly, the model distinguishes between three 
types of infections: (I) primary infections in immunologically naive individuals; (II) breakthrough 
infections in individuals whose immune system has been primed by vaccination or infection; and 
(III) asymptomatic infections (note that all primary and breakthrough infections were assumed to be 
symptomatic). Also, four types of immunity are specified: (1 & 2) fully immune (i.e., immunity against 
transmission and disease) by either vaccination or infection, and; (3 & 4) partially immune (i.e., 
immunity against disease only) by either vaccination or infection. All epidemiological assumptions 
and parameters were taken from the base–case analysis in Rozenbaum et al. unless stated 
otherwise352 and are reported in Appendix 1. The model is able to capture effects at the population 
level, including herd protection and possible shifts in the average age of infection.
Economical data and QALys
The analysis was performed from a societal perspective including both direct health care costs and 
indirect costs of production losses, updated to 2011 Euros when necessary (using the consumer 
price index from the Netherlands’ Central Bureau of Statistics). Direct medical costs included in the 
analysis were those associated with vaccination, diagnostic procedures, hospitalization, prescribed 
medicines, prescription fee for the pharmacist, and GP consultation. Specific health quality (utility) 
scores were assigned to each health state in our model. Assumptions regarding both costs and 
quality of life are more thoroughly discussed in Appendix 2. 
Sensitivity analysis
To test the robustness of the outcomes we performed several sensitivity analysis on various 
economical and the epidemiological parameters. In the univariate sensitivity analyses, all relevant 
parameters were varied by 25% to explore the impact of each parameter relative to each other. 







Based on our previous modelling exercise352, we decided to explicitly focus on the duration 
of protection after a natural infection and on the underreporting factors as these are extremely 
important to drive conclusions about the epidemiology of pertussis after the introduction of an 
additional booster352. Age–specific Dutch factors were used to calculate the incidence of unnotified 
cases given that it was estimated that the incidence of pertussis including (very) mild and 
asymptomatic cases in the Netherlands was more than 600 times higher than the notified cases for 
children and adults342. As these ratios are surrounded by uncertainty, especially for adolescents and 
elderly people, the impact of reducing the underreporting factors by 25% or 50% (ie, reducing the 
number of unnotified cases) was also investigated. The duration of protection after natural infection 
was assumed to be on average 12 years (fully protected for 2 years and partially protected for 10 
years) in the base case scenario333, similar to our previous estimate352. In one scenario, we reduced 
this period to 8 years (fully protected for 2 years and partially protected for 6 years) while in another 
scenario we increased it up to 16 years (fully protected for 2 years and partially protected for 14 
years). Finally, the impacts of excluding direct costs, varying the vaccine uptake and the discount 
rates were explored.
Cost–effectiveness analysis
In the model, cohorts of 185,000 newborns, representing Dutch birth cohorts were followed, once 
using the current pertussis booster programme, and once with an extended pertussis vaccination 
programme implemented. In the model it was assumed that it would be possible to implement a 
potential booster in 2013. Finally, the time horizon used in the model was 25 years. 
 The model tracks the cases of infections, costs, life years (LYs) and quality–adjusted life years 
(QALYs). Summing all the costs, LYs and QALYs and consequently calculating the differences for the 
respective outcomes with and without the extended programme rendered net costs, LYs gained 
and QALYs gained. Dividing the net costs by either one of the health effects defined the incremental 
cost–effectiveness ratio. Future health effects and the costs of treatment were discounted according 
to the Dutch guidelines for cost–effectiveness research at 1.5% and 4%, respectively142. 
RESULTS
Result base case
The implementation of an adolescent pertussis booster dose resulted in a reduction of all types of 
pertussis infections with the relative decrease being most apparent for primary pertussis infections. 
In total 22,400 cases of primary infections, 628,200 of breakthrough and 2.1 million asymptomatic 
infections could be avoided (see Table 1). Around 25,200 QALYs could be gained in children. However, 
due to an increase in the number of symptomatic infections in adults and elderly as described 
previously in more detail352, 4400 QALYs would be lost resulting in a net overall number of 20,800 
QALYs. Similar to the QALYS, both the overall direct and indirect costs would increase in adults and 
elderly (see Figure 1). This increase in direct costs did only partially offset the savings obtained in 
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children. However, due to indirect costs, productivity losses in adults outweighs the limited benefits 
obtained by prevented cases in children (work loss due to mothers taking care of their children), 
there is a net overall increase in productivity losses. The total net costs of an adolescent booster 
program is €107.4 Million. Dividing the incremental costs by the incremental health benefits results 
in an incremental cost–effectiveness ratio of €5600 per QALY (undiscounted) or €4200 per QALY 
when discounted.









Direct costs* Indirect costs QALYs
Without vaccination  135.9  11,088  85,640  736,592  28,387 1,189,260  289.1 
With vaccination  113.5  10,460  83,523  844,006  26,821  1,199,390  268.3 


















































Figure 1. Age specific impact of a pertussis booster dose administered at the age of 12 years on the incremental 
QALY (dashed line) and total incremental costs (solid line). Horizontal lines show the zero axis for QALYs (dashed 
line) and costs (solid line).
Other vaccination strategies
Vaccination at the age of 10 years was the most cost–effective vaccination strategy (solid black line 
in Figure 2). Increasing the age of the third booster dose also gradually increased the ICER. Excluding 
indirect costs resulted in a slightly more favorable ICER when the third booster was given between 
the 12 and 14 years of age. However, if the third booster was provided from 15 years onwards, the 
inclusion of indirect costs would result in more favorable ICERs. Combining a third booster dose at 
the age of 10 with an adult (18–30 years) booster dose always resulted in favorable ICERs (<€10,000/
QALY). Finally the every 10 year booster dose resulted in an ICER of €16,872 per QALY.
























Health-care perspective & discounting Health-care perspective & no discounting
Societal perspective & discounting Societal perspective & no discounting
0
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Age (in years) of third booster dose
Figure 2. Impact of age of the third booster dose, discounting and indirect costs on the incremental cost–
effectiveness ratio (ICER) in the base–case analysis. The solid black line shows the base–case ICERs (societal 
perspective combined with Dutch discount rates) while the dashed black line shows the ICERs from the health 
care perspective (ie only direct costs). The solid gray line shows the ICERs without discounting from the societal 
while the dashed gray line shows the ICERs without discounting from the health care perspective (ie only direct 
costs).
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Figure 3. Sensitivity analysis on the base–case cost–effectiveness ratio. The parameters were varied by 25%. 
Dark bars show th  ICER after a 25% decrease in the parameter (note that it was not possible to increase 
vaccine efficacy), whereas light bars show the ICER after a 25% increase. # cases notified but not hospitalized; 
QALY=Quality Adju ted Life Year; GP=General Practitioner
Scenario and sensitivity analyses
Apart from varying the vaccine efficacy of the booster dose, the QALY losses associated with 
unnotified pertussis cases and the vaccine price, the impact of the other parameters was very 
limited (see Figure 3). Varying the duration of protection after natural infection had only a negligible 
influence on the ICER when the third booster was given around the age of 12 (Figure 4). However, 
above the age of 15 a reduction in the duration of natural protection resulted in a more favorable 
ICER, while an increase resulted in a less favorable ICER as compared to the base case. Decreasing 
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the underreporting factor resulted in more favorable ICERs (Figure 5). In the base–case the impact 
of the vaccine uptake was very limited as the incremental costs of the booster programme linearly 
increased with the QALY gains (data not shown). This was related to the high pressure of infection 
which resulted in only minimal herd effects. The impact of the coverage was much larger when a 
booster dose was given every 10 years. Surprisingly, when health and costs were not discounted 
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Base-case analysis (12 years of protection)
8 years of protection
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Figure 4. Impact of age and duration of natural protection on the incremental cost–effectiveness ratio (ICER). 
The solid line shows the ICERs for the base–case analysis (12 years of protection), the dotted line corresponds to 


















Age (in years) of third booster dose
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Figure 5. Impact of age and underreporting on the incremental cost–effectiveness ratio (ICER). The solid line 
shows the ICERs for the base–case analysis, the dashed line in case the underreporting factor is reduced by 25%, 
and the dotted line when the underreporting factor is reduced by 50%. 








In this paper, we show that an additional booster dose against pertussis is likely to be considered 
as cost–effective by using an age–structured deterministic pertussis model integrated with a 
health economical model. Furthermore, by using this model we were able to show that the impact 
of different assumptions, regarding the disease epidemiology, disease–related parameters, and 
vaccination program–related issues, does not change the main result: vaccination is likely to be 
considered cost–effective.
 Only two previous studies estimated the cost–effectiveness of an additional pertussis booster 
dose by using a dynamic transmission model328,329. The most recent model was also developed for 
the Netherlands, and was used to estimate the cost–effectiveness of an additional pertussis booster 
dose at the age of 12 years. It was a stochastic and individual–based model, while our model is 
a population–based model. The main advantage of our model is the running time, which made 
it possible to explore, within a reasonable time, the impact of different assumptions on disease 
epidemiology (e.g., underreporting factors), on disease–related parameters (e.g., duration of 
protection after natural immunity), and on vaccination program–related issues (e.g., age of the 
booster and vaccine uptake). Moreover, in this paper we used the most recent cost data available. 
Despite these differences both models showed that an additional booster dose at the age of 12 
years can be labeled as cost–effective, as interventions with an ICER of less than €20,000/QALY are 
considered favorable in the Netherlands43,47. The second study328 used a dynamical compartment 
model to estimate the cost effectiveness of pertussis vaccination strategies in the USA. This study 
showed that implementation of booster vaccination could be considered as cost effective or even 
cost saving. Unfortunately, this study did not take underreporting cases in adults into account, 
which could potentially overestimate the ICER as we showed in this paper. An advantage of the 
USA study was that it also modeled the impact of cocooning. That is protecting infants indirectly by 
vaccinating their parents. Unfortunately, specific household contact patterns for parents and infants 
were not available for the Netherlands which made it impossible to consider such strategy with our 
dynamic model. However, previous work based on a static model showed that cocooning was likely 
to be considered as cost–effective354.
 One of the advantages of our model was the possibility to investigate the impact of several 
scenarios. We showed that the impact of non–disease related parameters such as cost parameters 
and utility decrements had only a very limited impact on the ICER. Also, the impact of different 
disease related parameters was very limited. However, the impact of these parameters became more 
apparent with an increase of the age of the third booster. Surprisingly, discounting resulted in more 
favorable ICERs as compared to no discounting. The reason for this is related to the future increase 
in pertussis infections in the older age groups (age shift) resulting in a doubling of the productivity 
losses. These productivity losses are more heavily discounted (4%) compared to the health effects 
(1.5%). Furthermore, also the future incremental vaccination costs are 50% higher, when the 
outcome measures were not discounted. Both factors contribute to the fact that discounting the 
outcomes resulted in a more favorable ICERs. Decreasing the underreporting factors resulted in 
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more favorable ICERs. With a lower underreporting rate, the pressure of infection decreased resulting 
in the prevention of relatively more symptomatic cases by herd effects in younger individuals. In 
addition, the relative increase in the number of symptomatic cases in the older individuals was 
reduced. Finally, we note that exclusion of indirect costs resulted in a more favorable ICER when the 
booster was given at 12–14 years of age, but inclusion of these costs resulted in a more favorable 
ICER when the booster was provided at 15 years of age and onwards. This is directly related to 
the fact that when a booster is provided at 15 years productivity losses are prevented leading to 
cost saving, while if the vaccine is provided at the age of 12 years this would result in an increase 
in productivity losses and costs. This difference is indirectly caused by the waning immunity of 
the vaccine. If a booster dose was provided at the age of 12 years, the increase in the number of 
breakthrough infection would start at an earlier age than when the booster was provided at the 
age of 15 years. Furthermore, with regard to productivity losses we assumed that individuals start to 
have productivity losses at the age of 15 years. As a consequence, when a booster was given at the 
age of 15 years, more productivity losses would be avoided in the “targeted” population. 
 An assumption of our model structure is that pertussis, or pertussis immunization, induces 
immunity against transmission and disease. As a consequence vaccinating individuals against 
pertussis can prevent the transmission of pertussis to other individuals resulting in herd protection. 
Although, the exact duration of this immunity against transmission is not known, there is evidence 
that vaccinations does induce herd protection. For example, in Sweden after the re–introduction 
of the pertussis vaccine in 1995 after 16 years, a significant reduction in the number of isolates 
in unvaccinated infants was noticed355. Also, several other observational studies355-357 have 
demonstrated a decrease in B. pertussis incidence rates in unvaccinated subgroups (when the 
vaccination uptake was higher than 80%). Furthermore, a decrease in the transmission of B. pertussis 
infection from vaccinated through household contacts was observed in several vaccine efficacy 
studies358-361.
 In this analysis we estimated the cost–effectiveness of a pertussis booster vaccine. Given that 
a single pertussis booster vaccine is not available, we assumed that the pertussis booster would 
be given in the formulation together with diphtheria and tetanus toxoids (dTpa vaccine). We 
explicitly looked at the cost–effectiveness of a pertussis booster dose without taking into account 
the potential effects of the booster dose for diphtheria and tetanus. To fully evaluate the health 
economic consequences of this combination vaccine, all three diseases should be taken into 
account in the model. 
 We did not consider deaths due to pertussis infections because in the last decade in the 
Netherlands on average less than one death per year was reported362. Including deaths might have 
resulted in a slightly more favorable ICER as deaths are assumed to occur most frequently in the 
youngest age groups. On the other hand, if (unreported) deaths occurred more frequently as a 
result of breakthrough infections in adults and elderly, that could result in a slightly less favorable 
ICER. 







 In conclusion, we developed a flexible dynamic model and showed that a pertussis booster 
vaccination given at approximately the age of 12 years is cost–effective given a wide range of 
assumptions. Our results can be used to support decision makers on the introduction of a pertussis 
booster into the Dutch national immunization programme. 
Supplementary data associated with this article can be found at: 
http://dx.doi.org/10.1016/j.vaccine.2012.06.026.





Despite childhood vaccination programs, pertussis remains endemic. To reduce the burden of 
pertussis, various extended pertussis vaccination strategies have been suggested. The aim of this 
review is to evaluate dynamic models used to assess the cost–effectiveness of vaccination. In total, 
16 studies using a dynamic model were included in our review, of which four also studied the cost–
effectiveness of extended pertussis vaccination strategies. Generally, adolescent vaccination was 
found to be cost effective, but not highly effective in protecting infants too young to be vaccinated. 
The models also predicted that owing to age shifts, reduced pertussis disease in adolescents and 
young adults comes with an increase in later stages of life. This underpins the use of dynamic 
transmission models for interventions directed against pertussis. In future, dynamic transmission 
models for pertussis should be used widely to further enhance understanding of pertussis 
epidemiology and of extended pertussis vaccination programs that are currently considered in 
various countries.








Pertussis, or whooping cough, is a highly contagious infection of the respiratory tract. It is caused by 
the bacteria Bordetella pertussis and it was one of the main causes of morbidity and mortality before 
the introduction of widespread vaccination against pertussis. With mass vaccination programs, the 
incidence and severity drastically dropped. However, resurges of epidemic episodes, infections 
in infants too young to be vaccinated, and pertussis disease in adults and adolescents remain, 
resulting in renewed attention by authorities in the recent decade to further improve pertussis 
control and optimize the system of protection rendered by vaccination363. In this respect, extended 
vaccination strategies are often mentioned354,363,364, including cocooning, adolescent–and adult 
booster vaccination or even maternal vaccination to directly protect newborns.
 The cornerstone of pertussis vaccination is provided with a schedule that comprises at least 
three doses within the first year of life. A fourth dose is often given as a first booster somewhere 
between the first and second year of life. Sometimes, a second booster is provided preschool 
or during the first years in school. Various vaccine formulations exist and often the pertussis (P) 
component exists within a combination vaccine with diphtheria (D), tetanus (T), inactivated polio 
virus (IPV), Haemophilus type b (Hib) and hepatitis B virus (HBV). For example, existing formulations 
comprise DTP, IPV–DTP and IPV–DTP–Hib–HBV. Within these formulations, the P–component can 
be either cellular (whole cell; wP) or acellular (aP), with the latter reflecting the newest technology. 
Many countries have shifted from vaccines with the P–component to those with an aP–component 
in the last decade, in particular, owing to the superior safety profile of the latter.
 Some countries have already introduced an adolescent booster in the schedule, primarily with 
the notion to reduce spread and indirectly protecting those very young yet to be vaccinated348. 
Among these countries are France, Germany, Canada and the USA; however, most countries are 
reluctant in implementing this owing to health economic reasons and the potential shift in the age 
of infection up to the childbearing age. Moreover, it has already been argued to extend boostering 
beyond the adolescent age and all throughout life348,364.
 Since the 1990s, there have been increases in the number of cases of pertussis reported and 
of outbreaks, including in countries with a very high coverage, such as the Netherlands (coverage 
of 95%)365-367. This is a concern as adults are identified as an important source of transmission to 
children, including very young infants with potentially severe disease321,323,368-371. Notably, it is 
suggested that, particularly, those aged between 19 and 39 years play an important role in pertussis 
transmission in households372, and therefore, pertussis vaccination in adolescents/young adults 
may decrease the dissemination of pertussis in households. The potential for adults and adolescents 
to transmit the bacteria to infants319,320,348,373, together with the increasing number of cases in these 
groups might pose a continued spread for severe disease in infants. Moreover, pertussis seems to be 
poorly controlled in older age groups in the absence of boostering due to waning vaccine–induced 
immunity after the often high–coverage initial infant vaccination schedules314,374. Finally, it has been 
noted in these same studies that the incidence of pertussis in vaccinated infants has increased 
significantly, which might be related to an increase in awareness, changes in vaccine characteristics 
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and disease susceptibility, shifting demographics, variations in vaccinations coverage and genetic 
variations of B. pertussis348. The shift to acellular vaccines might not have resolved this as the primary 
difference between wP and aP is related to safety rather than efficacy37. The efficacies of aP vaccines 
and wP vaccine differ, with the best aP vaccines being more efficacious than low–efficacy wP 
vaccines but the former may have a lower efficacy than the most efficacious wP vaccines37.
 Health economics is important in assessing new technologies in health. Therefore, new 
strategies to control pertussis are also prone to health economic evaluation. Recently, Millier et 
al. have reviewed the health economic analyses in pertussis353, updating some previous reviews 
on the topic375,376. They noted a general lack of studies into the health economics of pertussis 
booster vaccination, with only 13 studies examining the economics of vaccination strategies into 
adolescence, every–10–year adult or cocooning (mothers and fathers). However, the lack of studies 
deploying dynamic models within such contexts is even more startling as dynamic models seem 
to reflect the only class of models that are actually suitable to validly analyze the issue. Notably, 
dynamic models take the spread of the infection explicitly into account, whereas the so–labeled 
static models do not. As such, only dynamic models are able to predict herd–protection effects 
of protective vaccination efficacy in unvaccinated populations. As the major issue of pertussis 
boostering is reducing spread and protecting the infants too young to be vaccinated or being only 
partially vaccinated, the need for the deployment of dynamic models is eminent. Out of the models 
identified by Millier et al., only three models involved transmission dynamic models328,329,377. 
 The aims of this paper was to review the dynamic transmission models developed for pertussis, 
their application in health economic analyses and to update the landscape of health economic 
studies with special reference to those deploying dynamic models. 
METHODS
Literature search 
We searched PubMed and EMBASE for modeling studies of pertussis booster vaccinations. For 
this purpose, the authors inserted the search term ‘pertussis’, in combination with any of ‘cost(–)
effectiveness’, ‘cost(–)utility’, ‘cost’ and/or (pharmaco–)economic evaluation. Moreover, the authors 
analyzed ‘pertussis’ combined with any of ‘compartmental model’, ‘dynamic(al) model’ and/ or 
‘mathematical model’, to adequately cover the regularly used synonyms of dynamic models in the 
literature. Out of the list generated, the authors selected those studies that predicted the impact of 
extending or changing currently used pertussis booster programs. Snowballing was performed on 
all studies found in the first or second stage of the literature search to potentially identify further 
studies. Not unexpectedly, the approach resulted in only a limited number of papers, generally 
focusing on epidemiology alone and hardly any including the economics as well326,328-332,336,352,377-384. 
In particular, the authors identified four studies deploying dynamic models with the final purpose 
of health economic analysis328,329,377,378. 








In the following section, the authors report their findings separately regarding dynamical models 
that have been developed for analyzing the epidemiology of pertussis vaccination and for those 
that have extended these models to health economic analysis. Next to a narrative approach to both 
aspects, the authors analyze the results on epidemiology and economics to explain the specific 
features on adolescent and adult booster vaccinations. For this purpose, the authors have tabulated 
several study characteristics including, the duration of natural and vaccine–induced protection, the 
mixing pattern used, the potential correction for underreporting. Notably, for underreporting, a 
difference should be made between non–notified symptomatic cases and asymptomatic cases that 
are obviously not prone to notification at all but may drive the epidemiology329. 
RESULTS
First–generation dynamic models 
The first dynamic mathematical models for pertussis were developed by Knox and Shannon, and 
Grenfell and Anderson381,384. A decade later, Hethcote et al. developed a model for the USA where 
multiple doses of pertussis vaccine were given to young children379. It was an age–dependent 
compartmental model that included 12 different epidemiological classes over 32 age groups with 
very small age classes for infants and adolescents up to age of 19 years. The demographic structure 
of the American population was carefully taken into account and a demographic equilibrium in 
the age distribution was assumed. The 12 compartments corresponded to a class of susceptible 
individuals, three disease classes according to the infectivity (weak–disease class when infectivity 
is low because people cough less and are less likely to infect; mild–disease class; full–disease class), 
four recovered classes that capture the decrease in the immunity and four vaccination classes. In the 
model, the assumption of proportionate mixing was assumed for the contact matrix. The authors 
performed a sensitivity analysis changing demographic and epidemiologic parameters, vaccine 
efficacy, vaccine coverage and duration of protection.
 Hethcote’s initial model has been further developed to cover the option of analyzing adult and 
adolescent booster vaccination, in particular an adolescent/adult booster every 10 years (from the 
age of 10 years onwards) was assumed380. In analyses for the USA, it was shown that although the 
program had a profound effect on overall pertussis incidence with the potential of decreasing it 
by 30–60% over a period of 50 years, incidence in infants and young children was only modestly 
affected. Van Rie and Hethcote extended further on the modeling by including the potential of a 
cocooning strategy within a methodological mix of the initial dynamic approach and some static 
properties332. The study reinforced previous conclusions that adolescent/adult vaccinations could 
only modestly contribute to the control infants and young children, whereas the cocooning had 
clearly visible effects on the incidence of typical pertussis in children up to the age of 5 years. 
Notably, for example, in 1–month old infants, cocooning had the potential to reduce incidence by 
up to 75%. Finally, the model was applied to the Australian setting330, with the aim of analyzing a 
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potential transfer of the infant booster at 18 months to an adolescent booster between 12 and 17 
years. Slightly differing results were found, compared with the USA analyses, in particular, regarding 
a 30% decrease in pertussis cases aged 0–23 months old, suggesting an impact of adolescent 
vaccination on the very young. This advantage was partly offset by an increase in incidence in the 
age group of 2–4 years. However, with the very young being most prone to severe disease, this shift 
seems favorable. Moreover, the study did not reinforce the general concern on adolescent pertussis 
boosters in shifting the peak incidence from adolescence to young adulthood, with potentially 
higher contact intensity with infants in the latter. One might doubt, however, whether the contact 
patterns inserted in the model were specific enough to adequately capture such details. 
 None of the analyses with the initial Hethcote generation of models was extended with economic 
analysis, although the papers generally stated the need330,332,379,380. However, recently, Coudeville et 
al. have developed a compartmental, age–structured mathematical model on US pertussis data, 
using the van Rie and Hethcote version of the model with the explicit aim of subsequent economic 
evaluation326,328,380. With the cocooning strategy being analyzed as well (using a static approach 
within the dynamic model), the authors state that routine adult vaccination may exhibit the greatest 
impact on pertussis incidence in all age groups, but the resources needed may be high compared 
with that for cocooning. The authors have shown that applying the van Rie and Hethcote model, 
adolescent vaccination can potentially impact on pertussis in the very young infants 0–3 months. 
In particular, nationwide pertussis incidence in this group may drop from approximately 1000 cases 
to less than 400 owing to adolescent vaccination. Addition of either cocooning or routine adult 
booster vaccination every 10 years would almost eliminate pertussis in these very young infants. 
The latter is probably mostly due to vaccination in the childbearing decades of life. The authors note 
the lack of reliable data on contact patterns, while illustrating the major impact on the results of the 
exact specification of the contact matrix (assortative, proportional or constant mixing).
Subsequent model approaches
Some years later, another relevant dynamic model for pertussis was developed by van Boven et al. 
336. The aim of the paper was to study the outbreak of pertussis that took place in the Netherlands 
in 1996–1997. The model had less compartments than Hethcote’s model, with only six in total 
(immune naive, primed susceptibles, protected after vaccination, protected after natural infection, 
primary infection and secondary infection). The goal of the paper was to investigate the subclinical 
infection and waning immunity in the transmission dynamics. Two types of infections were 
distinguished: infection in immunologically naive individuals or primary infections, and infection 
in individuals whose immune system had been primed before by vaccination or infection, labeled 
secondary infections. People could recover and become immune after primary or secondary 
infection or vaccination. The duration of infection was assumed to be 2 weeks, shorter than the 
3 weeks in Hethcote’s model. The duration of protection was instead assumed to last 20 years on 
average, whereas in Hethcote’s model, it was 15 years. However, for both the durations, van Boven 
et al. considered different scenarios as sensitivity analysis. An important aspect of this model was 







the formal estimation of the age–specific force of infection, estimated from age–specific Dutch 
incidence data and the stable age distribution of the endemic equilibrium in the model being 
assumed. Moreover, in later specifications of the Hethcote model, the estimates of the age–specific 
forces of infection were based on those available in the literature, mainly fitted to data from England 
and Wales347,384,385. Finally, van Boven et al. also assumed a proportionate mixing.
 A next model by the same group extended the six compartments to seven by separating those 
protected by natural infection into those protected after primary infection and after secondary 
infection331. The analyses reinforce pervious findings that there exists a relevant contribution of 
adults to the spread of pertussis and that the duration of protection after vaccination had decreased 
from pre– to post–1995 periods. Notably, the idea is expressed in the van Boven et al. paper that 
immunity for pertussis disease might last 10–20 years after natural infection and only 5–10 years 
after vaccination. Others have expressed that immunity for (subclinical) infection might even be 
significantly shorter329.
 Finally, two dynamic models for Latin American countries have been developed382,383. The first 
model focused on Rio de Janeiro (Brazil) and was divided into two submodels, one capturing the 
demographic and the other the epidemiological dynamics. The structure of the epidemiological 
model was drawn from previous published papers and consisted of nine compartments including 
one susceptible compartment, one primary and one secondary infection compartment, three 
immunological stages (full immune, intermediate immune and minimum immune), and three levels 
of vaccination depending on the number of doses received. Furthermore, the model consisted of 
12 age groups; the rate of interaction between individuals was stratified as a function of their age. 
The aim of this paper was to reconstruct the impact of the introduction of pertussis vaccination 
and to optimize the currently used strategy consisting out of three doses before the age of 1 year 
and two boosters at 15–18 months and 4 and 5 years. One of the conclusions was that it might be 
more effective to eliminate one of the boosters if it could be guaranteed that coverage of the other 
booster would increase (as the current coverage is <30%). Another conclusion was that a better 
understanding of the social contact structure is urgent especially that of the very young people. 
The other paper assessed the impact of a booster at 11 years for Argentina382. An age–structured 
compartmental model was developed based on Hethcote’s model379. The population was divided 
into nine classes including susceptibles, three classes of infections, two classes of complete protected 
individuals (after vaccination and natural infection) and four classes of partial protected individuals, 
and 30 age groups. As no specific contact patterns were available for Argentina, three different sets 
of contact patterns were used. They found that although a booster at 11 years significantly reduces 
the incidence of disease, the impact on infants of less than 1 year was very low and that the impact 
of a higher coverage of the first dose would be much larger.
Points of uncertainty
As described earlier, there are several mathematical modeling studies that assess the effectiveness 
of different pertussis vaccination strategies. However, none of them explicitly considers subclinical 
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infections, and the studies may partly neglect the difficulties in interpreting notification data. 
Notification data report only (part of ) symptomatic cases, whereas pertussis is characterized by 
mostly subclinical/asymptomatic or mildly symptomatic cases in older age groups314,374. Kretzschmar 
et al. have used different methods to estimate the incidence from individual data on pertussis titers 
rather than notification data386. In their approach, they estimate basic reproduction numbers that 
are remarkably similar across countries at approximately 5.5.
 Several studies, including the first being published on this topic, describe that the current 
generation of vaccines with limited duration of protection cannot eliminate pertussis from the 
population. Owing to vaccination, the pertussis burden of disease is shifted forward from infants 
and children to adolescents and young adults, potentially requiring new control strategies. Notably, 
the debate on duration of immunity continues with analyses being performed on notification data 
and based on models for infections, regarding natural infections and/or vaccination, and concerning 
infection or disease329,333,387. Recent studies, for example, indicated a duration of immunity of 7–20 
years after infection and 4–12 years after vaccination333, or even long lasing after infection beyond 
30 years387. The authors also note that differentiating between immunity against infection versus 
disease might help clarifying some of the issues in this discussion329.
 Another point of concern is the increase in the age of infection to women of childbearing 
age, which might infect their children as shown by several studies328,329,332,378,383. Current contact 
parameters are unable to capture these within household contacts. Although studies show that 
additional booster dose (slightly) reduces the incidence in infant, conclusions should be made 
carefully as an increase in women at childbearing age might result in an overall increase in pertussis 
cases in these infants.
Health economic studies
As mentioned, four health economic studies could be detected that explicitly applied dynamic 
models to get to the results328,329,377,378. Studies have in common that they are all directed towards 
analyzing adolescent vaccination, potentially extended with adult vaccination or even further 
strategies. Notably, in the studies, adolescent vaccination is studied in contexts where the vaccination 
is already in place (e.g., the USA) or where it is compared with potentially highly cost–effective 
comparators not yet in place, such as toddler booster vaccination388 (e.g., the UK). In addition, 
in most papers, adult vaccination strategies on top of, or instead of, adolescent boostering are 
analyzed. Notably, the two studies for the Netherlands both build on a similar modeling approach 
and are integrated in the reviews below.
Brief descriptions of the four health economic studies
Edmunds et al. analyzed the potential cost–effectiveness of introducing acellular pertussis booster 
doses at either 4 or 15 years, using the equilibrium state of a transmission dynamic model to estimate 
the indirect protection of those too young to be vaccinated377. In particular, the latter referred to 
those infants aged <3 months, prior to the protective effect of the infant vaccination schedule 







in place in the UK around the turn of the century. Obviously, herd protection was an important 
parameter in the analysis – if not the most important – however, the authors acknowledge the 
uncertainties surrounding the potential acellular vaccines to confer herd protection, as compared 
with the whole–cell vaccines. Rather than extensively elaborating on this discussion, the authors 
present extensive sensitivity and scenario analysis on this aspect. Whereas some other studies had 
the period until indirect protection occurs as a result of the modeling, Edmunds et al. assumed this 
parameter at 5 years (range: 2.5–7.5 years). The exact rationale of the study was to analyze which 
strategy outperformed in protecting the young (partly) unvaccinated infants: either vaccinating at 
4 years or at 15 years? A major part of the epidemiological model was unpublished by the time the 
study was reported and referred to as ‘Gay, unpublished materials’. Analyses were targeted at the 
specific situation in the UK.
 Coudeville et al.328 built an economic analysis following up their epidemiological analysis326. In 
particular, they wanted to address the economic issues on pertussis adolescent and adult boostering, 
given the lack of consensus in the literature389-393. In view of the explicit recommendation of the 
US Advisory Committee on Immunization Practices for routine adolescent booster vaccination394, 
Coudeville et al. exhibited a specific interest in analyzing the incremental value of adult booster 
strategies over and above adolescent vaccination. However, next to this approach, the authors also 
analyzed the cocooning strategy. Supposedly though, the full benefit of the population dynamic 
approach is present in the adolescent and adult vaccination strategies rather than in the cocooning 
approaches. For that purpose, we focus on the analyses on adolescent and adult booster strategies 
in the following section. The study was performed using data and assumptions for the USA.
 The publications by de Vries et al.329 and Rozenbaum et al.378 are both based on the same 
model structure described in the former and separately in yet another paper352. In particular, the 
second report extended on the first by using a more user friendly and less computational–intensive 
version of the same model structure, allowing extensive scenario and sensitivity analyses that the 
initial version was lacking. Underlying this was a reprogramming of the model into another type 
of software. In particular, the follow–up paper378 analyzed several adult vaccination strategies in 
the Netherlands in addition to adolescent vaccination, whereas the former analysis only allowed 
analysis of the latter. 
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Table 1: Results and key features of the studies selected
Edmunds et al. Coudeville et al. De Vries et al./ Rozenbaum et al.
Comparison(s) Booster at 4 years vs. 15 years 
both compared to initial
infant schedule only
Adolescent vs. 
adolescent+ adult booster 
compared to initial infant 
schedule
Adolescent and adult booster both 
compared to initial infant +
4-years booster
Perspective Health care and societal Primarily societal Primarily societal
Discount rates Money: 3%; Health: 3% Money: 3%; Health: 3% Money: 4%; 
Health: 1.5%
Diff. discounting in SA? Yes No Done in base case
Cost-effectiveness(utility)
Health care <£50,000 vs. <56,000/LYG dominant vs. dominant €4400 and <16,900/QALY
Societal <£37,000 vs. <47,000/LYG dominant vs. dominant €5100/QALY (adolescent)
Probabilistic SA Yes No No
LYG: Life-year gained; QALY: Quality adjusted life years; SA: Sensitivity analysis.
Results & key features of studies 
Table 1 lists some of the results and key features of the four studies. In particular, the authors 
consider the exact comparison(s) made, costs per quality–adjusted life years (QALYs) or life–year 
gained (LYG), the perspective, discount rates used, whether differential discounting was used in 
sensitivity analysis and whether probabilistic sensitivity analysis was included. 
 Edmunds et al. analyzed the cost–effectiveness of boostering at 4 versus 15 years, both compared 
with the initial set of infant doses only377. Costs per LYG were reported from the healthcare and 
societal perspectives, which presented an important difference. In particular, work days lost for 
the society was set at 7 days with average wages taken from the Office for National Statistics350. 
Profound impact of the perspective was illustrated in cost–effectiveness still <£50,000 per LYG for 
boostering 4–year olds from the healthcare perspective, but always <£37,000 per LYG for that same 
strategy from societal point of view. Equal discounting was used to derive these results: 3% for 
costs and 3% for health outcomes. The results appeared sensitive to differential discounting (costs 
at 6% and life years at 1.5%), grossly reducing cost–utility rates by a thirds. From the probabilistic 
sensitivity analysis, it appeared that for boostering at 4 years, 50% of simulations would be <£10,000 
per LYG from the healthcare perspective, whereas this would be 75% from the societal perspective, 
with even 20% consistently indicating cost savings. Results were reported to be sensitive to the 
assumptions on indirect costs of production losses, in particular related to assumptions on this 
aspect for mild cases. 
 The US study found that compared with the initial infant vaccination strategy, both adolescent 
and adolescent+adult boostering dominate from both perspectives328. In addition, the incremental 
analysis of adolescent+adult over and above adolescent only indicates dominance of the former over 
the latter. The extra vaccination costs at approximately half a million dollars per million population 
are more than offset by savings on disease costs from both perspectives. Notably, the sensitivity 







analysis was only done from the societal perspective, with however, the general picture reflecting 
direct and indirect costs, and savings at grossly similar orders of magnitude. The study assumed 
plausible coverage rates for the different strategies investigated comprising close to 100% coverage 
for the initial infant schedule, 75% for adolescent vaccination, 65% for cocooning and 40% for 
routine adult vaccination every 10 years. Higher coverage – in particular, for the latter – analyzed in 
the sensitivity analysis did not change the conclusion of the study. Most strategies and combinations 
of strategies remained highly attractive from the economic point of view. As not specified in any 
US guidelines on health economic analysis, the US study lacked differential discounting in the 
sensitivity analysis. However, the authors analyzed different percentages for equal discounting: 
as is the case for most vaccination strategies, higher discount rates deteriorate cost–effectiveness 
ratios, lower ones improve395. As most strategies were dominating, the subsequent comparators 
were only reported for the strategy of ‘childhood+adolescent+routine adult’ compared with the 
‘childhood+adolescent+cocooning+1 adult dose at 40 years’ strategy at $678,500 per LYG in the 
base case, $482,100 at 0% discounting and $837,400 at 5%. The authors note the similarities in the 
set of strategies investigated compared with Lee et al. 391,392, whereas inferences differ. In neglecting 
herd immunity and potential resurgence of pertussis incidence, Lee et al. found that addition of 
adult vaccination to adolescent boostering unlikely to be cost effective. Neglecting herd immunity 
is obviously related to the model approach chosen: static versus dynamic.
 Primary focus in the first paper on the Dutch analysis329 was the adolescent vaccination strategy 
at the age of 12 years, with an aim to protect infants too young to be (fully) vaccinated. It appeared 
that this strategy had only limited impact in this respect given the Dutch mixing patterns modeled. 
However, the strategy was cost effective in the preferred Dutch societal perspective primarily 
owing to direct QALY gains, and inclusive age shifts and related changing indirect cost patterns. 
In particular, indirect costs seem to be shifted from adolescents and young adults to childbearing 
and parental ages and beyond. A similar pattern can be observed for QALYs; that is, adolescent 
vaccination lowers QALY losses in the former group at the expense of increased QALY losses in 
the latter groups. Related to the age shift explicitly modeled and related effects on indirect costs, 
lower discount rates worsened the cost–effectiveness: €4400–6400 per QALY in the base case at 
differential discounting using 4% for money and 1.5% for health, €5200–7400 per QALY for equal 
discounting at 4% and even up to €7900 per QALY in the absence of discounting. Notably, this result 
is seldom seen but can occur as a result of age shifts in dynamic models. No probabilistic sensitivity 
analysis was performed; however, the respecification of the model for the second paper378 would 
allow probabilistic sensitivity analysis in the future to be embarked upon. All in all, the Dutch 
analyses indicated favorable cost–effectiveness for adolescent vaccination due to QALY gains in 
adolescents and shifts in indirect costing patterns, with an optimal age of vaccination of 10 years 
from the economic perspective352,378. In particular, reduced pertussis disease in adolescents and 
young adults comes with an increase in later stages of life. Thus, age shifts might increase pertussis 
in the childbearing and parental ages, providing potential for additional booster strategies in 
adulthood. Rozenbaum et al. found both one–off and every–10–year adult vaccination on top of 
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adolescent boosting to be cost effective in the Netherlands378. 
Table 2: Specific characteristics of selected cost-effectiveness studies.
Edmunds et al. Coudeville et al. De Vries et al./ Rozenbaum et al.
Underreporting explicitly taken into account? Yes Yes Yes / varied in scenarios
Asymptomatic cases included? No Yes Yes 
Duration of protection
Natural infection 5 years 8 years 13 years/ 8, 12 and 16 years
Vaccination 5 years 4 years 8 years
Direct and indirect effects separately reported
Herd protection Yes No Yes
Age shift No No Yes
Contact matrix used Unpublished material# 332 343
#  Extensive sensitivity analysis was performed (personal communication)
Specific characteristics of studies
Table 2 lists some further specific characteristics of the studies. In the following paragraph, these 
aspects are described in detail.
 The UK model was built to validly analyze epidemiology using registration systems for GP visits 
(Royal College of General Practitioners Weekly Returns Service) and hospitalizations. The Royal College 
of General Practitioners Weekly Returns Service was corrected for non–notified cases; a multiplier of 
2.5 was specifically used for this purpose. Notably, if higher, but still plausible, underreporting was 
assumed, cost savings became within the realm of potential results if the societal perspective was 
taken. Duration of protection was set at 5 years for both natural and vaccine–induced protection, 
although in scenario analyses sets of protective durations with consistently lower vaccine–induced 
durations than natural at half of the natural duration were analyzed (e.g., 5 years after infection and 
2.5 years after vaccination or 10 and 5 years, respectively). Owing to the design of the model, results 
were not highly sensitive to this specific assumption. Five different mixing matrices were specified 
and analyzed, reflecting different levels of mixing between age groups. Direct and indirect effects 
were analyzed separately in the study by focusing once on herd protective effects on infants <3 
months only. Generally, this analysis illustrated that these indirect herd protective effects drove the 
model results and that inclusion of the direct vaccination effects on the toddlers and adolescents 
in the respective vaccination strategies had only modest impacts. Inclusion of the direct effect was 
relatively more important in adolescent vaccination and in the societal perspective.
 The US model explicitly included asymptomatic disease. After waning of natural or vaccine–
induced immunity, subsequent infections may result in asymptomatic manifestations in approx-
imately 50% of cases. Inherent to the dynamic nature of the models considered and the crucial 
age–structured element in this, all models included both age shifting and herd protection in the 







epidemiology. However, in the reporting on the US model, these specific aspects were not explicitly 
addressed, which is a pity as reporting would provide important insights in the relative contribu-
tions of the various dynamical effects involved. Moreover, indirect costs could not be separated in 
the reporting on the sensitivity analysis. Ideally, reporting would allow specification of herd protec-
tion and age–shifting effects with corresponding changes in direct medical and indirect non–medi-
cal, respectively. The mixing pattern in the contact matrix was taken from the previous analysis by 
van Rie and Hethcote332 that analyzed, within an extensive sensitivity analysis, all from assortative 
mixing to proportional mixing in the epidemiological analysis326. However, in the economic analysis 
on the original, van Rie and Hethcote matrix was used332. Specific attention was directed at the con-
tribution of household members to pertussis transmission to allow detailed scenarios on cocooning 
strategies. In particular, this relative contribution ranged from almost 40% to just up to 50% for 
preschool children, and approximately 25% for children 5 years of age. Beyond 5 years, no impact of 
cocooning was assumed anymore.
 In some aspects, the Dutch studies did benefit from some more recently published specific 
materials. For example, the Dutch study could make use of an extensive analysis on underreporting, 
estimating infections to be in general 660–fold of symptomatic diseased and notified cases, obviously 
with age–specific patterns underlying the overall estimate332,342. A specific study for contact patterns 
could be used, estimating recent European contact patterns343. Furthermore, a cost–of–illness study 
was available, facilitating the parameterization of the costing modules in the overall design. A 
specific feature of the Dutch study was to differentiate between immunity against infection and 
disease. As all dynamic models were considered, both herd immunity and age–shifting patterns 
were included in the analysis; however, reporting was done much more extensively. In particular, 
the Dutch study explicitly reported the age shift simulated with the model in more detail than both 
other studies analyzed here. As mentioned, the age shift clearly illustrates how reduced pertussis 
disease in adolescents and young adults comes with an increase in later stages of life, providing 
potentials for adult strategies. In pertussis, what goes around seems certainly to come back around.
DISCUSSION
Pertussis vaccines have been licensed in the USA since the second world war, both as monovalent 
vaccine and combined with diphtheria and tetanus. Its widespread use has become eminent, 
supported by WHO recommendations and initiatives396,397. Despite widespread use, pertussis disease 
and infections are still around and periodic resurgences occur. One of the reasons is that immunity 
induced by pertussis vaccination or even natural infection is relatively short and heterogeneous. 
In particular, immunity might protect significantly longer against disease than against infection, 
enhancing potentials for continued spread despite relatively high vaccination coverages in infants 
and toddlers. Notably, it is yet to be determined how effective vaccine coverage will be for the 




 Dynamic models are becoming increasingly important in analyzing the control strategies for 
infectious diseases398. Notably, whereas still control strategies may exist that can sufficiently be 
analyzed with static models, such as travelers’ vaccinations, the vast majority of issues can be more 
validly addressed with dynamic models10,399,400. Adolescent and adult strategies should ideally be 
analyzed using dynamic models with their aim of influencing epidemiology rather than directly 
protecting the adolescents and adults targeted with the vaccine. Non–dynamical approaches 
to these strategies might fail to provide insight into these indirect protections and may fail to 
adequately mimic the age shifts incurred through vaccination programs401-403, although they might 
provide valuable first gross insights391,392. Finally, areas for in–between types of models certainly exist. 
For example, cocooning strategies require insight into transmission dynamics in households but 
may be analyzed with models lacking the full contact matrix structures within the full populations. 
Such quasi dynamic approaches have indeed been applied to cocooning as a control strategy, 
limiting the contact pattern to parents, siblings and potentially others without the comprehensive 
population approach328,354,404. Notably, these analyses indicate potentials for cocooning to be highly 
cost effective, but also indicate the practical issues concerning effectively and broadly implementing 
such strategies outside the routine structures provided within existing immunization programs. In 
particular, for example, Westra et al. found cost–effectiveness for cocooning at €4600 per QALY for 
the Dutch society taking the healthcare perspective, whereas from the societal perspective cost 
savings were even indicated354. Similar superior profiling of cocooning, as from the Dutch societal 
perspective, was indicated by Coudeville et al. for the USA328. 
 Dynamic models should capture recent insights in pertussis epidemiology and spread on 
differing types of models suggested, induced immunity provided and transmissibility405,406. A 
recent paper focuses on the different types of models to be used, in particular, SIR versus potential 
extended compartmental approaches405. Notably, the vaccine is considered to better protect 
against pertussis manifest disease than to (subclinical) infection, providing an immune escape and 
continued circulation despite high infant coverage – or even – adolescent vaccination329,386,406. In 
addition, the models should consider differing transmissibility of the bacteria depending on the 
disease manifestation in the host: symptomatic disease might certainly lead to higher transmission 
than asymptomatic disease does. Exact coverage needed to achieve cost–effectiveness is another 
issue that can be addressed with dynamic models. However, this will crucially depend on country–
specific issues in health economics (costing, discounting and perspective chosen), surveillance, 
reporting and epidemiology.
 The exact roles of all relevant factors in pertussis epidemiology remain uncertain, however, 
evidence is accumulating. It is obvious that with regard to the major issue of pertussis transmission 
to young infants too young to be (fully) vaccinated, both the household and the community 
play their roles323,372,407. For example, it was found that at least 34% of cases in young infants was 
infected through casual community contacts in a study in France, Germany, Canada and the USA323. 
Furthermore, regarding close contacts, parents accounted for 55%, siblings for 16% and other family 
members (and close friends) for 27%407. In this specific study, part–time caretakers only accounted 







for just 2% of the transmissions. In another study conducted in the Netherlands, for those infants 
where the source could be detected, siblings contributed to 41% of cases, mothers 38% and 
fathers 17%327. All these studies contribute to further understanding mixing patterns, populating 
assumptions in dynamic and quasi–dynamic pertussis cost–effectiveness models. For full dynamic 
models analyzing adolescent and adult strategies, recent initiatives on establishing comprehensive 
contact matrices in populations will further help in targeting and validating these models344,390. 
Failing to adequately integrate information from age–structured contact patterns probably results 
in misunderstanding epidemiological patterns, enhancing the wrong control strategies rather than 
focusing on the right ones and invalid inferences on cost–effectiveness profiles408.
 Dynamic models have up to now focused on adolescent vaccination strategies and adult 
strategies on top of those. Adolescent vaccination was investigated at the age of 10, 12 and 15 
years, although a study even analyzed the whole spectrum during teenage years initially378. Notably, 
adolescent vaccination was generally found to be cost effective, as well as adult boostering on top 
of it. In the reporting of the results of the dynamics models so far, the exact contribution of such 
strategies on protection of the very young infants yet too young to be (fully) vaccinated. Only de Vries 
et al. report extensively on this and show the limited effect329. Indeed, it has been argued, found and 
seems highly plausible that age–mixing patterns are such that contacts between adolescents and 
young infants are infrequent, rendering the adolescent strategy as unsuitable for indirect protection 
of (partly) unvaccinated infants344,406. Obviously, cost–effectiveness of adolescent vaccination is 
driven by other factors such as direct protection and age shifts. Actually, for the former even no 
dynamical models would be required, for the latter dynamical models are still crucial. In particular, 
reduced pertussis disease in adolescents and young adults comes with an increase in later stages of 
life. In pertussis, what goes around comes around.
 We conclude that dynamic model approaches in pertussis are highly valuable in analyzing 
adolescent and adult vaccination strategies. We recommend continued and extended use of 
dynamic models for these strategies, inclusive separate analysis of the cost–effectiveness of adult 
boostering strategies.
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Pneumococcal and pertussis vaccination programs
Vaccination is considered to be one of the most effective methods of preventing infectious diseases. 
In the Netherlands, a routine infant pertussis vaccination programme has been in place since the 
1950s while a routine pneumococcal programme was initiated more recently in 2006. Inclusions 
of pertussis and pneumococcal vaccination into national immunization programmes (NIPs) had 
a tremendous impact on the mortality and morbidity in the Netherlands and other countries 
worldwide36,84,409-411. Nevertheless, extending pertussis vaccination to other age groups, replacing 
the currently used pneumococcal vaccine to one with a broader coverage, introducing a risk-
groups-targeted or elderly pneumococcal vaccination programme, could reduce the morbidity and 
mortality due to these bacteria even further. 
 This thesis deals with both the epidemiological and economic impact of such new pneumococcal 
and pertussis vaccination strategies. This chapter summarizes and discusses the main results, 








PRINCIPLE FINDINGS AND FUTURE PERSPECTIvE
PART I: EPIDEMIOLOGy AND ECONOMICS OF PNEUMOCOCCAL vACCINATION.
Chapter 2 described a literature review aiming to address the following aspects: first, to provide 
a descriptive overview of the available epidemiological post–marketing data and experience with 
7–valent pneumococcal conjugate vaccine (PCV7) in different countries and populations; second, 
to explore potential factors that could explain observed differences; and third, to discuss issues 
related to the use of national data in (cost–)effectiveness modeling. It showed that there are large 
differences in the observed disease epidemiology after implementation of pediatric pneumococcal 
immunization programs between the USA and Europe, but also between European countries and 
even between regions within countries. Possible factors responsible for these differences may 
include vaccine–serotype coverage, implemented vaccination schedules, antibiotic resistance rates 
and pneumococcal disease incidence prior to vaccination. A potential limitation can be found in 
the installation or enhancement of existing surveillance systems as well as other potential factors 
possibly causing confounding bias, which may have influenced observed disease rates in the 
included observational studies. Based on the findings in Chapter 2, it was concluded that the health 
and economic impact should be addressed in the light of the country–specific pneumoccocal 
disease epidemiology to support decisions on national immunization programs.
 Several published European cost–effectiveness studies on PCV7 have included net–indirect 
vaccine benefits (herd protection minus serotype replacement) in their analyses. These net–indirect 
benefits were often extrapolated based on a specific observational study from the USA, after the 
introduction of PCV746. In Chapter 3 the impact of including indirect effects on the cost effectiveness 
of PCV7 vaccination in the Netherlands (3+1 dose schedule) was calculated. Also, the level of net–
positive indirect effects needed (as a percentage of that observed in the USA) in order to label 
routine infant vaccination as cost–effective was estimated. Using a previously developed cohort 
model133,135, updated with the most recent Dutch costs and epidemiological data, it was shown that 
without net–indirect benefits for non–vaccine protected groups included the incremental cost–
effectiveness ratio (ICER) of a routine infant PCV7 program was €72,360 per QALY. Full inclusion of 
indirect effects would lower this ICER to €16,750 per QALY. Furthermore, it was shown that in order 
to obtain ICERs below a threshold of €50,000 per QALY the net–indirect protective effect should at 
least be 16% of those observed in the USA after the introduction of PCV7.
 Given that net–indirect effects considerably affect the cost effectiveness of the current Dutch 
vaccination program, the cost–effectiveness estimates of PCV7 vaccination were updated using 
recent data on these indirect vaccination effects in Chapter 4. In this same chapter also the 
cost effectiveness of reduced dose schedules and vaccine price reductions combined with the 
implementation of PCV10 and PCV13 were estimated. At the time of the study only a relatively small 
number of IPD cases were reported during the surveillance period of two years after the introduction 
of PCV7 in the Netherlands. It was therefore necessary to partly base the estimations for indirect 
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effects on epidemiological data from the UK, a country with a similar pneumococcal epidemiology 
before the introduction of PCV779,81,104. In particular, an increase of 100% for NVT IPD for children less 
than 5 years was included combined with the absence of an overall net indirect effect for individuals 
aged 5 years and older. Nevertheless, a recent study from the UK, which corrected the incidence 
for underlying trends and case ascertainment, showed net–indirect benefits in older age groups 
and less serotype replacement than previously assumed in children aged less than 5 years36. This 
suggests that the base–case results, which showed that vaccination with PCV7 in the Netherlands 
was unlikely to be considered cost effective, might be too conservative, although specific Dutch 
data would be required to confirm this. Finally, the study concluded that vaccinating with the 10–or 
13–valent pneumococcal vaccines would result in cost-effectiveness estimates which are likely to be 
considered as cost effective. 
 Next to infants, elderly and individuals with specific conditions are at increased risk of 
pneumococcal infections40,163,412,413. Therefore, the cost effectiveness of PCV13 vaccination among 
(high–risk) elderly and individuals with specific high–risk conditions was explored in Chapter 5 
and Chapter 6, respectively. To estimate the cost effectiveness of elderly vaccination (Chapter 5) 
a cohort model in which vaccination was assumed to occur at the age of 65 years was developed. 
Because of the uncertainty surrounding the net–indirect effects, different scenarios were explored 
in the base case. In a first scenario indirect effects were excluded, given the absence of specific data 
for those aged ≥65 years in the Netherlands or any other European country at that time. This might 
be considered too optimistic a scenario from a cost effectiveness point of view because it assumed 
no herd–protection benefits among older adults as a result of infant pneumococcal vaccination. 
In a next scenario, it was assumed that the PCV7 infant vaccination program would increase the 
incidence of NVT IPD (replacement) while reducing the incidence of VT IPD. Furthermore, as there is 
much uncertainty regarding the efficacy, first the cost effectiveness was estimated by only assuming 
protection against bacteraemic community acquired pneumonia (CAP). In subsequent analyses, 
the protection was extended to other IPD and to CAP resulting in general–practitioner visits and 
hospitalizations. The model showed that the ICER remained below €80,000 per LYG, except when 
PCV13 was assumed to protect only against bacteraemic CAP, with a relatively low effectiveness 
(40%) in combination with a high vaccine price (€65), and indirect effects of serotype replacement 
would largely offset the direct effect of vaccination. Based on these outcomes it was concluded that 
vaccinating elderly with PCV13 might potentially be cost–effective. 
 The aim of Chapter 6 was to estimate the cost effectiveness of vaccinating individuals of 2 years 
and older with high–risk conditions for IPD using PCV13. In contrast to the previous chapters, in which 
the cost–effectiveness analyses were performed from a societal perspective for the Netherlands, 
this study was performed for the UK from a National Health Service (NHS) perspective. A cohort 
model was developed which differentiated between individuals who are immunocompromised, 
such as those with HIV, asplenia, or splenic dysfunction or who respond poorly to the vaccine, 
such as people with chronic kidney disease; and those in immunocompetent risk groups such as 








uncertainty around the potential impact of non–bacteraemic pneumonia no net effect against 
non–bacteraemic pneumonia was assumed in the base–case analysis. The model showed that 
increasing indirect protection resulting from the infant PCV13 program means that the burden of 
disease preventable by targeting high risk groups will diminish in time. Assuming that a vaccination 
campaign could be launched in 2012/13, the ICER was estimated to be >£30,000 per QALY for most 
risk groups, with the exception being patients with chronic liver disease. If, however, the vaccine 
program would be effective against non–bacteraemic pneumococcal pneumonia or the vaccine 
would have been introduced concomitantly with the infant PCV13 program, vaccinating high risk 
individuals would (more) likely be cost–effective. It was concluded that without an assumed effect 
against non–bacteraemic pneumococcal pneumonia, a risk–group pneumococcal vaccination 
program is unlikely to be considered cost effective. It should be noted that the results of this analysis 
cannot directly be transferred to the Netherlands. Firstly, the health-economic methodological 
requirements differ between the Netherlands and the UK. For example, in the UK an equal discount 
rate should be used and analyses are performed from the NHS perspective while in the Netherlands 
differential discount rates for costs and health are used and studies are performed from the societal 
perspective142,208. Secondly, in the Netherlands PCV10 has been introduced rather than PCV13. In 
contrast to PCV13414, PCV10 has not demonstrated herd effects (yet), and does not cover serotype 
19A, which is one of the key replacement serotypes. Therefore,  it is likely that a high–risk group 
vaccinating strategy in the Netherlands will be more favorable as compared to the UK.
 Next to the assumed vaccine efficacy and the assumed herd protection effects from the 
infant vaccination program the main driver of the ICERs in Chapters 5 and 6 was the proportion 
of pneumonia that could be attributed to Streptococcus pneumoniae. Therefore, a meta–analysis 
to estimate this fraction and the factors influencing this fraction was performed in Chapter 7. 
Using a systematic literature search, 77 articles were assessed that covered human subjects with 
CAP over the period January 1990–November 2011 across European countries. A mixed effects 
regression model was developed and populated with 24,410 patients obtained from 77 articles 
that met inclusion criteria. The model showed that the observed prevalence of S. pneumoniae in 
CAP significantly varies between European regions even after adjusting for explanatory covariates, 
including patient characteristics, diagnostic tests, antibiotic resistance and health–care setting. The 
probability of detecting S. pneumoniae was substantially higher in studies that performed more 
frequently a diagnostic PCR assay compared to all the other diagnostic tests included. Furthermore, 
S. pneumoniae was more likely to be confirmed as the cause of a CAP in studies with ICU patients as 
compared to those with hospital or community treated patients.
PART II: EPIDEMIOLOGy AND ECONOMICS OF PERTUSSIS vACCINATION
Despite widespread vaccination, there has been a resurgence of pertussis in many countries during 
the past decade, particularly in adolescents and adults314,317-320. Although infections in infants and 
young children are more severe than in adolescents, the increasing incidence in adolescents and 
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adults is a major concern because adults are identified as important sources of transmission to 
young infants, and infection in adults causes significant significant morbidity and high costs349-351. 
Therefore, we explored the optimal vaccination strategy for reducing the number of infections 
in this population in Chapter 8. It was shown that, over a wide range of variations, an additional 
booster dose can reduce both the incidences of symptomatic and asymptomatic pertussis cases 
in the population although the incidence of symptomatic infections in older age groups can 
increase due to an age shift. A similar age shift was observed after the introduction of a pertussis 
booster vaccination in 2001 for 4–year–old children in Netherlands. The introduction of this booster 
dose reduced the number of hospitalizations among infants less than 4 months of age, while the 
incidence in adolescents and adults increased318. Furthermore, it was shown in Chapter 8 that the 
optimal timing for the third booster dose in the Netherlands is between the ages of 10 and 15 
years. However, this strategy only offered limited indirect protection to the (partly) unvaccinated 
infants with potentially most serious disease which might be a primary aim of extended pertussis 
vaccination. The most optimal strategy explored in terms of primary and/or total cases averted was 
a booster dose provided every 10 years. However, this strategy may certainly differ from the most 
cost–effective strategy. 
 Two previous studies used dynamic models to estimate the cost effectiveness of extended 
pertussis vaccination schedules328,329. Although both studies provide plausible insights, they could 
not be used for decision making in the Netherlands. Firstly, because the only study that did focus 
on the Netherlands was unable to investigate the impact of multiple vaccination scenarios and 
the impact of different assumptions for parameters surrounded by uncertainty (e.g., duration of 
protection after natural infection, underreporting factors) due to long computational times329. 
Secondly, the other study focused specifically on the USA with limited options for transferability 
to other settings328. Therefore, an economical model was developed which was integrated into 
the dynamical transmission model. The advantage of this model is the short running time after 
reprogramming, which made it possible to explore, within a reasonable time, the impact of 
different assumptions on disease epidemiology, on disease–related parameters, and on vaccination 
program–related issues328,329. This model showed in Chapter 9 that an additional booster dose 
against pertussis would result in QALYs gained in children. However, the QALYs gained in children 
were partially offset due to an overall loss in QALYs in adults and elderly as a result of an increase in 
the number of symptomatic infections in these groups. Similar to the QALYs, both the overall direct 
and indirect costs would increase in adults and elderly. It was found that vaccination at the age of 
10 years was the most cost–effective vaccination strategy (€4,200 per QALY gained). A booster dose 
provided every 10 years could also be considered as cost effective (ICER of €16,872 per QALY).
 Chapter 10 described a literature review aiming to provide an overview of dynamical 
transmission models developed for pertussis, their application in health–economic analyses, and 
to update the landscape of health–economic studies with a special reference to those deploying 
dynamic models. Various studies using a dynamical model predicting the epidemiological effects 








economic analysis (with 2 studies actually using the same model structure) were found. Notably, use 
of dynamical models is yet scarce in this area. The studies show that adolescent and adult vaccinating 
strategies may be cost–effective, but lack the desired effectiveness in indirectly protecting the 
infants too young to be vaccinated, where the major risks for serious pertussis disease and mortality 
exists. It was concluded that dynamic model approaches in pertussis are highly valuable in analysing 
adolescent and adult vaccination strategies. Furthermore, the continued and extended use of 
dynamic models for these strategies, inclusive separate analysis of the cost effectiveness of adult 
boostering strategies was recommended.
GENERAL DISCUSSION
Advanced technologies resulted in the development of a number of vaccines that can enhance the 
possibility to prevent and control infectious diseases415. However, as new vaccines, as well other 
health–care technologies, become more expensive the pressure on health care budgets is rapidly 
increasing. Cost–effectiveness analyses can be used as a tool to inform decision makers who have to 
determine where to allocate the limited healthcare resources. These kinds of analyses compare the 
costs and (health) effects of an intervention to assess the extent to which such an intervention can 
be regarded as providing value for money. In this thesis several cost–effectiveness analyses which 
can be used to support decision making were presented. Indeed two of these analyses presented 
in this thesis were already used to support the decision making process in the Netherland and in 
the UK43,313.
 In contrast to most medical interventions that are directed to ameliorate the health of specific 
individuals, one of the primary goals of NIPs is to decrease transmission of an infectious disease to 
prevent disease in a whole country or even supranational. Vaccination against a specific infectious 
disease not only lowers the likelihood that the vaccinated individual will become infected and 
infectious but can also reduce the exposure of the potential infection to others. Especially, when 
a sufficiently large part of a population is vaccinated, the likelihood of an individual to contact an 
infectious individual will decrease. In most cases, reducing the transmission of infectious diseases in 
the population will bring overall benefits although in some circumstances there can also be indirect 
negative effects for some groups.
 A positive indirect effect of vaccination is that individuals with little or no protection can be 
indirectly protected if the chance of meeting an infectious individual is reduced sufficiently146,416. 
This indirect protective effect is labeled ‘herd protection’ and can be achieved by mass vaccination 
against infectious diseases that are transmissible from person–to–person (e.g., pneumococcal, 
pertussis, measles) and for those for which humans are an important reservoir (e.g., polio, 
malaria)16,146,416. To induce herd protection on a population level, the proportion of the population 
that needs to be vaccinated should exceed a specific threshold which differs among infectious 
diseases. This threshold depends on the basic reproduction number, which specifies the average 
number of secondary infections generated by one typical infectious case in a fully susceptible 
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population over the course of its infectious period. The higher the basic reproduction number 
of an infectious agent the higher the vaccination coverage must be to eradicate the disease146. 
Theoretically, pertussis could be eliminated with the current vaccine uptake in the Netherlands 
as pertussis is less transmissible than other childhood infections such as measles and rubella386. 
Unfortunately, vaccination–induced immunity against Bordetella pertussis is relatively short, with 
estimations ranging from 4 to 12 years333. This waning immunity causes that, as illustrated with our 
estimations, the desired elimination of pertussis cannot be reached even when an every 10 year 
booster would be introduced into the population352. 
 Next to positive indirect effects, vaccination can also have negative indirect effects. For example, 
the introduction of a varicella infant vaccination program, to avoid generally mild infections, could 
potentially prevent the boosting of natural immunity against the varicella zoster virus, possibly 
resulting in an increased herpes zoster incidence in elderly417-420. Furthermore, vaccination might 
result in an increase in the average age of infection421. This effect has been observed in Greece, as 
a result of a very low vaccine uptake (50%), with rubella vaccination422. Also, our model predicted 
an increase in the incidence of symptomatic pertussis infections in older age groups after the 
introduction of adolescent pertussis booster. Due to this increase in symptomatic secondary 
infections in adults and elderly it was predicted that there would be an overall loss in productivity 
and QALYs in adults and elderly. Nevertheless, introducing a booster was considered highly cost 
effective due to the benefits (both costs and health) obtained in infants, children, adolescents and 
young adults.
 Another potentially negative indirect effects of vaccination is an increase in the prevalence of 
certain strains of bacteria as a result of vaccination against other strains423. After the introduction 
of the infant immunization program against S. pneumoniae (using PCV7), reductions in carriage 
and disease caused by serotypes included in the vaccine have been observed57-60. However, near 
eradication of these vaccine serotypes (VTs) in asymptomatic carriers has created an ecological 
niche for NVTs, which has led to rapid increase of colonization by NVTs57-60. This indirect effect 
is known as serotype replacement. However, even if the carried pneumococcal serotypes are 
completely replaced by pneumococcal serotypes not included into the vaccine, the overall disease 
incidence would be reduced as these replacement serotypes have less invasive potential36,84. In 
addition to serotype replacement, it might also be possible that the carriage of other bacteria such 
as Staphylococcus aureus could increase as a result of PCV7 vaccination although conflicting results 
have been reported424,425. 
 All the indirect effects discussed above are only assessable with so called dynamic transmission 
models14,15,426. In these kinds of models the risk of acquiring a transmissible infection is related to 
the number of infectious individuals in the population enabling us to predict the effects of reduced 
transmission (see TEXT BOX 1 for more technical details about dynamic modeling). A key concept in 
a dynamic model is the force of infection, which denotes the rate at which susceptible individuals 
will be infected within a given time period. In this thesis, a dynamical model was presented which 
was used to predict the costs and effectiveness of extended pertussis booster programs. However, 








to–person or if humans are not an important reservoir of infection (e.g., tetanus, rabies and West 
Nile virus) dynamic models are not required, as vaccination will not lead to any indirect effects. 
Also, for interventions targeting small groups, such as screening and treatment programs against 
Chlamydia in pregnant women or offering hepatitis A vaccination for travelers, transmission models 
are not required426,427. So in general, a dynamic model is not required if the vaccination program is 
not expected to have any influence on the transmission dynamics of an infection disease426. Also, it 
might not always be feasible to develop a dynamic model as dynamic models are analytically more 
complex and time consuming to develop and require specific epidemiological data such as detailed 
information regarding mixing patterns, carriage, transmissibility, and the potential of an infection to 
cause disease80,120.
 In case a dynamic model is not required or it is not possible to develop one, a so called static 
model can be used. The key difference between dynamic and static models is that static models 
assume that the force of infection is a fixed parameter while in dynamic models this is dependent 
on the number of infectious individuals in the population426. Although, static models cannot 
predict indirect effects, these effects can be included into models by making assumptions. These 
assumptions could, for example, be based on a similar population that has undergone the same 
intervention or on previously implemented vaccination programs. This latter approach was used 
to predict the herd effects in the unvaccinated population due to PCV13 in the UK. In this analysis 
it was assumed that the herd–effects for five out of the six additional serotypes in PCV13 would be 
similar to the observed herd effects for the serotypes in PCV7 after the introduction of the routine 
infant PCV7 program in 200640. Also in Chapter 6, a static model was used to calculate the cost 
effectiveness of implementing a routine PCV7 vaccination program in the Netherlands. Previously 
it was already shown that the cost effectiveness of PCV7 vaccination would be critically dependent 
on the level of herd effects and serotype replacement included into the analysis47. To predict these 
effects, a dynamic model would be required. However, as the reliability of a dynamic model for 
S. pneumoniae is dependent on the structure and underlying assumptions such as the serotype 
specific carriage, transmissibility, and the potential to cause disease and because at the time of 
the analysis detailed data regarding these parameters were only very limited it was decided to use 
a static model209,214. Indeed, a more recent study showed that the impact of an infant program is 
extremely sensitive to assumptions regarding the level of competition between VTs and NVTs, even 
predicting an increase in the overall incidence of disease depending on the level of protection for 
VT from NVT acquisition209. 
 Models always are a simplification of reality and all models are based on assumptions. Dynamic 
models are not necessarily better than static ones as greater uncertainty is introduced as the 
number of assumptions and parameters increase and data to validate the developed model become 
scarce. In the light of model limitations, the cost effectiveness can be most accurately estimated by 
using observational data after the introduction of vaccination programs. To make this possible, it 
will however be required that comprehensive surveillance systems will be in place (even before 
the introduction of the program to avoid bias) closely monitoring the epidemiology of specific 
infectious diseases under study.
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TEXT BOX 1: Dynamic modeling428 
The first dynamic epidemiological model was probably developed in 1906 by Hamer, being used 
for understanding the recurrence of the measles epidemic428,429. Since then, mathematical models 
have slowly increased in complexity and are currently able to include aspects such as, maternally–
derived immunity, gradual loss of vaccine efficacy (waning immunity), disease–acquired immunity, 
different stages of infection, age structures and social and sexual mixing patterns.
 A frequently used type of dynamic model for economic evaluations of vaccination programs 
is the so–called SIR model (Susceptible–Infected–Recovered). This model basically assumes that 
the population is divided into three mutually exclusive subpopulation or compartments (Figure 
1). The first compartment contains that part of the population being susceptible to a particular 
disease, the infected and infectious part of the population is included in the second compartment, 
and the last compartment consists of those who are removed from the infected population, 
through death or recovery from infection resulting in immunity to subsequent infection. 
Depending on the type of infectious disease, additional compartments can be included into the 
model. For example, when infant varicella vaccination is modeled, it should be taken into account 
that neonates are protected during the first months after birth due to maternal antibodies, and 
a corresponding compartment ‘maternally–derived immunity’ should be added for newborns 
(Figure 1). After a few months when the maternal antibodies have waned, the infant would move 
to the susceptible compartment. Between the susceptible and the next (infected) compartment, 
an additional compartment can be added, including that part of the population being infected 
but not being infectious. In this way multiple compartments can be added to the SIR model, 
enlarging its complexity to a level depending on the disease being modeled and the purpose of 
the model. Furthermore, the dynamics of infectious disease are not only time dependent but also 
age dependent. For example, the risk of infection may be related to age as different age groups 
mix heterogeneously rather than homogeneously, and the fraction of the population recovered 
from infection usually increases with age. Using an age–structured model is also necessary when 
vaccination programs are focused on specific age groups. Thus, realistic infectious disease models 
should often include both time and age as independent variables. Further information on dynamic 
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Figure 1. The MSEIR model (basic SIR model shaded in grey); M=Maternally derived immunity, S=Susceptible, 








Extrapolation of epidemiological data
In the Netherlands, as in many other European countries, the decision to introduce PCV7 in 2006 
into the Dutch NIP for infants has in part been driven by cost-effectiveness considerations131-134,139,145. 
The Dutch Health Council estimated the cost–effectiveness ratio (CER) of vaccination with PCV7 
compared with no vaccination at €70,000 and less than €20,000 per quality adjusted life year (QALY) 
in 2001 and 2005, respectively11. Crucial factors responsible for the change from a potentially 
unfavorable CER in 2001 to a favorable ratio in 2005 were the inclusion of data on observed herd 
protection effects in adults after nationwide implementation of PCV7 in the USA in 2000, yet 
limited disease development caused by pneumococcal serotypes not present in the PCV7 replacing 
pneumococcal serotypes eliminated by the vaccine (replacement disease) and a change in the 
discount rate for health effects44-46. However, as argued in Chapter 2, extrapolating these effects 
from the USA was deemed inappropriate on the longer run and resulted in too favorable CERs in 
later years. To avoid over– or underestimation of the impact of potential new vaccination programs 
future cost effectiveness, analyses should preferably not extrapolate the epidemiological impact of 
a vaccination program from one country to another. However, if there are no other possibilities, first 
the pre–vaccination epidemiology (e.g., incidence, coverage by the vaccine etcetera) and differences 
between populations (e.g., vaccine uptake, age distribution, mixing patterns), and other parameters 
such as the (expected) vaccine uptake and immunization schedules should be compared in order 
to judge whether extrapolation of data can be deemed appropriate or specific corrections should 
apply and are feasible. In Chapter 4, the estimations for indirect effects were also partly based on 
epidemiological data from the UK. In contrast to the US data, the UK data seemed more relevant for 
the Netherlands because the UK has a comprehensive surveillance system, comparable IPD rates, 
and a similar serotype coverage by PCV779,139. Furthermore, the Dutch data available at that time 
showed a similar increase in IPD caused by non–vaccine serotypes as observed in the UK two years 
post–vaccination81,151.
Further issues in health economics of vaccination
The conclusions drawn from our analyses largely depend on the specific cost–effectiveness 
thresholds applied. Very recently the Dutch Healthcare Insurance Board (CVZ) advised the Ministry 
of Health to use a threshold of €80,000 per QALY gained which can be lower or higher depending 
on the context431. This context might, for example, be dependent on the severity of disease or on the 
age of the population involved. Applying the threshold, as suggested by the CVZ, all interventions 
investigated for the Netherlands in this thesis are likely to be considered as cost–effective.
 The cost effectiveness of preventive interventions largely depends on discounting395,432. 
Discounting is used to devalue future costs and health outcomes relative to current ones. This is done 
to reflect the time preference of individuals and societies, due to uncertainty about the future and 
the growing (economic) wealth in particular433,434. In contrast to discounting future costs, which has 
a clear basis in economics, discounting health outcomes has been subject of much debate152,395,435. 
Especially, the cost effectiveness of preventive interventions is influenced by discounting, and led 
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some to argue for specific discounting rules for preventive interventions152,395,435. In particular with 
vaccination, the costs of the program are incurred at the time of vaccination while the benefits can 
occur in the middle–to long term. This is in particular true for HPV, where the benefits of vaccination, 
i.e. the prevention of cervical cancer, occur several decades after the initial vaccination395. However, 
the impact is also significant for vaccines which prevent mortality in young children such as the 
pneumococcal vaccine, as future life years saved are also discounted.
 The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guidelines 
state that the time horizon of an analysis should be long enough to capture all the differential effects 
of the interventions compared. Especially with vaccination programs, where costs are incurred 
immediately, while potential savings and health benefits are spread out over a prolonged period of 
time, a long time frame seems to be necessary on the one hand. On the other hand, very long time 
horizons may not be very informative for decision makers and uncertainty is high. Indeed, it is very 
unlikely that models are able to predict disease impact in 50 or 100 years, due to the uncertainty 
regarding the disease dynamics, and because external factors such as demographic changes and 
the developments of new medical technologies are difficult to predict. Despite that, costs and 
benefits occurring far in the future will be so heavily discounted that the effects are likely to be 
marginal395. An interesting approach used sometimes is to report the outcomes at the equilibrium 
state (i.e. when the full impact of vaccination has been reached)328. Similarly, indirect effects can also 
be included in a static model by using equilibrium outcomes of a separate dynamic model377. Again, 
given the discussion on the time horizon, the validity of these outcomes might be questioned 
because the time to reach an equilibrium state may take more than a century328 and because using 
the outcomes at the equilibrium state ignores the (potentially more relevant) period between the 
start and reaching the steady state, when disease prevalence may fluctuate398. The impact of the 
chosen time horizon depends on the infectious disease being modelled and should be explored 
in the sensitivity analysis, in particular if a steady state has not been reached within the chosen 
time horizon. If a steady state has not been reached, cost effectiveness can change in time as has 
been shown for varicella vaccination398. In conclusion, the issue of the time horizon warrants specific 
attention in the area of vaccine health economics.
 Specific groups can be at increased risk of infection compared to healthy population40,436. For 
example, the majority of the IPD cases in individuals aged 2 years and older occur in those with 
specific underlying conditions40. As characteristics between the general population and high–
risk groups differ, this group warrants specific attention. It is, for example, essential that cost–
effectiveness analyses focusing on preventative interventions use the life expectancy of the targeted 
at risk population rather than using the life expectancy of the overall population (see also Figure 2) 
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Figure 2. Survival curves for high–risk immunocompromised individuals, high–risk immunocompent  individuals 
(based on Read codes mapped to ICD–9 codes) and the general UK population. Data taken from Royal College 
of General Practitioners (RCGP) database (including 0.8 million patients; more than 1% of the population of the 
UK) and collected for the years 2005 to 2010. The RCGP data was validated by comparing the calculated survival 
curves with the survival curve of the general population based on mortality data obtained from the Office for 
National Statistics (ONS) for the year 2008210.
Notably, any extension of the NIP should be carefully considered because since the early introduction 
of vaccines, opponents have claimed that they are ineffective, dangerous (e.g., compromising 
the immune system), and unnecessary (e.g., attribute success in controlling infectious diseases 
to social and environmental developments rather than vaccination). These arguments may lead 
to a reduction in vaccination coverage in certain communities, increasing the risk of preventable 
outbreaks of infectious diseases437-439. For example, while the compliance with the Dutch NIP is high 
(95%), a large rubella outbreak occurred in the Netherlands in a population subgroup with religious 
objections to vaccination437. Next to these known clusters, the anti–vaccine lobby and the media 
can have a considerable impact on the vaccination coverage in general. For example, the initial 
coverage of the HPV vaccination program in the Netherlands was only 53% with regional uptakes 
varying from 40%–61%440. The debate on the HPV vaccine’s safety and efficacy was widely relayed 
in the national media, inclusive skepticism of some Dutch scientists and the anti–vaccination lobby, 
resulting in mixed messages and a feeling of confusion in the population441. Several other events 
demonstrated the impact of the anti–vaccine movement in the past. In the 1970s the diphtheria–
pertussis–tetanus (DPT) immunization was disrupted by anti–vaccine movements in several 
countries resulting in much higher incidence of pertussis compared to countries where high 
vaccine coverage was maintained442. Another example of the impact of media was the decrease in 
vaccination rates after the publication of a paper implying a link between the measles, mumps and 
rubella (MMR) vaccine and autism and bowel disease443. Although, the scientific limitation of this 
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paper was clear when it appeared, vaccination rates in the UK dropped to 80% in the years following 
the study and as a result measles was declared endemic again in England and Wales in 2008 for the 
first time in 14 years444,445. After being heavily criticized on scientific and ethical grounds, in 2010 The 
Lancet retracted the paper446,447. This illustrates the relevance and potential impact of the media, but 
also the general lack of valid scientific arguments to underpin such standpoints.
OTHER (FUTURE) POSSIBLE vACCINATION STRATEGIES
Pneumococcal vaccination
Several countries have already introduced infant pneumococcal vaccination schedules of which 
most are currently using the 13–valent vaccine in either a 2+1 or 3+1 dose schedule. To prevent 
disease among high–risk groups and elderly, with the highest burden of disease, many countries 
recommend vaccination with the 23–valent polysaccharide vaccine (PPV23) which has been 
available since the 1980s. Nevertheless, the efficacy and the duration of protection of this vaccine 
is limited, and there is a reduced antibody response to revaccination20,21. The use of conjugated 
pneumococcal vaccines could potentially overcome the limitations of PPV23199,200. Indeed, efficacy 
data that are available suggest that PCVs are effective in preventing IPD (and possibly pneumonia) 
in HIV infected adults and children, a group in whom PPV23 is ineffective199,200. As the indication 
for PCV13 was recently extended to adults aged 50 years and over35 some European countries are 
already recommending PCV13 for risk–groups or adults. For example, in Austria and Greece PCV13 
is recommended for those aged 50 years and older220,221, while in France, parts of Germany and Italy 
the vaccine is being recommended for (specific) risk groups222,223. This thesis showed that the cost 
effectiveness of such programs will be crucially dependent on the effectiveness of PCV13 against 
non–bacteraemic pneumonia and on the time since the introduction of the infant PCV13 program. 
Interestingly, in the Netherlands the government decided to switch to PCV10 rather than PCV13. As 
PCV10 has shown mixed effects in nasopharyngeal carriage and has not demonstrated herd effects 
after the introduction of routine infant pneumococcal programs the cost effectiveness of a risk–
based PCV13 program might not decrease (as fast) in time as was predicted for the UK158,448. Another 
difference is that economic evaluations in the Netherlands should include indirect costs and future 
health gains are discounted with a lower rate which could also result in more favorable ICERs.
 In many countries, the decision on switching from PCV7 to either PCV10 or PCV13 was largely 
driven by the observed increase in disease due to serotypes not included in PCV7 and the sheer 
fact that PCV7 is not available anymore (i.e. Pfizer replaced PCV7 by PCV13). In particular, after the 
introduction of routine infant PCV7 vaccination serotypes 19A, 7F, 3, 22F, 10A and 33F have become 
the most important causing disease116-118. In addition to PCV7, PCV10 also contains serotypes 
1, 5 and 7F, while PCV13 includes the PCV10–serotypes and adds serotypes 3, 6A, and 19A. The 
broader serotype coverage of the 10– and 13–valent vaccines might reduce the potential for disease 
caused by serotypes not included in the vaccine in both children and the elderly215. However, it 








the immunogenicity issues, it seems unlikely that vaccines will eventually include all serotypes. 
Therefore, it might be necessary, depending on the level of serotype replace ment, to revise the 
composition of the protein conjugated vac cines in the future. The expenses of developing such 
new conjugated vaccines prompted the consideration of novel vaccines including those targeting 
broadly conserved proteins or killed whole–cell pneumococcal vaccines449. Until these new vaccines 
will become available, it is important to continue IPD surveillance in order to identify the emergence 
of new relevant strains and to switch to vaccines with the broader or otherwise different coverage. 
Pertussis
Despite widespread vaccination, infection with pertussis remains endemic even in countries 
with high vaccination coverage314-317. Moreover, there has been a resurgence of pertussis in many 
countries during the past decade, particularly in adolescents and adults314,317-320. Therefore, several 
countries, including Australia, Canada, France and Germany, have incorporated adolescent booster 
doses into their vaccination programs37. Our dynamic model showed that extension of the current 
pertussis vaccination program in the Netherlands could be considered cost–effective. Nevertheless, 
it was also shown that even with an every 10 year pertussis booster it was unlikely that pertussis 
would be eliminated from the population. This means that neonates and infants too young to be 
vaccinated will still be at risk of infection. Additional strategies, aiming to protect unvaccinated 
or incompletely vaccinated infants that can be considered, include, vaccination of the mother in 
the third trimester of pregnancy (maternal immunization), vaccination of family members after or 
before birth of the child (cocooning), vaccinating infants directly after birth, or administering the 
first dose already at six weeks of age.
 Family members present a substantial source of infection in newborn babies and young 
infants321,323,327,450. Vaccinating these family members (and other close contact persons) could 
avoid transmission of pertussis to the non–immune and/or incompletely vaccinated infant. A 
recent Dutch cost–effectiveness analysis showed that vaccinating the parents directly after birth 
could be considered as cost–effective354. A disadvantage of this strategy is that the infant can still 
be infected by infectious individuals as cocooning does not offer direct protection for the infant. 
Direct protection of the infant may be conferred by maternal or neonatal vaccination. Maternal 
vaccination potentially offers both direct protection to the mother and temporary protection to 
the neonate due to placental transferred maternal antibodies451-453. Preferably, maternal vaccination 
should take place in the third trimester taking into account the immune response of the mother, 
the maternal–fetal IgG transport454,455, and potential side–effects456. An additional advantage of 
maternal vaccination is that breastfed infants may passively acquire IgA antibodies after birth457. 
Potential disadvantages of this strategy might include the temporarily antibody interference with 
the infant immunization schedule453,458; yet limited availability of efficacy data hinders to adequately 
analyze this. Nevertheless, maternal vaccination studies carried out in the 1930s to 1950s using the 
high–dose whole–cell vaccine showed no serious side–effects in mothers or children. In addition, 
maternal vaccination against tetanus has been shown to be effective and safe over long periods 
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of time454,459. Notably, also the Advisory Committee on Immunization Practices (ACIP) recommends 
(partly based un yet unpublished literature) to vaccinate pregnant women who previously have 
not received Tdap404. Two clinical trials currently being performed will provide more information 
of the safety and immunogenicity of Tdap during pregnancy460,461. Another possibility to increase 
the protection of neonates against pertussis is the administration of a pertussis dose at birth. 
Studies have shown that neonatal immunization with acellular pertussis vaccines can act as a 
basis for future immune response by priming T and B cells462,463. Nevertheless, vaccination at birth 
might result in interference with subsequent vaccinations (against other pathogens)436. Additional 
studies exploring this effect and the efficacy of vaccinating newborns against pertussis are currently 
underway436. Similar to the cocooning strategy, a disadvantage of neonatal vaccination and the 
accelerated programme is that it will leave the infant susceptible to pertussis for some weeks 
depending on how fast immunity an immune response will be induced. 
 Each of the above discussed strategies have their specific advantages and disadvantages but 
all can be effective in preventing infant pertussis cases. However, the most (cost–)effective way 
to reduce the pertussis burden would probably be to develop vaccines which induce long lasting 













1. Lund O, Nielsen M et al. Immunological Bioinformatics (Computational Molecular Biology). The MITT Press; 
2005.
2. Lombard M, Pastoret PP, et al. A brief history of vaccines and vaccination. Rev Sci Tech 2007; 26(1):29-48.
3. Nationaal kompas gezondheid. Overzicht van de verstrekking van vaccins vanaf 1952. Available at: http://
www.nationaalkompas.nl/preventie/van-ziekten-en-aandoeningen/infectieziekten/rijksvaccinatiepro-
gramma/overzicht-van-de-verstrekking-van-vaccins-vanaf-1952. Accessed on: 27-06-2012.
4. Rutten W. ‘De vreselijkste aller harpijen’ - Pokkenepidemieën en pokkenbestrijding in Nederland in de 
achttiende en negentiende eeuw; een sociaal-historische en historisch-demografische studie. Centraal 
Boekhuis; 2012.
5. Ratulangie CJ. Whooping cough mortality & vaccination. Ned Tijdschr Geneeskd 1957; 101(39):1801-6.
6. Cohen HH. Development of pertussis vaccine production and control in the national institute of public 
health in the netherlands during the years 1950-1962. Antonie Van Leeuwenhoek 1963; 29:183-201.
7. Lindner U, Blume SS. Vaccine innovation and adoption: polio vaccines in the UK, the Netherlands and West 
Germany, 1955-1965. Med Hist 2006; 50(4):425-46.
8. The National Institute for Public Health and the Environment (RIVM). National Immunization 
Programme, vaccination schedule. Available at: http://www.rivm.nl/onderwerpen/onderwerpen/r/
rijksvaccinatieprogramma/de_inenting/ vaccinatieschema. Accessed on: 23-02-2012. 
9. Rozenbaum MH, Mangen MJ, et al. Cost-effectiveness of rotavirus vaccination in the Netherlands; the 
results of a consensus model. BMC Public Health 2011; 11:462.
10. Rozenbaum MH, van Hoek AJ, et al. Cost-effectiveness of varicella vaccination programs: an update of the 
literature. Expert Rev Vaccines 2008; 7(6):753-82.
11. Health Council of the Netherlands. Vaccination of infants against pneumococcal infections. Available at: 
http://www.gezondheidsraad.nl/sites/default/files/05@13n.pdf. Accessed on: 24-11-2011
12. Dutch National Immunization Programme. Available at: http://www.rivm.nl/onderwerpen/onderwerpen/r/
rijksvaccinatieprogramma/de_inenting/vaccinatieschema. Accessed on: 01-08-2012. 
13. van der Eerden MM, Vlaspolder F, et al. Value of intensive diagnostic microbiological investigation in low- 
and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005; 24(4):241-
9.
14. Beutels P, Van Doorslaer E, et al. Methodological issues and new developments in the economic evaluation 
of vaccines. Expert Rev Vaccines 2003; 2(5):649-60.
15. Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic 
analysis of vaccination programs. Med Decis Making 2006; 26(5):434-46.
16. Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev 1993; 15(2):265-302.
17. Hausdorff WP, Feikin DR, et al. Epidemiological differences among pneumococcal serotypes. Lancet Infect 
Dis 2005; 5(2):83-93.
18. Hausdorff WP, Bryant J, et al. Which pneumococcal serogroups cause the most invasive disease: implications 
for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000; 30(1):100-21.
19. Macleod CM, Hodges RG, et al. Prevention of pneumococcal pneumonia by immunization with specific 
capsular polysaccharides. J Exp Med 1945; 82(6):445-65.
20. Huss A, Scott P, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180(1):48-
58.
21. Musher DM, Sampath R, et al. The potential role for protein-conjugate pneumococcal vaccine in adults: 
what is the supporting evidence? Clin Infect Dis 2011; 52(5):633-40.
22. Jefferson T. Pneumococcal vaccines: confronting the confounders. Lancet 2009; 373(9680):2008-9.
23. Pollard AJ, Perrett KP, et al. Maintaining protection against invasive bacteria with protein-polysaccharide 
conjugate vaccines. Nat Rev Immunol 2009; 9(3):213-20.
24. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory 
Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49(RR-9):1-35.
25. Black S, Shinefield H, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate 




26. EMA. Scientific Discussion Prevenar. Available at: http://www.ema.europa.eu/humandocs/Humans/EPAR/
prevenar/prevenar.htm. Accessed on: 08-10-2009. 
27. Andrews N, Waight PA, et al. Using the indirect cohort design to estimate the effectiveness of the seven 
valent pneumococcal conjugate vaccine in England and Wales. PLoS One 2011; 6(12):e28435.
28. Whitney CG, Pilishvili T, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against 
invasive pneumococcal disease: a matched case-control study. Lancet 2006; 368(9546):1495-502.
29. Barricarte A, Castilla J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-
based case-control study. Clin Infect Dis 2007; 44(11):1436-41.
30. Deceuninck G, De WP, et al. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule 
in Quebec, Canada. Pediatr Infect Dis J 2010; 29(6):546-9.
31. Mahon BE, Hsu K, et al. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine 
dosing regimens. Vaccine 2006; 24(14):2514-20.
32. Bakaletz LO. Viral potentiation of bacterial superinfection of the respiratory tract. Trends Microbiol 1995; 
3(3):110-4.
33. Ruckinger S, van der Linden M, et al. Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: 
An analysis using the indirect cohort method. Vaccine 2010; 28(31):5012-6.
34. EMA. Scientific Discussion synflorix. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/
synflorix/H-973-en6.pdf. Accessed on: 06-09-2009. 
35. EMA. Scientific Discussion Prevenar 13. Available at: http://www.ema.europa.eu/humandocs/Humans/
EPAR/Prevenar13/Prevenar13.htm. Accessed on: 10-01-2010. 
36. Miller E, Andrews NJ, et al. Herd immunity and serotype replacement 4 years after seven-valent 
pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect 
Dis 2011; 11(10):760-8.
37. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 2010; 85(40):385-400.
38. Jefferson T, Rudin M, et al. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003; 
21(17-18):2003-14.
39. National Institute for Public Health and the Environment (RIVM). The National Immunisation Programme 
(NIP) in the Netherlands. Available at: http://www.rivm.nl/en/infectious-diseases/topics/nip/. Accessed on: 
24-02-2012. 
40. van Hoek AJ, Andrews N, et al. The effect of underlying clinical conditions on the risk of developing invasive 
pneumococcal disease in England. J Infect 2012.
41. Progress in introduction of pneumococcal conjugate vaccine worldwide, 2000-2008. MMWR Morb Mortal 
Wkly Rep 2008; 57(42):1148-51.
42. De Carvalho GH, Muscat M, et al. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 
2001-2007. Euro Surveill 2009; 14(12).
43. Rozenbaum MH, Sanders EA, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: 
economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 
13 valent vaccines. BMJ 2010; 340:c2509.
44. Hsu HE, Shutt KA, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J 
Med 2009; 360(3):244-56.
45. Lexau CA, Lynfield R, et al. Changing epidemiology of invasive pneumococcal disease among older adults 
in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294(16):2043-51.
46. Whitney CG, Farley MM, et al. Decline in invasive pneumococcal disease after the introduction of protein-
polysaccharide conjugate vaccine. N Engl J Med 2003; 348(18):1737-46.
47. Rozenbaum MH, Hoek AJ, et al. Huge impact of assumptions on indirect effects on the cost-effectiveness of 
routine infant vaccination with 7-valent conjugate vaccine (Prevnar). Vaccine 2010; 28(12):2367-9.
48. Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 
report. Wkly Epidemiol Rec 2010; 85(43):434-6.
49. FDA. Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein) Prevnar®. Available at: http://
www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM137038.pdf. Accessed 
on: 08-10-2009. 
50. Goldblatt D, Southern J, et al. Immunogenicity and boosting after a reduced number of doses of a 
pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 2006; 25(4):312-9.
Reference list
175
51. FDA. Approval Letter - Prevnar 13. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/
ApprovedProducts/ucm201741.htm. Accessed on: 25-2-2010. 
52. Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate 
vaccine: Synflorix. Expert Rev Vaccines 2009; 8(11):1479-500.
53. WHO. Meeting ReportWHO/ Health Canada consultation on serological criteria for evaluation and 
licensing of new pneumococcal vaccines 7 - 8 july 2008, Ottawa, Canada. Available at: http://www.who.int/
biologicals/publications/meetings/areas/vaccines/pneumococcal/Executive%20Summary%20FINAL%20
version%205%20pneumo%2030_July_08%20_2_.pdf. Accessed on: 24-04-2008. 
54. Kayhty H, Ahman H, et al. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate 
vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J 2005; 24(2):108-14.
55. Centers for Disease Control and Prevention. Vaccine Information Statement.Available at: http://www.cdc.
gov/vaccines. Accessed on: 22-10-2009. 
56. EUVAC.NET. Childhood Vaccination Schedule. Available at: http://www.euvac.net/graphics/euvac/
vaccination/cyprus.html. Accessed on: 16-03-2010. 
57. van Gils EJ, Veenhoven RH, et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate 
vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 2009; 
302(2):159-67.
58. Ghaffar F, Barton T, et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal 
colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 2004; 39(7):930-8.
59. O’Brien KL, Millar EV, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization 
among immunized and unimmunized children in a community-randomized trial. J Infect Dis 2007; 
196(8):1211-20.
60. Mbelle N, Huebner RE, et al. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent 
pneumococcal conjugate vaccine. J Infect Dis 1999; 180(4):1171-6.
61. Robinson KA, Baughman W, et al. Epidemiology of invasive Streptococcus pneumoniae infections in 
the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 2001; 
285(13):1729-35.
62. Jefferson T, Ferroni E, et al. Streptococcus pneumoniae in western Europe: serotype distribution and 
incidence in children less than 2 years old. Lancet Infect Dis 2006; 6(7):405-10.
63. Singleton RJ, Hennessy TW, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among 
alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007; 
297(16):1784-92.
64. Weatherholtz R, Millar EV, et al. Invasive pneumococcal disease a decade after pneumococcal conjugate 
vaccine use in an American Indian population at high risk for disease. Clin Infect Dis 2010; 50(9):1238-46.
65. Lacapa R, Bliss SJ, et al. Changing epidemiology of invasive pneumococcal disease among White Mountain 
Apache persons in the era of the pneumococcal conjugate vaccine. Clin Infect Dis 2008; 47(4):476-84.
66. Hicks LA, Harrison LH, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate 
vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J 
Infect Dis 2007; 196(9):1346-54.
67. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction—eight states, 
1998-2005. MMWR Morb Mortal Wkly Rep 2008; 57(6):144-8.
68. Johnson HL, Deloria-Knoll M, et al. Systematic evaluation of serotypes causing invasive pneumococcal 
disease among children under five: the pneumococcal global serotype project. PLoS Med 2010; 7(10).
69. Roche PW, Krause V, et al. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 2008; 
32(1):18-30.
70. Australian Government Department of Health and Ageing. National Immunisation Program Schedule. 
Available at: http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/nips2#footnotee. 
Accessed on: 07-01-2010. 
71. Wals PD, Carbon M, et al. Reduced physician claims for otitis media after implementation of pneumococcal 
conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 2009; 28(9):e271-e275.
72. Kellner JD, Vanderkooi OG, et al. Changing epidemiology of invasive pneumococcal disease in Canada, 




73. Lepoutre A, Varon E, et al. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases 
in France, 2001-2006. Euro Surveill 2008; 13(35).
74. Ardanuy C, Tubau F, et al. Epidemiology of invasive pneumococcal disease among adult patients in 
barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. 
Clin Infect Dis 2009; 48(1):57-64.
75. Fenoll A, Gimenez MJ, et al. Susceptibility of pneumococci causing meningitis in Spain and prevalence 
among such isolates of serotypes contained in the 7-valent pneumococcal conjugate vaccine. J Antimicrob 
Chemother 2009; 64(6):1338-40.
76. Dias R, Canica M. Invasive pneumococcal disease in Portugal prior to and after the introduction of 
pneumococcal heptavalent conjugate vaccine. FEMS Immunol Med Microbiol 2007; 51(1):35-42.
77. Ruckinger S, van der LM, et al. Reduction in the incidence of invasive pneumococcal disease after general 
vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 2009; 27(31):4136-41.
78. Vestrheim DF, Lovoll O, et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination 
programme on invasive pneumococcal disease among children in Norway. Vaccine 2008; 26(26):3277-81.
79. Jansen AGSC, Rodenburg GD, et al. Invasive pneumococcal disease in the Netherlands: Syndromes, 
outcome and potential vaccine benefits. Vaccine 2009; 27:2394-401.
80. Trotter CL, Waight P, et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: 
England and Wales, 1996-2006. J Infect 2009.
81. Health Protection Agency (HPA). Cumulative weekly number of reports of invasive pneumococcal disease 
in England and Wales by epidemiological year July-June. Available at: http://www.hpa.org.uk. Accessed on: 
09-12-2009.
82. Harboe ZB, Valentiner-Branth P, et al. Early effectiveness of heptavalent conjugate pneumococcal 
vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization 
Programme. Vaccine 2010.
83. Rendi-Wagner P, Paulke-Korinek M, et al. National paediatric immunization program of high risk groups: no 
effect on the incidence of invasive pneumococcal diseases. Vaccine 2009; 27(30):3963-8.
84. Pilishvili T, Lexau C, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate 
vaccine. J Infect Dis 2010; 201(1):32-41.
85. Byington CL, Hulten KG, et al. Molecular Epidemiology of Pediatric Pneumococcal Empyema 2001-2007. J 
Clin Microbiol 2009.
86. Kaplan SL, Barson WJ, et al. Serotype 19A Is the Most Common Serotype Causing Invasive Pneumococcal 
Infections in Children. Pediatrics 2010; 125(3):429-36.
87. Moore MR, Gertz RE, Jr., et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in 
the United States, 2005. J Infect Dis 2008; 197(7):1016-27.
88. Flannery B, Heffernan RT, et al. Changes in invasive Pneumococcal disease among HIV-infected adults living 
in the era of childhood pneumococcal immunization. Ann Intern Med 2006; 144(1):1-9.
89. Bettinger JA, Scheifele DW, et al. The effect of routine vaccination on invasive pneumococcal infections in 
Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine 2009.
90. Roche PW, Krause VL, et al. Invasive pneumococcal disease in Australia, 2004. Commun Dis Intell 2006; 
30(1):80-92.
91. Bingen E, Levy C, et al. Pneumococcal meningitis in the era of pneumococcal conjugate vaccine 
implementation. Eur J Clin Microbiol Infect Dis 2008; 27(3):191-9.
92. Dubos F, Marechal I, et al. Decline in pneumococcal meningitis after the introduction of the heptavalent-
pneumococcal conjugate vaccine in northern France. Arch Dis Child 2007; 92(11):1009-12.
93. Calbo E, Diaz A, et al. Invasive pneumococcal disease among children in a health district of Barcelona: early 
impact of pneumococcal conjugate vaccine. Clin Microbiol Infect 2006; 12(9):867-72.
94. Obando I, Arroyo LA, et al. Molecular epidemiology of paediatric invasive pneumococcal disease in southern 
Spain after the introduction of heptavalent pneumococcal conjugate vaccine. Clin Microbiol Infect 2007; 
13(3):347-8.
95. Guevara M, Barricarte A, et al. Changing epidemiology of invasive pneumococcal disease following 




96. Perez-Trallero E, Marimon JM, et al. Invasive Streptococcus pneumoniae infections in children and older 
adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate 
vaccine. Eur J Clin Microbiol Infect Dis 2009; 28(7):731-8.
97. Munoz-Almagro C, Jordan I, et al. Emergence of invasive pneumococcal disease caused by nonvaccine 
serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008; 46(2):174-82.
98. Aristegui J, Bernaola E, et al. Reduction in pediatric invasive pneumococcal disease in the Basque Country 
and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin 
Microbiol Infect Dis 2007; 26(5):303-10.
99. Casado-Flores J, Rodrigo C, et al. Decline in pneumococcal meningitis in Spain after introduction of the 
heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2008; 27(11):1020-2.
100. Benito-Fernandez J, Raso SM, et al. Pneumococcal bacteremia among infants with fever without known 
source before and after introduction of pneumococcal conjugate vaccine in the Basque Country of Spain. 
Pediatr Infect Dis J 2007; 26(8):667-71.
101. Salleras L, Dominguez A, et al. Changes in serotypes causing invasive pneumococcal disease (2005-2007 
vs. 1997-1999) in children under 2 years of age in a population with intermediate coverage of the 7-valent 
pneumococcal conjugated vaccine. Clin Microbiol Infect 2009; 15(11):997-1001.
102. Aguiar SI, Serrano I, et al. Changes in Streptococcus pneumoniae serotypes causing invasive disease with 
non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 2008; 
14(9):835-43.
103. Vestrheim DF, Hoiby EA, et al. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. 
Vaccine 2010.
104. Rodenburg GD, de Greeff SC, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, 
the Netherlands. Emerg Infect Dis 2010; 16(5):816-23.
105. de Greef SC, de Melker HE, et al. Impact of seven-valent pneumococcal conjugate vaccine on the incidence 
and serotype distribution of invasive pneumococcal disease in the Netherlands. Poster presented at the 
ISPPD 2010.
106. Hanna JN, Humphreys JL, et al. Invasive pneumococcal disease in Indigenous people in north Queensland: 
an update, 2005-2007. Med J Aust 2008; 189(1):43-6.
107. Dagan R, Givon-Lavi N, et al. Introduction and proliferation of multidrug-resistant Streptococcus 
pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 
2009; 199(6):776-85.
108. Choi EH, Kim SH, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 
2008; 14(2):275-81.
109. Kyaw MH, Rose CE, Jr., et al. The influence of chronic illnesses on the incidence of invasive pneumococcal 
disease in adults. J Infect Dis 2005; 192(3):377-86.
110. Principi N, Marchisio P, et al. Risk factors for carriage of respiratory pathogens in the nasopharynx of healthy 
children. Ascanius Project Collaborative Group. Pediatr Infect Dis J 1999; 18(6):517-23.
111. Goldblatt D, Southern J, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 
23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009; 49(9):1318-25.
112. Moore MR, Whitney CG. Emergence of nonvaccine serotypes following introduction of pneumococcal 
conjugate vaccine: cause and effect? Clin Infect Dis 2008; 46(2):183-5.
113. Amrine-Madsen H, Van EJ, et al. Temporal and spatial distribution of clonal complexes of Streptococcus 
pneumoniae isolates resistant to multiple classes of antibiotics in Belgium, 1997 to 2004. Antimicrob Agents 
Chemother 2008; 52(9):3216-20.
114. van Gils EJ, Veenhoven RH, et al. Pneumococcal conjugate vaccination and nasopharyngeal acquisition of 
pneumococcal serotype 19A strains. JAMA 2010; 304(10):1099-106.
115. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era 
of pneumococcal conjugate vaccines. Clin Infect Dis 2002; 35(5):547-55.
116. Aguiar SI, Pinto FR, et al. Denmark14-230 clone as an increasing cause of pneumococcal infection in 
Portugal within a background of diverse serotype 19A lineages. J Clin Microbiol 2010; 48(1):101-8.
117. Dortet L, Ploy MC, et al. Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular 




118. Munoz-Almagro C, Esteva C, et al. Emergence of invasive pneumococcal disease caused by multidrug-
resistant serotype 19A among children in Barcelona. J Infect 2009; 59(2):75-82.
119. Hanage WP, Kaijalainen TH, et al. Invasiveness of serotypes and clones of Streptococcus pneumoniae 
among children in Finland. Infect Immun 2005; 73(1):431-5.
120. Brueggemann AB, Griffiths DT, et al. Clonal relationships between invasive and carriage Streptococcus 
pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 2003; 
187(9):1424-32.
121. Brueggemann AB. Vaccine escape recombinants emerge after pneumococcal vaccination in the United 
States. 2007.
122. Brueggemann AB, Peto TE, et al. Temporal and geographic stability of the serogroup-specific invasive 
disease potential of Streptococcus pneumoniae in children. J Infect Dis 2004; 190(7):1203-11.
123. Sjostrom K, Spindler C, et al. Clonal and capsular types decide whether pneumococci will act as a primary or 
opportunistic pathogen. Clin Infect Dis 2006; 42(4):451-9.
124. Harboe ZB, Thomsen RW, et al. Pneumococcal serotypes and mortality following invasive pneumococcal 
disease: a population-based cohort study. PLoS Med 2009; 6(5):e1000081.
125. Martens P, Worm SW, et al. Serotype-specific mortality from invasive Streptococcus pneumoniae disease 
revisited. BMC Infect Dis 2004; 4:21.
126. Weinberger DM, Trzcinski K, et al. Pneumococcal capsular polysaccharide structure predicts serotype 
prevalence. PLoS Pathog 2009; 5(6):e1000476.
127. Ruckinger S, von KR, et al. Association of serotype of Streptococcus pneumoniae with risk of severe and fatal 
outcome. Pediatr Infect Dis J 2009; 28(2):118-22.
128. Alanee SR, McGee L, et al. Association of serotypes of Streptococcus pneumoniae with disease severity and 
outcome in adults: an international study. Clin Infect Dis 2007; 45(1):46-51.
129. Rozenbaum MH, Hak E, et al. Results of a cohort model analysis of the cost-effectiveness of routine 
immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the 
Netherlands. Clin Ther 2010; 32(8):1517-32.
130. Tan TQ. Serious and invasive pediatric pneumococcal disease: epidemiology and vaccine impact in the USA. 
Expert Rev Anti Infect Ther 2010; 8(2):117-25.
131. Claes C, Reinert RR, et al. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in 
Germany considering herd immunity effects. Eur J Health Econ 2009; 10(1):25-38.
132. Silfverdal SA, Berg S, et al. The cost-burden of paediatric pneumococcal disease in Sweden and the potential 
cost-effectiveness of prevention using 7-valent pneumococcal vaccine. Vaccine 2009; 27(10):1601-8.
133. Hubben GA, Bos JM, et al. Enhanced decision support for policy makers using a web interface to health-
economic models—illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 
7-valent pneumococcal conjugate vaccine in the Netherlands. Vaccine 2007; 25(18):3669-78.
134. McIntosh ED, Conway P, et al. Pneumococcal pneumonia in the UK—how herd immunity affects the cost-
effectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine 2005; 23(14):1739-45.
135. Bos JM, Rumke H, et al. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 
7-valent conjugated pneumococcal vaccine in the Netherlands. Clin Ther 2003; 25(10):2614-30.
136. Black SB, Shinefield HR, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children 
younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002; 21(9):810-5.
137. Fireman B, Black SB, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis 
J 2003; 22(1):10-6.
138. Nelson JC, Jackson M, et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of 
community acquired pneumonia in children and adults. Vaccine 2008; 26(38):4947-54.
139. Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England 
and Wales. Vaccine 2004; 22(31-32):4203-14.
140. Oostenbrink R, HA AM, et al. The EQ-5D and the Health Utilities Index for permanent sequelae after 
meningitis: a head-to-head comparison. J Clin Epidemiol 2002; 55(8):791-9.
141. Krabbe PF, Hinderink JB, et al. The effect of cochlear implant use in postlingually deaf adults. Int J Technol 
Assess Health Care 2000; 16(3):864-73.
Reference list
179
142. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FHH. Guidelines for costing research, 
methods and standardized prices for economic evaluations in health care. Health Care Insurance Board. 
2004. Diemen, The Netherlands. 
143. Council for Public Health and Health Care. Sensible and Sustainable Care. 2006. Zoetermeer, The Netherlands. 
144. Bos JM, Postma MJ. Using pharmacoeconomics for policy making: is rational decision making enhanced by 
applying thresholds for cost-effectiveness? Expert RevPharmacoeconomics Outcomes Res 2004;247-50.
145. Tilson L, Usher C, et al. Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination 
Strategy in Ireland. Value Health 2008.
146. Fine P, Eames K, et al. “Herd immunity”: a rough guide. Clin Infect Dis 2011; 52(7):911-6.
147. Giorgi-Rossi P, Merito M, et al. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to 
routine free immunizations for infants in Lazio, Italy. Health Policy 2009; 89(2):225-38.
148. Dutch Healthcare Authority (NZa). Maximum tariff for Dutch General Practitioners [in Dutch]. Dutch 
Healthcare Authority. Available at: http://www.nza.nl/9439/10249/41655/5000-1900-08-3-volgnr201.pdf. 
Accessed on: 17-01-2008
149. Health Care Insurance Board (CVZ). Tariffs of medical specialists [in Dutch].Available at: http://www.cvz.nl/
resources/feokostprijzen-tarieven-medischeverrichtingentcm28-17015.xls. Accessed on: 07-05-2009
150. Bennett JE, Sumner W, et al. Parents’ utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med 
2000; 154(1):43-8.
151. Rodenburg GD, Greef SC, et al. First 2 years of experience with pneumococcal conjugate vaccine 
implementation in the Netherlands. Accepted for publication in J Emerging infections 2009.
152. Brouwer WB, Niessen LW, et al. Need for differential discounting of costs and health effects in cost 
effectiveness analyses. BMJ 2005; 331(7514):446-8.
153. Madhi SA, Adrian P, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal 
vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster 
dose of vaccine. Vaccine 2007; 25(13):2451-7.
154. Hansen J, Black S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger 
than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization 
standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006; 25(9):779-81.
155. Eskola J, Kilpi T, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 
2001; 344(6):403-9.
156. Vespa G, Constenla DO, et al. Estimating the cost-effectiveness of pneumococcal conjugate vaccination in 
Brazil. Rev Panam Salud Publica 2009; 26(6):518-28.
157. Prosser LA, Ray GT, et al. Preferences and willingness to pay for health states prevented by pneumococcal 
conjugate vaccine. Pediatrics 2004; 113(2):283-90.
158. Prymula R, Peeters P, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention 
of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: 
a randomised double-blind efficacy study. Lancet 2006; 367(9512):740-8.
159. Fenoll A, Granizo JJ, et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and 
antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 2009; 47(4):1012-20.
160. Ray GT, Whitney CG, et al. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 
years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006; 25(6):494-501.
161. Jit M, Choi YH, et al. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 
2008; 337:a769.
162. Tilson L, Thornton L, et al. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic 
evaluation. Eur J Public Health 2008; 18(3):275-82.
163. Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect Dis 2004; 4(2):112-24.
164. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. 
Eur Respir J Suppl 2002; 36:20s-7s.
165. Garau J, Calbo E. Community-acquired pneumonia. Lancet 2008; 371(9611):455-8.




167. Health Care Insurence Board (CVZ). Recommendation for vaccination with Pneumovax [in Dutch]. Available 
at: http://www.fk.cvz.nl. Accessed on: 24-11-2009
168. Hak E, Sanders EA, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal 
vaccine efficacy among older adults. Neth J Med 2008; 66(9):378-83.
169. de Roux A, Schmole-Thoma B, et al. Comparison of pneumococcal conjugate polysaccharide and free 
polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune 
responses and immunological memory. Clin Infect Dis 2008; 46(7):1015-23.
170. Jackson LA, Neuzil KM, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-
protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide 
vaccine. Vaccine 2007; 25(20):4029-37.
171. Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect 
Dis 2008; 47(10):1328-38.
172. Postma MJ. Public health economics of vaccines in the Netherlands: methodological issues and application. 
Journal of Public Health 2008; 16(4):-267.
173. Postma MJ, Heijnen ML, et al. Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals 
in The Netherlands. Pharmacoeconomics 2001; 19(2):215-22.
174. Health Council of the Netherlands. Pneumococcal vaccine in elderly adults and risk groups. The Hague: 
Health Council of the Netherlands, 2003; publication no. 2003/10. 2009. 
175. Weisfelt M, van de BD, et al. Community-acquired bacterial meningitis in older people. J Am Geriatr Soc 
2006; 54(10):1500-7.
176. Boersma WG, Lowenberg A, et al. Pneumococcal capsular antigen detection and pneumococcal serology in 
patients with community acquired pneumonia. Thorax 1991; 46:902-6.
177. Bohte R, van Furth R, et al. Aetiology of community-acquired pneumonia: a prospective study among adults 
requiring admission to hospital. Thorax 1995; 50:543-7.
178. Prismant. Ziekenhuis statistieken [in Dutch]. Available at: http://www.prismant.nl/informatie-expertise/
thema%27s/ziekenhuisstatistieken. Accesssed on: 26-11-2009. 
179. Statistics Netherlands. Cause of death, age and sex. Available at: http://statline.cbs.nl/. http://statline.cbs.
nl/statweb/publication/?dm=slnl&pa=7233&d1=727-733&d2=a&d3=1-2&d4=l&vw=t. Accessed on: 09-09-
2009. 
180. Mangtani P, Roberts JA, et al. An economic analysis of a pneumococcal vaccine programme in people aged 
over 64 years in a developed country setting. Int J Epidemiol 2005; 34(3):565-74.
181. Ament A, Baltussen R, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 
western European countries. Clin Infect Dis 2000; 31(2):444-50.
182. Nivel. Continuous morbidity registration 2008 [in Dutch]. Available at: http://www.nivel.nl/pdf/rapport-
cmr-2008.pdf. Accessed on: 26-11-2009. 
183. Cabellos C, Verdaguer R, et al. Community-acquired bacterial meningitis in elderly patients: experience over 
30 years. Medicine (Baltimore) 2009; 88(2):115-9.
184. Ashwal S, Cranford R. Medical aspects of the persistent vegetative state—a correction. The Multi-Society 
Task Force on PVS. N Engl J Med 1995; 333(2):130.
185. Ogilvie I, Khoury AE, et al. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a 
systematic review of conclusions and assumptions. Vaccine 2009; 27(36):4891-904.
186. Merito M, Giorgi RP, et al. Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly 
in the Lazio region of Italy. Vaccine 2007; 25(3):458-65.
187. Mereckiene J, Cotter S, et al. National seasonal influenza vaccination survey in Europe, 2008. Euro Surveill 
2008; 13(43).
188. Jansen AG, Sanders EA, et al. Decline in influenza-associated mortality among Dutch elderly following the 
introduction of a nationwide vaccination program. Vaccine 2008; 26(44):5567-74.
189. Tacken M, Mulder J, van den Hoogen H, Tiersma W, Donkers J. Monitoring Nationaal Programma 
Grieppreventie 2008. Available at: http://www.iqhealthcare-indicatoren.nl/uploads/files/linh-grieprap0809.
pdf. Accessed on: 01-07-2009. 




191. Postma MJ, Bos JM, et al. Economic evaluation of influenza vaccination. Assessment for The Netherlands. 
Pharmacoeconomics 1999; 16 Suppl 1:33-40.
192. Sisk JE, Whang W, et al. Cost-effectiveness of vaccination against invasive pneumococcal disease among 
people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003; 138(12):960-
8.
193. O’Brien KL. Pneumococcal conjugate vaccine, polysaccharide vaccine, or both for adults? We’re not there 
yet. Clin Infect Dis 2009; 49(9):1326-8.
194. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 
2003; 21(16):1769-75.
195. Klugman KP, Madhi SA, et al. Novel approaches to the identification of Streptococcus pneumoniae as the 
cause of community-acquired pneumonia. Clin Infect Dis 2008; 47 Suppl 3:S202-S206.
196. Baltussen RM, Ament AJ, et al. Cost-effectiveness of vaccination against pneumococcal pneumonia in The 
Netherlands. EurJ Pub Health 1997; 7:153-61.
197. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization 
Practices (ACIP). MMWR Recomm Rep 1997; 46(RR-8):1-24.
198. Rozenbaum MH, Boersma C, et al. Observed differences in invasive pneumococcal disease epidemiology 
after routine infant vaccination. Expert Rev Vaccines 2011; 10(2):187-99.
199. French N, Gordon SB, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N 
Engl J Med 2010; 362(9):812-22.
200. Klugman KP, Madhi SA, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and 
those without HIV infection. N Engl J Med 2003; 349(14):1341-8.
201. Jit M. The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review 
and meta-analysis. J Infect 2010; 61(2):114-24.
202. Howard LS, Sillis M, et al. Microbiological profile of community-acquired pneumonia in adults over the last 
20 years. Journal of Infection 2005; 50:107-13.
203. Lim WS, Macfarlane JT, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted 
to hospital: implications for management guidelines. Thorax 2001; 56(4):296-301.
204. Miller E, Andrews NJ, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate 
vaccine. Vaccine 2011.
205. O’Hagen A, Buck C, Daneshkhah A, Eiser JR, Garthwaite PH, Jenkinson D. Uncertain judgements: eliciting 
experts’ probabilities. Wiley; 2006.
206. Andrews N, Kaye P, Slack M, George R, Miller E. Miller Effectiveness of the 13 valent pneumococcal 
conjugate vaccine against IPD in England and Wales. Available at: http://www2.kenes.com/isppd/scientific/
documents/finalabstractbook.pdf (page 179). Accessed on: 01-04-2012. 
207. BMJ Group and RPS Publishing. British National Formulary. 60th edition. September 2010. Available at: 
http://bnf.org/bnf/. Accessed on: 01-10-2010. 
208. National Institute for Health and Clinical Excellence. Updated guide to the methods of technology appraisal 
- June 2008. NICE. 2008. 
209. Melegaro A, Choi YH, et al. Dynamic models of pneumococcal carriage and the impact of the Heptavalent 
Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. BMC Infect Dis 2010; 10:90.
210. Office for National Statistics (ONS). Available at: http://www.statistics.gov.uk. Accessed on: 13-08-2011. 
211. Curtis L. Unit costs of health & social care. Personal Social Services Research Unit; 2010.
212. Department of Health. The green book. Immunisation against infectious disease. Available at: http://www.
dh.gov uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_122639 pdf. 
Accessed on: 24-03-2011
213. Begun F, Pebody R. Seasonal influenza vaccine uptake among the 65 years and over and under 65 years 
at risk in England. Available at: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@
en/@ps/documents/digitalasset/dh_118645.pdf. Accessed on: 11-8-2010. 
214. Choi YH, Jit M, et al. 7-valent pneumococcal conjugate vaccination in England and wales: is it still beneficial 
despite high levels of serotype replacement? PLoS One 2011; 6(10):e26190.
215. Flasche S, van Hoek AJ, et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage 
and invasive disease in England: a cross-sectional study. PLoS Med 2011; 8(4):e1001017.
Reference list
182
216. Smith KJ, Wateska AR, et al. Cost-effectiveness of adult vaccination strategies using pneumococcal 
conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012; 307(8):804-12.
217. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the 
BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313(7052):275-83.
218. Zakikhany K, Degail MA, et al. Increase in invasive Streptococcus pyogenes and Streptococcus pneumoniae 
infections in England, December 2010 to January 2011. Euro Surveill 2011; 16(5).
219. Joint Committee on Vaccination and Immunisation (JCVI) pneumococcal sub committee. JCVI statement on 
the routine pneumococcal vaccination programme for adults aged 65 years and older. Available at: http://
www.dh.gov.uk/ab/jcvi/dh094744. Accessed on: 01-04-2012. 
220. Impfplan Österreich 2012. Available at: http://www.bmg.gv.at/home/schwerpunkte/praevention/impfen/
oesterreichischer_impfplan_2012. Accessed on: 18-04-2012. 
221. http://static.diavgeia.gov.gr/doc/45øøè-2èì. Accessed on: 18-4-2012. 
222. Haut conseil de la Sante Publique. Available at: http://www.hcsp.fr/explore.cgi/avisrapports?ae=avisrappo
rts&menu=09. Accessed on: 18-04-2012. 
223. Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat 
Sachsen. Available at: http://www.slaek.de/60infos/infosarzt/36impfen/pdf/e1.pdf. Accessed on: 18-04-
2012. 
224. Lim WS, Baudouin SV, et al. BTS guidelines for the management of community acquired pneumonia in 
adults: update 2009. Thorax 2009; 64 Suppl 3:iii1-55.
225. Welte T, Torres A, et al. Clinical and economic burden of community-acquired pneumonia among adults in 
Europe. Thorax 2010.
226. Holm A, Nexoe J, et al. Aetiology and prediction of pneumonia in lower respiratory tract infection in primary 
care. Br J Gen Pract 2007; 57(540):547-54.
227. United Nations Statistics Division. Composition of macro geographical (continental) regions, geographical 
sub-regions, and selected economic and other groupings. Available at: http://millenniumindicators.un.org/
unsd/methods/m49/m49regin.htm. 2011. Accessed on: 20-08-2012
228. Goossens H, Ferech M, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-
national database study. Lancet 2005; 365(9459):579-87.
229. Muller A, Coenen S, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic 
use in Europe, 1998-2005. Euro Surveill 2007; 12(10):E071011.
230. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 
2010. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). 2011. 
Stockholm, ECDC. 
231. Schweizerisches Zentrum für Antibiotikaresistenzen. Available at: http://www.anresis.ch/de/index.html
#javascript:loadContent%28%27#content-data%27,%27include/resistancedataselection.html%27%29. 
Accessed on: 24-11-2011. 
232. Poulakou G, Katsarolis I, et al. Nationwide surveillance of Streptococcus pneumoniae in Greece: patterns of 
resistance and serotype epidemiology. Int J Antimicrob Agents 2007; 30(1):87-92.
233. European Centre for Disease Prevention and Control. EARSS Annual Report 2001. 2001. Stockholm, ECDC. 
234. Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med 2004; 
23(11):1663-82.
235. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 
2002; 21(11):1559-73.
236. Bolker BM. Generalized linear mixed models: a practical guide for ecology and evolution 2009 Trends in 
Ecology and Evolution Vol.24 No.3. 
237. Akaike H. A new look at the statistical model identification. 1974. 
238. Handbook of advanced multilevel analysis. In: Joop J, .Hox J, Roberts K, editors. 2011. 173.
239. Sung Su Y, Gelman A, et al. Multiple Imputation with Diagnostics (mi) in R: Opening Windows into the Black 
Box. Journal of Statistical Software 2009.
240. Development Core Team (2011). R: A language and environment for statistical computing. R Foundation 
for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. Available at: http://www.r-project.org/. 
Accessed on: 24-11-2012. 
Reference list
183
241. Bates D, Maechler M, Bolker B. lme4: Linear mixed-effects models using S4 classes. R package version 
0.999375-42. Available at: http://cran.r-project.org/package=lme4. Accessed on: 24-11-2011.
242. Ewig S, Schlochtermeier M, et al. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal 
impact on treatment decisions. Chest 2002; 121(5):1486-92.
243. Marques MR, Nunes A, et al. Community-acquired pneumonia in an intensive care unit. Rev Port Pneumol 
2010; 16(2):223-35.
244. Manali E, Papadopoulos A, et al. The impact on community acquired pneumonia empirical therapy of 
diagnostic bronchoscopic techniques. Scand J Infect Dis 2008; 40(4):286-92.
245. Muller F, Christ-Crain M, et al. Procalcitonin levels predict bacteremia in patients with community-acquired 
pneumonia: a prospective cohort trial. Chest 2010; 138(1):121-9.
246. Muller B, Harbarth S, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in 
community-acquired pneumonia. BMC Infect Dis 2007; 7:10.
247. Janssens JP, Gauthey L, et al. Community-acquired pneumonia in older patients. J Am Geriatr Soc 1996; 
44(5):539-44.
248. Genne D, Siegrist HH, et al. Enhancing the etiologic diagnosis of community-acquired pneumonia in adults 
using the urinary antigen assay (Binax NOW). Int J Infect Dis 2006; 10(2):124-8.
249. Kirk O, Glenthoj J, et al. Penicillin as empirical therapy for patients hospitalised with community acquired 
pneumonia at a Danish hospital. Dan Med Bull 2001; 48(2):84-8.
250. Ostergaard L, Andersen PL. Etiology of community-acquired pneumonia. Evaluation by transtracheal 
aspiration, blood culture, or serology. Chest 1993; 104(5):1400-7.
251. Farina C, Arosio M, et al. Urinary detection of Streptococcus pneumoniae antigen for diagnosis of 
pneumonia. New Microbiol 2002; 25(2):259-63.
252. Guglielmo L, Leone R. Aetiology and therapy of community-acquired pneumonia: a hospital study in 
northern Italy. Veneto Pneumonia Research Group. Eur J Clin Pharmacol 1997; 51(6):437-43.
253. Michetti G, Pugliese C, et al. Community-acquired pneumonia: is there difference in etiology between 
hospitalized and out-patients? Minerva Medica 1995; 86(9):341-51.
254. Burman LA, Trollfors B, et al. Diagnosis of pneumonia by cultures, bacterial and viral antigen detection tests, 
and serology with special reference to antibodies against pneumococcal antigens. Journal of Infectious 
Diseases 1991; 163:1087-93.
255. Johansson N, Kalin M, et al. Etiology of community-acquired pneumonia: increased microbiological yield 
with new diagnostic methods. Clin Infect Dis 2010; 50(2):202-9.
256. Ortqvist A, Hedlund J, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia 
requiring hospitalization. European Respiratory Journal 1990; 3:1105-13.
257. Stralin K, Olcen P, et al. Definite, probable, and possible bacterial aetiologies of community-acquired 
pneumonia at different CRB-65 scores. Scand J Infect Dis 2010; 42(6-7):426-34.
258. Hohenthal U, Vainionpaa R, et al. Aetiological diagnosis of community acquired pneumonia: utility of rapid 
microbiological methods with respect to disease severity. Scand J Infect Dis 2008; 40(2):131-8.
259. Jokinen C, Heiskanen L, et al. Microbial etiology of community-acquired pneumonia in the adult population 
of 4 municipalities in eastern Finland. Clin Infect Dis 2001; 32(8):1141-54.
260. Beovic B, Bonac B, et al. Aetiology and clinical presentation of mild community-acquired bacterial 
pneumonia. European Journal of Clinical Microbiological Infectious Diseases 2003; 22(10):159-69.
261. Socan M, Marinic-Fiser N, et al. Microbial aetiology of community-acquired pneumonia in hospitalised 
patients. European Journal of Clinical Microbiological Infectious Diseases 1999; 18:777-82.
262. Melbye H, Berdal BP, et al. Pneumonia—a clinical or radiographic diagnosis? Etiology and clinical features of 
lower respiratory tract infection in adults in general practice. Scand J Infect Dis 1992; 24(5):647-55.
263. Leesik H, Ani U, et al. Microbial pathogens of adult community-acquired pneumonia in Southern Estonia. 
Medicina (Kaunas ) 2006; 42(5):384-94.
264. Fantin B, Aubert JP, et al. Clinical evaluation of the management of community-acquired pneumonia by 
general practitioners in France. Chest 2001; 120(1):185-92.
265. Georges H, Leroy O, et al. Epidemiological features and prognosis of severe community-acquired 
pneumococcal pneumonia. Intensive Care Med 1999; 25(2):198-206.
Reference list
184
266. Leroy O, Georges H, et al. Severe community-acquired pneumonia in ICUs: prospective validation of a 
prognostic score. Intensive Care Med 1996; 22(12):1307-14.
267. Moine P, Vercken JB, et al. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis 
factors. Chest 1994; 105(5):1487-95.
268. Paganin F, Lilienthal F, et al. Severe community-acquired pneumonia: assessment of microbial aetiology as 
mortality factor. Eur Respir J 2004; 24(5):779-85.
269. Renaud B, Coma E, et al. Routine use of the Pneumonia Severity Index for guiding the site-of-treatment 
decision of patients with pneumonia in the emergency department: a multicenter, prospective, 
observational, controlled cohort study. Clin Infect Dis 2007; 44(1):41-9.
270. Laurichesse H, Sotto A, et al. Pre- and in-hospital management of community-acquired pneumonia in 
southern France, 1998-99. Eur J Clin Microbiol Infect Dis 2001; 20(11):770-8.
271. Blasi F, Cosentini R, et al. Emerging pathogens of community-acquired pneumonia: a two-year prospective 
study. J Chemother 1995; 7 Suppl 4:115-6.
272. Cosentini R, Blasi F, et al. Severe community-acquired pneumonia: a possible role for Chlamydia pneumoniae. 
Respiration 1996; 63(2):61-5.
273. Woodhead MA, Arrowsmith J, et al. The value of routine microbial investigation in community-acquired 
pneumonia. Respir Med 1991; 85(4):313-7.
274. Boersma WG, Daniels JM, et al. Reliability of radiographic findings and the relation to etiologic agents in 
community-acquired pneumonia. Respir Med 2006; 100(5):926-32.
275. Endeman H, Schelfhout V, et al. Clinical features predicting failure of pathogen identification in patients 
with community acquired pneumonia. Scand J Infect Dis 2008; 40(9):715-20.
276. Holloway Y, Snijder JA, et al. Demonstration of circulating pneumococcal immunoglobulin G immune 
complexes in patients with community-acquired pneumonia by means of an enzyme-linked immunosorbent 
assay. J Clin Microbiol 1993; 31(12):3247-54.
277. Templeton KE, Scheltinga SA, et al. Improved diagnosis of the etiology of community-acquired pneumonia 
with real-time polymerase chain reaction. Clin Infect Dis 2005; 41(3):345-51.
278. Vegelin AL, Bissumbhar P, et al. Guidelines for severe community-acquired pneumonia in the western world. 
Neth J Med 1999; 55(3):110-7.
279. Cilloniz C, Ewig S, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. 
Thorax 2011; 66(4):340-6.
280. Falco V, Fernandez de Sevilla T, et al. Legionella pneumophila. A cause of severe community-acquired 
pneumonia. Chest 1991; 100:1007-11.
281. Falguera M, Sacristan O, et al. Nonsevere community-acquired pneumonia: correlation between cause and 
severity or comorbidity. Archive of Internal Medicine 2001; 161(15):1866-72.
282. Garcia-Ordonez MA, Garcia-Jimenez JM, et al. Clinical aspects and prognostic factors in elderly patients 
hospitalised for community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2001; 20(1):14-9.
283. Garcia-Vazquez E, Soto S, et al. Simple criteria to assess mortality in patients with community-acquired 
pneumonia. Med Clin (Barc ) 2008; 131(6):201-4.
284. Garcia-Vidal C, Carratala J, et al. Aetiology of, and risk factors for, recurrent community-acquired pneumonia. 
Clin Microbiol Infect 2009; 15(11):1033-8.
285. Gomez J, Banos V, et al. Prospective study of epidemiology and prognostic factors in community-acquired 
pneumonia. Eur J Clin Microbiol Infect Dis 1996; 15(7):556-60.
286. Ewig S, Bauer T, et al. Prognostic analysis and predictive rule for outcome of hospital-treated community-
acquired pneumonia. Eur Respir J 1995; 8(3):392-7.
287. Kruger S, Ewig S, et al. Inflammatory parameters predict etiologic patterns but do not allow for individual 
prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir 
Res 2009; 10:65.
288. Steinhoff D, Lode H, et al. Chlamydia pneumoniae as a cause of community-acquired pneumonia in 
hospitalized patients in Berlin. Clin Infect Dis 1996; 22(6):958-64.
289. Bella F, Tort J, et al. Value of bacterial antigen detection in the diagnostic yield of transthoracic needle 
aspiration in severe community acquired pneumonia. Thorax 1993; 48(12):1227-9.
290. Blanquer J, Blanquer R, et al. Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre 
prospective study. Thorax 1991; 46(7):508-11.
Reference list
185
291. Briones ML, Blanquer J, et al. Assessment of Analysis of Urinary Pneumococcal Antigen by 
Immunochromatography for Etiologic Diagnosis of Community-Acquired Pneumonia in Adults. Clinical and 
Vaccine Immunology 2006; 13(10):1092-7.
292. Valencia M, Badia JR, et al. Pneumonia severity index class v patients with community-acquired pneumonia: 
characteristics, outcomes, and value of severity scores. Chest 2007; 132(2):515-22.
293. Rello J, Rodriguez R, et al. Severe community-acquired pneumonia in the elderly: epidemiology and 
prognosis. Study Group for Severe Community-Acquired Pneumonia. Clin Infect Dis 1996; 23(4):723-8.
294. Rello J, Bodi M, et al. Microbiological testing and outcome of patients with severe community-acquired 
pneumonia. Chest 2003; 123(1):174-80.
295. Rello J, Quintana E, et al. A three-year study of severe community-acquired pneumonia with emphasis on 
outcome. Chest 1993; 103(1):232-5.
296. Riquelme R, Torres A, et al. Community-acquired pneumonia in the elderly: A multivariate analysis of risk 
and prognostic factors. Am J Respir Crit Care Med 1996; 154(5):1450-5.
297. Ruiz-Gonzalez A, Falguera M, et al. Is Streptococcus pneumoniae the leading cause of pneumonia of 
unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-
acquired pneumonia. Am J Med 1999; 106(4):385-90.
298. Sorde R, Falco V, et al. Current and potential usefulness of pneumococcal urinary antigen detection in 
hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med 
2011; 171(2):166-72.
299. Torres A, Serra-Batlles J, et al. Severe community-acquired pneumonia. Epidemiology and prognostic 
factors. Am Rev Respir Dis 1991; 144(2):312-8.
300. Zalacain R, Torres A, et al. Community-acquired pneumonia in the elderly: Spanish multicentre study. Eur 
Respir J 2003; 21(2):294-302.
301. The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care 
unit. The British Thoracic Society Research Committee and The Public Health Laboratory Service. Respir Med 
1992; 86(1):7-13.
302. Venkatesan P, Gladman J, et al. A hospital study of community acquired pneumonia in the elderly. Thorax 
1990; 45(4):254-8.
303. Gutierrez F, Masia M, et al. The influence of age and gender on the population-based incidence of 
community-acquired pneumonia caused by different microbial pathogens. J Infect 2006; 53(3):166-74.
304. Lorente ML, Falguera M, et al. Diagnosis of pneumococcal pneumonia by polymerase chain reaction (PCR) 
in whole blood: a prospective clinical study. Thorax 2000; 55:133-7.
305. Martinez-Moragon E, Garcia FL, et al. [Community-acquired pneumonia among the elderly: differences 
between patients living at home and in nursing homes]. Arch Bronconeumol 2004; 40(12):547-52.
306. Menendez R, Cordoba J, et al. Value of the polymerase chain reaction assay in noninvasive respiratory 
samples for diagnosis of community-acquired pneumonia. Am J Respir Crit Care Med 1999; 159(6):1868-73.
307. Molinos L, Fernandez R, et al. Adenosine deaminase activity in the aetiological diagnosis of community-
acquired pneumonia. Scand J Infect Dis 1997; 29(3):287-90.
308. Molinos L, Clemente MG, et al. Community-acquired pneumonia in patients with and without chronic 
obstructive pulmonary disease. J Infect 2009; 58(6):417-24.
309. Sopena N, Sabria M, et al. Prospective study of community-acquired pneumonia of bacterial etiology in 
adults. Eur J Clin Microbiol Infect Dis 1999; 18(12):852-8.
310. Pachon J, Prados MD, et al. Severe community-acquired pneumonia. Etiology, prognosis, and treatment. Am 
Rev Respir Dis 1990; 142(2):369-73.
311. Pareja A, Bernal C, et al. Etiologic study of patients with community-acquired pneumonia. Chest 1992; 
101:1207-10.
312. Querol-Ribelles JM, Tenias JM, et al. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment 
of adults with community-acquired pneumonia requiring hospitalization. Int J Antimicrob Agents 2005; 
25(1):75-83.
313. Rozenbaum MH, van Hoek AJ, Miller E, Edmunds WJ. Cost effectiveness of vaccinating risk groups in England 
using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ 2012;345:e6879. 2012. 
314. Celentano LP, Massari M, et al. Resurgence of pertussis in Europe. Pediatr Infect Dis J 2005; 24(9):761-5.
Reference list
186
315. de Melker HE, Conyn-van Spaendonck MA, et al. Pertussis in The Netherlands: an outbreak despite high 
levels of immunization with whole–cell vaccine. Emerg Infect Dis 1997; 3(2):175-8.
316. Ntezayabo B, de Serres G., et al. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr 
Infect Dis J 2003; 22(1):22-7.
317. Quinn HE, McIntyre PB. Pertussis epidemiology in Australia over the decade 1995-2005--trends by region 
and age group. Commun Dis Intell 2007; 31(2):205-15.
318. de Greeff SC, Mooi FR, et al. Impact of acellular pertussis preschool booster vaccination on disease burden 
of pertussis in The Netherlands. Pediatr Infect Dis J 2008; 27(3):218-23.
319. Guris D, Strebel PM, et al. Changing epidemiology of pertussis in the United States: increasing reported 
incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999; 28(6):1230-7.
320. Skowronski DM, De SG, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis 2002; 
185(10):1448-53.
321. Bisgard KM, Pascual FB, et al. Infant pertussis: who was the source? Pediatr Infect Dis J 2004; 23(11):985-9.
322. Elliott E, McIntyre P, et al. National study of infants hospitalized with pertussis in the acellular vaccine era. 
Pediatr Infect Dis J 2004; 23(3):246-52.
323. Wendelboe AM, Njamkepo E, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 
2007; 26(4):293-9.
324. Tan T, Trindade E, et al. Epidemiology of pertussis. Pediatr Infect Dis J 2005; 24(5 Suppl):S10-S18.
325. Halperin SA. Canadian experience with implementation of an acellular pertussis vaccine booster-dose 
program in adolescents: implications for the United States. Pediatr Infect Dis J 2005; 24(6 Suppl):S141-S146.
326. Coudeville L, van Rie A., et al. Adult pertussis vaccination strategies and their impact on pertussis in the 
United States: evaluation of routine and targeted (cocoon) strategies. Epidemiol Infect 2008; 136(5):604-20.
327. de Greeff SC, Mooi FR, et al. Pertussis disease burden in the household: how to protect young infants. Clin 
Infect Dis 2010; 50(10):1339-45.
328. Coudeville L, Van RA, et al. Adult vaccination strategies for the control of pertussis in the United States: an 
economic evaluation including the dynamic population effects. PLoS One 2009; 4(7):e6284.
329. de Vries R, Kretzschmar M, et al. Cost-Effectiveness of Adolescent Pertussis Vaccination for The Netherlands: 
Using an Individual-Based Dynamic Model. PLoS One 2010; 5(10):e13392.
330. Hethcote HW, Horby P, et al. Using computer simulations to compare pertussis vaccination strategies in 
Australia. Vaccine 2004; 22(17-18):2181-91.
331. van Boven M., de Melker HE, et al. A model based evaluation of the 1996-7 pertussis epidemic in The 
Netherlands. Epidemiol Infect 2001; 127(1):73-85.
332. van Rie A., Hethcote HW. Adolescent and adult pertussis vaccination: computer simulations of five new 
strategies. Vaccine 2004; 22(23-24):3154-65.
333. Wendelboe AM, Van RA, et al. Duration of immunity against pertussis after natural infection or vaccination. 
Pediatr Infect Dis J 2005; 24(5 Suppl):S58-S61.
334. Ramsay ME, Farrington CP, et al. Age-specific efficacy of pertussis vaccine during epidemic and non-
epidemic periods. Epidemiol Infect 1993; 111(1):41-8.
335. Farrington CP. The measurement and interpretation of age-specific vaccine efficacy. Int J Epidemiol 1992; 
21(5):1014-20.
336. van Boven M., de Melker HE, et al. Waning immunity and sub-clinical infection in an epidemic model: 
implications for pertussis in The Netherlands. Math Biosci 2000; 164(2):161-82.
337. Zhang L, Prietsch SOM, et al. Acellular vaccines for preventing whooping cough in children. Cochrane 
Database of Systematic Reviews 2009, Issue 4 Art No : CD001478 DOI: 10 1002/14651858 CD001478 pub3 
2010.
338. Casey JR, Pichichero ME. Acellular pertussis vaccine safety and efficacy in children, adolescents and adults. 
Drugs 2005; 65(10):1367-89.
339. Ward JI, Cherry JD, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J 
Med 2005; 353(15):1555-63.
340. Frampton JE, Keam SJ. Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, 
adsorbed (Boostrix) US formulation): use as a single-dose booster immunization in adolescents aged 10-18 
years. Paediatr Drugs 2006; 8(3):189-95.
Reference list
187
341. De Greeff SC, Schellekens JFP, Mooi FR, de Melker HE. Pertussis in the Netherlands, 2001-2002. RIVM report 
128507010/2003. 
342. de Melker HE, Versteegh FG, et al. The incidence of Bordetella pertussis infections estimated in the 
population from a combination of serological surveys. J Infect 2006; 53(2):106-13.
343. Wallinga J, Teunis P, et al. Using data on social contacts to estimate age-specific transmission parameters for 
respiratory-spread infectious agents. Am J Epidemiol 2006; 164(10):936-44.
344. Mossong J, Hens N, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. 
PLoS Med 2008; 5(3):e74.
345. de Greeff SC, Schellekens JF, et al. Effect of vaccination against pertussis on the incidence of pertussis in The 
Netherlands, 1996-2003 [in Dutch]. Ned Tijdschr Geneeskd 2005; 149(17):937-43.
346. van Rie A., Wendelboe AM, et al. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J 2005; 
24(5 Suppl):S62-S65.
347. Anderson RM, May RM. Infectious diseases of humans.Oxford: Oxford University Press, 1991. 
348. Zepp F, Heininger U, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect 
Dis 2011; 11(7):557-70.
349. Lee GM, Lett S, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis 2004; 
39(11):1572-80.
350. De SG, Shadmani R, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000; 182(1):174-9.
351. Wood N, Quinn HE, et al. Pertussis in infants: preventing deaths and hospitalisations in the very young. J 
Paediatr Child Health 2008; 44(4):161-5.
352. Rozenbaum MH, De VR, et al. Modelling the impact of extended vaccination strategies on the epidemiology 
of pertussis. Epidemiol Infect 2011;1-12.
353. Millier A, Aballea S, et al. A critical literature review of health economic evaluations in pertussis booster 
vaccination. Expert Rev Pharmacoecon Outcomes Res 2012; 12(1):71-94.
354. Westra TA, De VR, et al. Cost-effectiveness analysis of various pertussis vaccination strategies primarily 
aimed at protecting infants in the Netherlands. Clin Ther 2010; 32(8):1479-95.
355. Taranger J, Trollfors B, et al. Immunologic and epidemiologic experience of vaccination with a 
monocomponent pertussis toxoid vaccine. Pediatrics 2001; 108(6):E115.
356. Gustafsson L, Hallander HO, et al. A controlled trial of a two-component acellular, a five-component 
acellular, and a whole–cell pertussis vaccine. N Engl J Med 1996; 334(6):349-55.
357. Trollfors B, Taranger J, et al. Immunization of children with pertussis toxoid decreases spread of pertussis 
within the family. Pediatr Infect Dis J 1998; 17(3):196-9.
358. Nielsen A, Larsen SO. Epidemiology of pertussis in Denmark: the impact of herd immunity. Int J Epidemiol 
1994; 23(6):1300-8.
359. Cooper E, Fitch L. Pertussis: herd immunity and vaccination coverage in St Lucia. Lancet 1983; 2(8359):1129-
32.
360. Olin P, Gustafsson L, et al. Declining pertussis incidence in Sweden following the introduction of acellular 
pertussis vaccine. Vaccine 2003; 21(17-18):2015-21.
361. Preziosi MP, Yam A, et al. Epidemiology of pertussis in a West African community before and after 
introduction of a widespread vaccination program. Am J Epidemiol 2002; 155(10):891-6.
362. Statistics Netherlands. Available at: http://statline.cbs.nl/statweb/publication/?vw=t&dm=slnl&pa=7233&
d1=33&d2=0&d3=0&d4=a&hd=120203-2201&hdr=g2,g1,g3&stb=t. Accessed on: 03-02-2012 
363. Crowcroft NS, Britto J. Whooping cough—a continuing problem. BMJ 2002; 324(7353):1537-8.
364. Edwards KM. Is pertussis a frequent cause of cough in adolescents and adults? Should routine pertussis 
immunization be recommended? Clin Infect Dis 2001; 32(12):1698-9.
365. Black S. Epidemiology of pertussis. Pediatr Infect Dis J 1997; 16(4 Suppl):S85-S89.
366. Crowcroft NS, Stein C, et al. How best to estimate the global burden of pertussis? Lancet Infect Dis 2003; 
3(7):413-8.
367. de Melker HE, Schellekens JF, et al. Reemergence of pertussis in the highly vaccinated population of the 
Netherlands: observations on surveillance data. Emerg Infect Dis 2000; 6(4):348-57.
368. von Konig CH, Halperin S, et al. Pertussis of adults and infants. Lancet Infect Dis 2002; 2(12):744-50.
Reference list
188
369. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory 
infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005; 18(2):326-
82.
370. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with 
the epidemiology of Bordetella pertussis infection. Pediatrics 2005; 115(5):1422-7.
371. Baptista PN, Magalhaes V, et al. Source of infection in household transmission of culture-confirmed pertussis 
in Brazil. Pediatr Infect Dis J 2005; 24(11):1027-8.
372. Baptista PN, Magalhaes VS, et al. The role of adults in household outbreaks of pertussis. Int J Infect Dis 2010; 
14(2):e111-e114.
373. Schellekens J, von Konig CH, et al. Pertussis sources of infection and routes of transmission in the vaccination 
era. Pediatr Infect Dis J 2005; 24(5 Suppl):S19-S24.
374. Tozzi AE, Pandolfi E, et al. Comparison of pertussis surveillance systems in Europe. Vaccine 2007; 25(2):291-7.
375. Rodriguez-Cobo I, Chen YF, et al. Clinical and economic assessment of different general population 
strategies of pertussis vaccine booster regarding number of doses and age of application for reducing 
whooping cough disease burden: a systematic review. Vaccine 2008; 26(52):6768-76.
376. Postma MJ, De VR, et al. Conclusions on (cost-)effectiveness of pertussis booster vaccination strategies 
highly dependent on selections made in evidence review. Vaccine 2009; 27(52):7242-3.
377. Edmunds WJ, Brisson M, et al. The potential cost-effectiveness of acellular pertussis booster vaccination in 
England and Wales. Vaccine 2002; 20(9-10):1316-30.
378. Rozenbaum MH, De CE, et al. Cost-effectiveness of pertussis booster vaccination in the Netherlands. Vaccine 
2012.
379. Hethcote HW. An age-structured model for pertussis transmission. Math Biosci 1997; 145(2):89-136.
380. Hethcote HW. Simulations of pertussis epidemiology in the United States: effects of adult booster 
vaccinations. Math Biosci 1999; 158(1):47-73.
381. Knox EG, Shannon HS. A model basis for the control of whooping cough. Int J Epidemiol 1986; 15(4):544-52.
382. Fabricius G, Bergero PE, et al. Modelling pertussis transmission to evaluate the effectiveness of an adolescent 
booster in Argentina. Epidemiol Infect 2012;1-17.
383. Luz PM, Codeco CT, et al. A modelling analysis of pertussis transmission and vaccination in Rio de Janeiro, 
Brazil. Epidemiol Infect 2006; 134(4):850-62.
384. Grenfell BT, Anderson RM. Pertussis in England and Wales: an investigation of transmission dynamics and 
control by mass vaccination. Proc R Soc Lond B Biol Sci 1989; 236(1284):213-52.
385. Anderson RM, May RM. Age-related changes in the rate of disease transmission: implications for the design 
of vaccination programmes. J Hyg (Lond) 1985; 94(3):365-436.
386. Kretzschmar M, Teunis PF, et al. Incidence and reproduction numbers of pertussis: estimates from serological 
and social contact data in five European countries. PLoS Med 2010; 7(6):e1000291.
387. Wearing HJ, Rohani P. Estimating the duration of pertussis immunity using epidemiological signatures. PLoS 
Pathog 2009; 5(10):e1000647.
388. de Greeff SC, Lugner AK, et al. Economic analysis of pertussis illness in the Dutch population: implications 
for current and future vaccination strategies. Vaccine 2009; 27(13):1932-7.
389. Purdy KW, Hay JW, et al. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and 
adults: a cost-benefit analysis. Clin Infect Dis 2004; 39(1):20-8.
390. Ortega-Sanchez IR, Lee GM, et al. Projected cost-effectiveness of new vaccines for adolescents in the United 
States. Pediatrics 2008; 121 Suppl 1:S63-S78.
391. Lee GM, LeBaron C, et al. Pertussis in adolescents and adults: should we vaccinate? Pediatrics 2005; 
115(6):1675-84.
392. Lee GM, Murphy TV, et al. Cost effectiveness of pertussis vaccination in adults. Am J Prev Med 2007; 32(3):186-
93.
393. Caro J, Denis G, et al. Pertussis in adolescents and adults: should we accept the results? Pediatrics 2005; 
116(5):1263-4.
394. Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of 
tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the 
Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-3):1-34.
Reference list
189
395. Westra TA, Parouty M, et al. On discounting of health gains from human papillomavirus vaccination: effects 
of different approaches. Value Health 2012; 15(3):562-7.
396. Edwards KM, Decker M. Pertussis vaccine. In: Plotkin SA, Orenstein WA (eds.) Vaccines (4th edition, 
Philidelphia, Saunders, pp 471-528). 2012. 
397. Pertussis vaccines: WHO position paper—recommendations. Vaccine 2011; 29(13):2355-6.
398. Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. 
Pharmacoeconomics 2011; 29(5):371-86.
399. Beutels P, Scuffham PA, et al. Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis 
2008; 8(11):727-33.
400. de Vries R. Health economics of Interventions aimed at Infectious Diseases; dynamic modeling inevitable 
for reliable decision making. ORO Grafisch Project Management, Koekange 2009. 2012. 
401. de Greeff SC, de Melker HE, et al. Seroprevalence of pertussis in The Netherlands: evidence for increased 
circulation of Bordetella pertussis. PLoS One 2010; 5(12):e14183.
402. Lavine JS, King AA, et al. Natural immune boosting in pertussis dynamics and the potential for long-term 
vaccine failure. Proc Natl Acad Sci U S A 2011; 108(17):7259-64.
403. Mooi FR, de Greeff SC. The case for maternal vaccination against pertussis. Lancet Infect Dis 2007; 7(9):614-
24.
404. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis 
vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant 
aged <12 months --- Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly 
Rep 2011; 60(41):1424-6.
405. Grenfell B. Boosting understanding of pertussis outbreaks. Proc Natl Acad Sci U S A 2011; 108(18):7279-80.
406. Lavine JS, Bjornstad ON, et al. Short-lived immunity against pertussis, age-specific routes of transmission, 
and the utility of a teenage booster vaccine. Vaccine 2012; 30(3):544-51.
407. Wendelboe AM, Hudgens MG, et al. Estimating the role of casual contact from the community in 
transmission of Bordetella pertussis to young infants. Emerg Themes Epidemiol 2007; 4:15.
408. Rohani P, Zhong X, et al. Contact network structure explains the changing epidemiology of pertussis. 
Science 2010; 330(6006):982-5.
409. Romanus V, Jonsell R, et al. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr 
Infect Dis J 1987; 6(4):364-71.
410. Tanaka M, Vitek CR, et al. Trends in pertussis among infants in the United States, 1980-1999. JAMA 2003; 
290(22):2968-75.
411. Roush SW, Murphy TV. Historical comparisons of morbidity and mortality for vaccine-preventable diseases 
in the United States. JAMA 2007; 298(18):2155-63.
412. Pilishvili T, Zell ER, et al. Risk factors for invasive pneumococcal disease in children in the era of conjugate 
vaccine use. Pediatrics 2010; 126(1):e9-17.
413. Hjuler T, Wohlfahrt J, et al. Risks of invasive pneumococcal disease in children with underlying chronic 
diseases. Pediatrics 2008; 122(1):e26-e32.
414. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the six serotypes 
in prevenar13™ but not in pcv7 : persons aged >5 years in england and wales by epidemiological 
year: july-june (2005 - july 2012). Available at: http://www.hpa.org.uk/topics/infectiousdiseases/
infectionsaz/pneumococcal/epidemiologicaldatapneumococcal/currentepidemiologypneumococcal/
inprevenar13notinprevenarpcv7/pneumo09cummulativeweekly5in13notin7vacc/. Accessed on: 01-07-
2012. 
415. Plotkin SA. Vaccines: past, present and future. Nat Med 2005; 11(4 Suppl):S5-11.
416. Rashid H, Khandaker G, et al. Vaccination and herd immunity: what more do we know? Curr Opin Infect Dis 
2012; 25(3):243-9.
417. Thomas SL, Wheeler JG, et al. Contacts with varicella or with children and protection against herpes zoster 
in adults: a case-control study. Lancet 2002; 360(9334):678-82.
418. Hope-Simpson R.E. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 
1965; 58:9-20.
419. Brisson M, Gay NJ, et al. Exposure to varicella boosts immunity to herpes-zoster: implications for mass 
vaccination against chickenpox. Vaccine 2002; 20(19-20):2500-7.
Reference list
190
420. Jumaan AO, Yu O, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated 
decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191(12):2002-7.
421. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med 
Decis Making 2003; 23(1):76-82.
422. Panagiotopoulos T, Antoniadou I, et al. Increase in congenital rubella occurrence after immunisation in 
Greece: retrospective survey and systematic review. BMJ 1999; 319(7223):1462-7.
423. Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci U S A 1997; 
94(12):6571-6.
424. van Gils EJ, Hak E, et al. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus 
colonisation in a randomised controlled trial. PLoS One 2011; 6(6):e20229.
425. Cohen R, Levy C, et al. Pneumococcal conjugate vaccine does not influence Staphylococcus aureus carriage 
in young children with acute otitis media. Clin Infect Dis 2007; 45(12):1583-7.
426. Edmunds WJ, Medley GF, et al. Evaluating the cost-effectiveness of vaccination programmes: a dynamic 
perspective. Stat Med 1999; 18(23):3263-82.
427. Welte R, Postma M, et al. Costs and effects of chlamydial screening: dynamic versus static modeling. Sex 
Transm Dis 2005; 32(8):474-83.
428. Hethcote HW. The mathematics of infectious diseases. SIAM Journal 2000; 42:599-653.
429. Hamer H. Epidemic disease in England. Lancet 1906; 1:733-9.
430. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and control. Oxford,UK: Oxford University 
Press; 1991.
431. Brief van de minister van volksgezondheid, welzijn en sport aan de voorzitter van de tweede kamer der 
staten-generaal. Available at: https://zoek.officielebekendmakingen.nl/kst-29689-394.pdf. Accessed on: 
15-6-2012. 
432. Tasset A, Nguyen VH, et al. Discounting: technical issues in economic evaluations of vaccination. Vaccine 
1999; 17 Suppl 3:S75-S80.
433. Gravelle H, Brouwer W, et al. Discounting in economic evaluations: stepping forward towards optimal 
decision rules. Health Econ 2007; 16(3):307-17.
434. Cairns JA. Left atrial myxoma mimicking vasculitis. Can Med Assoc J 1980; 122(3):282.
435. Bos JM, Postma MJ, et al. Discounting health effects in pharmacoeconomic evaluations: current 
controversies. Pharmacoeconomics 2005; 23(7):639-49.
436. Bechini A, Tiscione E, et al. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, 
newborns and health care workers): A review of evidences and recommendations. Vaccine 2012.
437. Hahne S, Macey J, et al. Rubella outbreak in the Netherlands, 2004-2005: high burden of congenital infection 
and spread to Canada. Pediatr Infect Dis J 2009; 28(9):795-800.
438. Wielders CC, van Binnendijk RS, et al. Mumps epidemic in orthodox religious low-vaccination communities 
in the Netherlands and Canada, 2007 to 2009. Euro Surveill 2011; 16(41).
439. Pertussis outbreak in an Amish community—Kent County, Delaware, September 2004-February 2005. 
MMWR Morb Mortal Wkly Rep 2006; 55(30):817-21.
440. Vaccinatiegraad Rijksvaccinatieprogramma Nederland Verslagjaar 2011. Available at: http://www.rivm.nl/
bibliotheek/rapporten/210021014.pdf. Accessed on: 26-10-2012. 
441. Rondy M, van LA, et al. Determinants for HPV vaccine uptake in the Netherlands: A multilevel study. Vaccine 
2010; 28(9):2070-5.
442. Gangarosa EJ, Galazka AM, et al. Impact of anti-vaccine movements on pertussis control: the untold story. 
Lancet 1998; 351(9099):356-61.
443. Wakefield AJ, Murch SH, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive 
developmental disorder in children. Lancet 1998; 351(9103):637-41.
444. Health Protection Agency. Completed primary course at two years of age: England and Wales, 1966-
1977, England only 1978 onwards. Available at: http://www.hpa.org.uk/web/hpaweb&hpawebstandard/
hpaweb_c/1195733819251. Accessed on: 09-07-2012. 
445. Health Protection Agency. Confirmed cases of measles, mumps and rubella 1996-2011. Available at: http://
www.hpa.org.uk/web/hpaweb&hpawebstandard/hpawebc/1195733833790. Accessed on: 09-07-2012. 
Reference list
191
446. Godlee F, Smith J, et al. Wakefield’s article linking MMR vaccine and autism was fraudulent. BMJ 2011; 
342:c7452.
447. Retraction—Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental 
disorder in children. Lancet 2010; 375(9713):445.
448. Prymula R, Kriz P, et al. Effect of vaccination with pneumococcal capsular polysaccharides conjugated to 
Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and 
H. influenzae in children under 2 years of age. Vaccine 2009; 28(1):71-8.
449. Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol 2011; 23(3):407-13.
450. Kowalzik F, Barbosa AP, et al. Prospective multinational study of pertussis infection in hospitalized infants 
and their household contacts. Pediatr Infect Dis J 2007; 26(3):238-42.
451. Gall SA, Myers J, et al. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal 
and neonatal serum antibody levels. Am J Obstet Gynecol 2011; 204(4):334-5.
452. Leuridan E, Hens N, et al. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in 
young infants. Pediatr Infect Dis J 2011; 30(7):608-10.
453. Van SJ, Decker MD, et al. Natural history of pertussis antibody in the infant and effect on vaccine response. 
J Infect Dis 1990; 161(3):487-92.
454. Glezen WP, Alpers M. Maternal immunization. Clin Infect Dis 1999; 28(2):219-24.
455. Simister NE. Placental transport of immunoglobulin G. Vaccine 2003; 21(24):3365-9.
456. Mooi FR, van Loo IH, et al. Bordetella pertussis strains with increased toxin production associated with 
pertussis resurgence. Emerg Infect Dis 2009; 15(8):1206-13.
457. Malek A, Sager R, et al. Evolution of maternofetal transport of immunoglobulins during human pregnancy. 
Am J Reprod Immunol 1996; 36(5):248-55.
458. Englund JA, Anderson EL, et al. The effect of maternal antibody on the serologic response and the incidence 
of adverse reactions after primary immunization with acellular and whole–cell pertussis vaccines combined 
with diphtheria and tetanus toxoids. Pediatrics 1995; 96(3 Pt 2):580-4.
459. Munoz FM, Englund JA. Vaccines in pregnancy. Infect Dis Clin North Am 2001; 15(1):253-71.
460. Dalhousie University. Pertussis maternal immunization study. Identifier: NCT00553228. Available at: http://
clinicaltrials.gov/show/nct00553228external. Accessed on: 13-10-2011. 
461. National Institute of Allergy and Infectious Diseases. Pertussis vaccine in healthy pregnant women. 
Identifier: nct00707148. Available at: http://clinicaltrials.gov/show/nct00707148external. Accessed on: 13-
10-2011. 
462. Siegrist CA. Neonatal and early life vaccinology. Vaccine 2001; 19(25-26):3331-46.




A crowded vaccination schedule and restrained health–care budgets limit the uptake of new 
vaccines into the Dutch national immunization programs (NIP).  Next to many other factors, cost-
effectiveness considerations highly influence the decision whether to introduce vaccines into Dutch 
NIP.
 The first part of this thesis focuses on the (cost-) effectiveness of pneumococcal vaccination.  It is 
shown that there are large differences in the observed disease epidemiology after implementation 
of paediatric pneumococcal immunization programs between the USA and Europe. In Europe, less 
cases of pneumococcal disease were avoided in unvaccinated individuals (herd effects) than in the 
USA, while significant replacement was observed in Europe with strains not included in the vaccine. 
As a consequence,  the 7-valent pneumococcal vaccine, which was previously used in the Dutch 
NIP, was less cost-effective as predicted beforehand. More valent pneumococcal vaccines are more 
likely to be considered cost-effective as more direct and herd effects and less serotype replacement 
effects are expected. These potential herd effects reduce the cost-effectiveness of elderly and adult 
(risk) groups vaccination in time. In particular, a modelling study showed that vaccinating risk 
groups in England was unlikely to be considered cost-effective in the base-case analysis unless the 
vaccine would also offer protection against non–bacteraemic pneumonia. Evidence on whether the 
latter occurs is awaited from a large Dutch clinical trial.
 The second part of the thesis explores the impact of extending the childhood pertussis 
vaccination programme to adolescents and adults. Given the nature of the problem, the 
development of a complex population dynamical model was required. The developed dynamic 
model showed that the most (cost-) effective age for the introduction of an additional booster is 
around 12 years. Nevertheless, this strategy only offered limited indirect protection to the (partly) 
unvaccinated infants with potentially most serious disease which might be considered the primary 
aim of extended pertussis vaccination. 
 In conclusion, the dynamics of infectious diseases makes it challenging to predict the impact 
of new vaccination programs. Extending the vaccination programs against pneumococcal disease 
and pertussis offers the possibility to prevent morbidity and mortality and decrease the economic 




Omdat het Nederlandse Rijksvaccinatieprogramma al intensief is en de gezondheidszorg kampt 
met gelimiteerde budgetten, zijn de mogelijkheden voor opname van nieuwe vaccins in het 
Rijksvaccinatieprogramma beperkt. Naast vele andere factoren,  hebben doelmatigheidsuitkomsten 
een groot effect op de beslissing om een vaccin op te nemen in het Rijksvaccinatieprogramma.
 In het eerste gedeelte van dit proefschrift ligt de focus op de (kosten-) effectiviteit van pneumo-
kokkenvaccinatie. Het blijkt dat er grote verschillen zijn in de geobserveerde epidemiologie na 
de introductie van het vaccin in Amerika en Europa. In Europa werden er minder pneumokokken 
gevallen voorkomen in ongevaccineerde individuen (‘herd immunity’) terwijl er meer ziekte 
werd waargenomen veroorzaakt door serotypen waartegen het vaccin geen bescherming biedt 
(serotypevervanging). Dit had tot gevolg dat de kosteneffectiviteit van het destijds gebruikte 
7-valente pneumokokkenvaccin minder gunstig was dan eerder voorspeld. Meer valente 
pneumokokkenvaccins hebben een grotere kans om te worden beschouwd als kosteneffectief 
omdat deze waarschijnlijk meer directe en herd immunity effecten bieden terwijl de kans op 
serotypevervanging kleiner is. Als gevolg van deze potentiele herd immunity zal het vaccineren 
van andere (risico-) groepen potentieel minder gunstig worden. Zo blijkt uit een economisch model 
dat het vaccineren van risicogroepen in Engeland waarschijnlijk niet als kosteneffectief kan worden 
beschouwd tenzij het vaccin ook bescherming biedt tegen niet-invasieve pneumonie. Dit laatste 
wordt momenteel onderzocht in een grote Nederlandse klinische trial.
 Het tweede gedeelte van dit proefschrift verkent de impact van de uitbreiding van het huidige 
pertussis vaccinatie programma naar adolescenten en volwassenen. Gegeven de complexiteit van 
de pertussis transmissie, was het nodig een dynamisch transmissie model te ontwikkelen. Dit model 
suggereert dat de meest kosteneffectieve leeftijd om een extra booster te introduceren rond de 12 
jaar is. Het beoogde beschermende effect voor (gedeeltelijk) ongevaccineerde zuigelingen bleek 
echter minimaal te zijn.
 Gezien de dynamiek van infectieziekten zijn soms complexe methoden nodig om de impact 
van nieuwe vaccinatieprogramma’s te voorspellen. Het uitbreiden van het huidige pneumokokken– 
en pertussis vaccinatieprogramma biedt de mogelijkheid  om de morbiditeit en mortaliteit te 
verminderen en de ziektegerelateerde kosten te verlagen. 
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· Lu W. Effectiveness of long-term follow-up of breast cancer (prof GH de Bock, prof T Wiggers)
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